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ABSTRACT 
The purpose of this project is to identify the causative gene for one type of autosomal 
recessive  retinitis  pigmentosa,  RP25.  Through  CGH  (comparative  genome 
hybridisation) and mutation screening, independent mutations were identified in arRP 
affected Spanish families mapping to RP25. These mutations were identified within a 
cluster of uncharacterised gene transcripts all which have EGF-like repeat domains; 
Q5T669,  Q5T1H1,  Q9H557_human,  Q5TEL3_human,  Q5TEL4_human, 
Q5VVG4_human,  and Q5T3C8. Through 5` and 3` RACE PCR analysis, the full 
length  gene  was  revealed  to  incorporate  the  EGFL11  gene.  On  assembling  all 
available data we noted that RP25 gene encompasses 30 exons belonging to nine 
previously  predicted  genes  and  13  newly  identified  exons,  totaling  43  exons and 
spanning the interval between 64,487,835 and 66,473,839 on chromosome 6q12. 
                   The  RP25  full  length  gene  transcript  is  retinal  specific.  The  genomic 
length  covers  over  2.0  MB  in  size  and  is  therefore  the  largest  eye  specific  gene 
identified  to  date.  It  is  also  the  fifth  largest  gene  in  the  human  genome  to  date. 
Homologs  of  the  RP25  gene  to  Drosophila  eys/eys-shut  (Spacemaker)  were 
identified, leading to the annotation of the name EYS (SPAM). An apparently intact 
eys gene is found across the mammalian clade, including monotremes (platypus) and 
marsupials  (opossum).  However,  despite  the  mutations  and  the  presumed  loss  of 
function associated with human disease, this gene has been dispensed with on at least 
four  separate  occasions  in  the  last  100  million  years  of  mammalian  evolution 
including  in  the  armadillo  (Dasypus  novemcinctus),  little  brown  bat  (Myotis 
lucifugus) and ruminant (cattle and sheep) lineages. EYS has acquired several (<3) 
reading-frame disruptions in three rodents (mouse, rat and guinea pig) representing                                                                              
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two of the three major rodent clades. Through immunohistochemical and electron 
microscopy  analysis,  a  signal  for  SPAM  was  identified  in  the  outer  segments  of 
photoreceptor cells.  
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CHAPTER 1 
INTRODUCTION 
1.1 The human eye 
The human eye is the organ which reacts to light and creates sight. The eyeball is set in 
a protective cavity in the skull called the orbit or socket. The eye is made up of three 
layers which enclose three transparent structures.  
    The outer layer is made of two parts: the anterior cornea and the posterior sclera. 
The cornea is transparent and allows entry of light into the eye; the sclera creates the 
“white” of the eye and is composed of fibrous tissue (Atchison and Smith, 2000). The 
middle layer is divided into three structures: the iris, the ciliary body and the choroid. 
The iris is the coloured part of the eye, and it controls light levels. The ciliary body 
produces aqueous humour, this clear fluid fills the front of the eye. The final segment 
of the middle layer is the choroid; this is the main source of blood in the eye. The 
innermost layer of the eye is the retina, which is an extension of the central nervous 
system and is connected to the brain through the optic nerve (Atchison and Smith, 
2000). The inside of the eye is divided into three segments. This includes the vitreous 
cavity which is between the lens and the retina and contains a transparent mass called 
the vitreous humour (Figure 1.1). The layer of most interest in this study is the retina. 
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￿
￿
￿
￿
 
Figure 1.1: A schematic view of the eye. The structure of the eye is made up of various layers of tissue, 
starting from the outset the conjunctiva, all the way through to the retina (Smith et al., 2009). 
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1.2 The Retina 
The retina is a specialised sensory cell layer that is capable of transforming light into an 
electrical signal. This signal is transmitted via the optic nerve to the visual centers of 
the brain.  
The retina is composed of 10 layers, from the outside (nearest the choroid) to the 
inside (nearest the vitreous humour) (Figure 1.2)  
Pigmented epithelium 
Photoreceptors 
External (outer) limiting membrane 
Outer nuclear layer 
Outer plexiform layer 
Inner nuclear layer 
Inner plexiform layer 
Ganglion cells 
Nerve Fiber layer  
Internal limiting membrane 
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￿
 
 
 
Figure 1.2: Layers and cell types of the retina. The direction of light through the cell layers is depicted 
by the arrow (Smith et al., 2009).  
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1.2.1 Pigmented Epithelium 
The retinal pigment epithelium (RPE) is a continuous monolayer of cuboidal epithelial 
cells that is densely packed with pigment granules (Schraermeyer and Heimann, 1999). 
This cell layer has many physical, optical, metabolic/biochemical and transport functions. 
These roles include maintaining adhesion of the retina, providing a selectively permeable 
membrane  between  the  choroid  and  the retina and  absorbing  light.  It  nourishes  retinal 
visual cells, and is firmly attached to the underlying retinal visual cells. The RPE consists 
of a single layer of approximately 4-6 million cells firmly attached to its basal lamina. The 
RPE is involved in the phagocytosis of the outer segment of photoreceptor cells. It is also 
involved in the vitamin A cycle; it isomerizes trans retinol to 11-cis retinal (Katz and Gao, 
1995). It also maintains the retinal environment by supplying small molecules such as D-
glucose. Interdigitations between the RPE microvillus and the photoreceptor outer segment 
provide a physical closeness between the two layers and the material that occupies the 
space between the two layers called the interphotoreceptor matrix (IPM) provides adhesive 
forces (Hageman et al., 1995).  
1.2.2 Photoreceptors 
Photoreceptors are the cells responsible for converting light into nerve signals that will 
be transmitted to the brain via the optic nerve. They send signals to other neurons by a 
change in their membrane potential when they absorb photons. This process is known 
as signal transduction. In vertebrates, there are two types of photoreceptor cells: rods 
and cones. The human retina has 120 million rods and 6 million cones (Koenekoop 
2009). Photopigment or coloured material fill the rods and cones and absorb particles                                                                                                Chapter 1 Introduction                                   
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of  light  that  strike  the  retina.  A  photoreceptor  cell  contains  a  membranous 
photoreceptor protein called an opsin which contains a pigment molecule called retinal.  
Both types of photoreceptors have the same basic structure. Closest to the visual field 
(and furthest from the brain) is the axon terminal, which releases a neurotransmitter 
called glutamate to bipolar cells. Further back is the cell body, which contains the cell' s 
organelles. Further back still is the inner segment, a specialized part of the cell full of 
mitochondria. The chief function of the inner segment is to provide ATP (energy) for 
the sodium-potassium pump. Finally, closest to the brain (and furthest from the visual 
field) is the outer segment, the part of the photoreceptor that actually absorbs light. 
Outer  segments  are  actually  modified  cilia  that  contain  discs  filled  with  opsin,  the 
molecule  that  actually  absorbs  photons,  as  well  as  voltage-gated  sodium  channels 
(figure  1.3).  Detailed  structure  of  Rods  and  Cones  will  be  described  under  the 
following subsection: 
1.2.2.1 Rods 
Rods  are  long  (100-120￿m)  slender  cells  whose  outer  segment  contains  the  visual 
pigment rhodopsin within the membrane-bound lamellae that are enclosed by a single 
cell membrane (Luo et al., 2008). The rod-shaped outer segment of a rod cell, which is 
the light-sensitive part, consists largely of a stack of flat and parallel unit membranes 
called discs. Discs are enclosed by the apical microvilli of the RPE. Rods are very 
sensitive to light nerve cells, because of which these cells Discs are enclosed by the 
apical microvilli of the RPE. Rods are very sensitive to light nerve cells, because of                                                                                                Chapter 1 Introduction                                   
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which these cells are responsible for night vision. The pigment in the rods is called 
rhodopsin or visual purple, and enables the eye to see shades of gray and see in dim 
light (figure 1.4). 
 
1.2.2.2 Cones 
Cones are adapted to detect colors, and function well in bright light.  They have a 
similar structure to rod cells but their outer segment which contains the photoreceptive 
pigments is cone shaped. Cones require a reasonable amount of light to be stimulated 
so only function during the day. This is why we have colour vision but mainly during 
the  daytime  when  the  light  intensity  is  high  enough  to  stimulate  the  cone 
receptors. Like rods, cones contain an opsin and the chromophore 11-cis-retinal (Reme 
and Wenzel, 2003). There are three types of pigment or opsins in cones: cyanolabe 
absorbs blue light, chlorabe absorbs green light and erythrolabe absorbs red light. The 
wavelengths of these opsins are at 560nm, 426nm and 530nm respectively which allow 
the eye to visualize colors and to detect sharp images in bright light. Cones are about 
60-75 ￿m in length and are spread throughout the retina. The discs in cones are not 
surrounded by a plasma membrane in the same manner as rods. Cones have a longer 
lifespan  than  rods  and  do  not  undergo  circadian  phagocytosis  by  the  RPE  cells 
(Schraermeyer and Heimann, 1999). 
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Figure 1.3: Structure of rod and cone photoreceptors, including the outer and inner segments. Direction 
of light hitting photoreceptors is depicted with the yellow arrow. http://www.ganfyd.org.  
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1.2.3 Outer limiting membrane, outer nuclear later, outer plexiform layer  
The  outer  limiting  membrane  is  the  site  of  cut  off  junctions  which  seal  off  the 
disposable  parts  of  rods  and  cones.  This  layer  has  the  false  appearance  of  a 
“membrane” in light microscopic preparations, due to the presence of many junctions 
tightly packed together. The outer limiting membrane acts as a barrier to keep the inner 
layers of the retina safe from harmful material.  
The outer nuclear layer contains the nuclei and cell bodies of rods and cones. The outer 
plexiform layer is a layer of neuronal synapses. It is composed of a network of synapses 
between dendrites of horizontal cells from the inner nuclear layer and photoreceptor 
cell inner segments from the outer nuclear layer. Horizontal cells span across cones and 
take inputs from them to control the amount of GABA (amino butyric acid) released 
back  onto  photoreceptor  cells.  There  are  three  basic  types  of  horizontal  cells, 
designated HI, HII and HIII (Kolb et al., 1992). 
1.2.4 Inner nuclear layer, Inner plexiform layer, Ganglion cells, Nerve Fiber layer, 
Internal limiting membrane 
The  cell  bodies  and  nuclei  of  the  integrator  neurons,  particularly  the  bipolar  and 
horizontal cells, are located in the inner nuclear layer, next inwards from the outer 
plexiform layer. The retina contains approximately 35.7 million bipolar cells which 
comprise  of  several  functional  and  morphologic  subtypes.  Bipolar  cells  relay 
information  from  photoreceptor  cells  to  horizontal  and  ganglion  cells  and  receive 
extensive synaptic feedback from amacrine cells (Ayoub and Matthews, 1992). Their                                                                                                Chapter 1 Introduction                                   
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cell bodies lie in the inner nuclear layer and are oriented in a radial fashion parallel to 
the photoreceptors. Bipolar cells can be divided into nine subtypes: one rod bipolar 
type and 8 cone bipolar cell types.  
The inner plexiform layer (IPI), like the outer one, is a region of synapses. Here the 
bipolar cell processes synapse with the dendritic processes of ganglion cells, the final 
neuronal element of the eye. These are interneurons which deliver ganglion cell input 
and regulate output of cone bipolar cells. They operate in the IPL of which there are 
approximately 40 subtypes, most lacking axons (Wassle and Boycott, 1991). Like other 
neurons, these ganglion cells have axons, which carry the generated signal. The axonal 
fibers from the ganglion cells, bundled together, run radially around the inner surface of 
the retina, converging at the site of origin of the optic nerve. At that point the nerve 
penetrates the retina and the sclera.  Here there are no light sensitive elements; this is 
known as “the blind spot” in vertebrates.  
The  innermost  layer  is  not  really  a  membrane, but  is  instead  a  place  of fused cell 
processes.  The  fusion  is  between  foot  processes  of  the  Muller  cells.  This  fusion 
completes  the  function  of  sealing  off  the  retinal  components  from  the  potentially 
harmful materials present in the vitreous chamber. Like the outer limiting membrane, it 
is a region of occluding junctions and a "tight" barrier which can be compared to that 
formed by glial cells in the brain.  
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1.3 Phototransduction Cascade 
Phototransduction is the process of converting light energy into electrical signals via 
photoreceptor  cells.  The  components  of  this  cascade  are  uniquely  expressed  in 
photoreceptors  and,  although  functionally  similar,  distinct  components  of  these 
cascades are expressed in rods and cones. The molecular reactions of phototransduction 
can  be  separated  into  two  major  divisions  (i)  activation  and  (ii)  termination  and 
modulation (Lamb and Pugh, 2006). Activation refers to the steps that lead to the onset 
of the light response. Termination and modulation refer to the steps that lead to the 
shut-off of the activated molecule. Light initiates the isomerization of 11-cis retinal to 
all-trans  retinal  resulting  in  the activated  state of  rhodopsin  (RHO),  also  known  as 
RHO*. RHO* is vital for the phototransduction cascade where it initiates the visual 
cycle.  RHO*  triggers  a  G-protein  (G)  coupled  enzymatic  cascade  catalyzing  the 
exchange of GDP for GTP, and converts transducin into an active form (T*). Activated 
transducin  in  turn  activates  cGMP-phosphodiesterase  (cGMP-PDE),  which  brings 
about the hydrolysis of channel bound cGMP to 5’-GMP. The resulting rapid decrease 
in intracellular cGMP levels causes the cGMP-gated channels to close and the rod cell 
becomes  hyperpolarized.  Termination  of  the  light-response  cascade  is  mediated  by 
inactivation of RHO* by phosphorylation catalysed by rhodopsin kinase and is then 
bound by arrestin, which prevents further interaction with transducin. Transducin and 
phosphodesetrase (PDE) are inactivated by the hydrolysis of GTP to GDP. Guanylate 
cyclase, the enzyme responsible for the synthesis of cGMP from GTP, is inactivated by 
the decrease in intracellular Ca
2+ after photoexcitation. As the cGMP  concentration                                                                                                Chapter 1 Introduction                                   
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increases, the cGMP-gated channels re-open, and the photoreceptor is returned to its 
depolarized state (Figure 1.4). 
 
1.4 The Visual Cycle 
The visual cycle which is also known as the retinoid cycle is the regeneration of the 
visual pigment. Light perception in vertebrates is mediated by a group of G protein–
coupled receptors called opsins (e.g. rhodopsin), which are bound to a chromophore 
(light-absorbing  compound),  11-cis-retinal,  derived  from vitamin  A  (Johnson  et  al., 
2003). Absorption of light induces an 11-cis-retinal to all-trans-retinal isomerisation, 
and the conformational change initiates the visual transduction cascade. In order for the 
activated opsin to participate again in the visual process, the all-trans-retinal must be 
isomerised back to the 11-cis form via an enzymatic pathway, the visual cycle (Figure 
1.5) which occurs mainly within the RPE. Following isomerization and release from 
the opsin protein, all-trans retinal is reduced to all-trans retinol and travels back to the 
RPE to be "recharged". It is first esterified by lecithin-retinol acyltransferase (LRAT) 
and  then  converted  to  11-cis  retinol  by  the  isomerohydrolase  RPE65.  Finally,  it  is 
oxidized to 11-cis-retinal before traveling back to the rod outer segment where it can 
again be conjugated to an opsin to form a new, functional visual pigment (rhodopsin). 
Any  protein  or  enzyme  mutated  at  any  stage  of  the  visual  cycle  or  the 
phototransduction cascade can lead to different types of retinal degenerations. These 
will be discussed in detail in the following sections. 
                                                                                                Chapter 1 Introduction                                   
 
  28
 
 
 
 
 
Figure 1.4 Phototransduction cascade- Overview of the events of the phototransduction pathway, 
from the initiation of the photon of light all the way through to the depolarization of the photoreceptor 
(Farrar et al., 2002). 
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Figure 1.5 The visual cycle. Light induced rhodopsin (RhO) produces a photoactivated metrhodopsin II 
(R*), which converts to opsin and all-trans retinal. This is reduced to all-trans retinol. In the RPE the all-
trans retinal is esterifed to fatty acids. The ester is converted by retinoid isomerase to 11-cis retinol. 
Interphotoreceptor  binding  protein  then  returns  the  11-cis  retinal  to  the  photoreceptor,  where  it 
recombines with opsin to form dark adapted RhO (Travis et al., 2007). 
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1.5 Retinitis Pigmentosa 
Retinitis  pigmentosa  is  a  broad  group  of  disorders  affecting  the  retina.  The  main 
subgroup of diseases is called retinitis pigmentosa (RP). For over 140 years RP has 
been  the  name  given  to  a  group  of  inherited  progressive  retinal  disorders  with  a 
combined incidence of  approximately 1/5000 (Rivolta et al., 2002). RP is a highly 
heterogeneous group of diseases which is characterised by retinal pigment deposits in 
the  midperiphery  of  the  retina  (Figure  1.6).  Patients  with  a  retinal  dysfunction  are 
usually diagnosed with RP based on night blindness which occurs early in life, this will 
be followed by tunnel vision later in life. RP is inherited by several modes, including 
autosomal dominant, autosomal recessive, X-linked, digenic and mitochondrial.  
 
1.5.1 Autosomal dominant RP 
This is usually the mildest form of RP, with many of the cases not beginning until the 
later  stages  of  life.  15-20%  of  all  cases  of  RP  are  autosomal  dominant  (adRP) 
(Inglehearn, 1998). This form of RP is caused by at least 12 genes, including PRPF31 
and RP1. Fourteen loci have been mapped for adRP, with more genes to be cloned. The 
first gene cloned for RP was Rhodopsin (RHO) identified in 1990 (Dryja et al., 1990). 
This gene is also the main causative gene for adRP.  
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Figure 1.6 Fundus of healthy and RP affected retina. Healthy human retina (A) and retinitis pigmentosa 
patient  retina  (B)  as  seen  through  the  ophthalmoscope.  RP  retina  shows  the  typical  bone  spicule 
pigmentary changes and attenuation of the blood vessels (Farrar et al., 2002).  
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1.5.2 X-linked RP 
X chromosome-linked RP (XLRP), which always presents with severe symptoms, early 
onset and rapid deterioration, accounts for 6-17% of familial RP cases (Jin et al., 2006). 
So far five genetic loci have been mapped for X-linked RP, including RPGR, RP2, 
RP6, RP23 and RP26. Mutations in the RPGR gene are estimated to cause
 15% to 20% 
of all cases of RP, higher than any other single
 RP locus (Bader et al., 2003). 
 
1.5.3 Digenic RP 
Digenic inheritance is the interplay of mutations of two different genes resulting in a 
heritable eye disorder. In this disease mutations in ROM1 and RDS gene combined give 
a digenic genetic phenotype. Affected individuals are heterozygous for both mutations 
(Dryja et al., 1997).  
 
1.5.4 Autosomal Recessive RP 
In contrast to adRP, autosomal recessive RP (arRP) is typically reported in younger 
patients and severity is much greater. There are 25 associated arRP loci and for 22 the 
causative  mutation  has  been  identified;  (see  table)  most  of  these  mutations  are 
responsible  for  a  small  percentage  of  cases  (1–5%)  (Abd-El  Aziz  et  al.,  2008).￿
Autosomal  recessive  RP  (arRP)  is  the  most  common  form  of  RP  worldwide  and 
accounts for 39% of cases in Spain (Abd-El Aziz et al., 2005). Several of the arRP 
genes are also implicated in other retinal disorders. One such gene causing arRP is 
CRB1; mutations in this gene also cause Leber congenital amaurosis (LCA), which is 
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    Table 1.1 Genes and loci for arRP: 
Gene 
 
Function  Location  Locus 
1. ABCA4  May play a role in photoresponse.  1p21-q32.1  RP19 
2. CERKL1  Role in cellular apoptosis and survival  2q31-q33  RP26 
3. CNGA1  Involved in Phototransduction pathway  4p14-q13  CNGA1 
4. CNGB1  Visual transduction cascade  16q13  ______ 
5. CRB1  Photoreceptor morphogenesis in the retina. 
Maintains cell polarity  
and adhesion 
 
1p31-q32.1  RP12 
6. LRAT  Catalyzes  the  esterification  of  all-trans-
retinol into all-trans-retinyl ester 
4q13  ______ 
7. MERTK  Associated with disruption of the 
retinal  pigment  epithelium  (RPE) 
phagocytosis pathway  
 
2q14.1  ______ 
8. NR2E3  Transcription factor that may have a role in 
the regulation of signaling pathways 
intrinsic to the photoreceptor cell function 
 
15q23  ______ 
9.  PDE6A  Phototransduction enzyme  5q31.2-q34  ______ 
10. PDE6B  Phototransduction enzyme  4p14-q13  ______ 
11. PRCD  Cytoplasmic protein  17q25.1  ______ 
12. RGR  Retinoid metabolism  10q23  ______ 
13. RPE65  Retinoid metabolism  1p31.2  RP20 
14. RLBP1  Retinoid metabolism  15q26.1  ______ 
15. RHO  Visual transduction cascade   3q21-24  ______ 
16. RP1  Protein transport and
 disc formation  8q12.1  ______ 
17. SAG  Visual transduction cascade  2q37.1  ______ 
18. EYS    6q14-q21  RP25 
19. TPA    8q12.3  TTPA 
20. TULP1  Photoreceptor cell transcription factor    RP14 
21. USH2A  Retinal development    _____ 
 
22.       RP22 
23.      RP28 
24.      RP29 
25.      RP32                                                                                                Chapter 1 Introduction                                   
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1.6 Syndromic RP 
1.6.1 Usher Syndrome 
Usher syndrome is a condition that involves both hearing and visual difficulties. 
Usher syndrome accounts for about 17% of all RP cases in the US (Williams 2007). 
There are three types of Usher syndrome depending on the severity of both hearing 
and  vision  loss.  Currently,  12  loci  have  been  found  to  cause  Usher  syndrome 
(Hilgert et al., 2009). 
 
1.6.2 Bardet Biedl syndrome (BBS) 
This  is  a  complex  disorder  which  affects  children  in  early  childhood.  It  is  also 
associated  with  RP.  Typical  characteristics  include  obesity,  mental  retardation, 
renal abnormalities along with retinal degenerations (Katsanis et al., 2001). It has 
been found to be linked to 12 loci. 
 
1.7 Other retinal degenerations 
1.7.1 Cone-rod dystrophy 
Cone  rod  dystrophies  (CRDs)  with  a  prevalence  1/40,000  are  inherited  retinal 
dystrophies that belong to the group of pigmentary retinopathies (Hamel, 2007). 
CRDs can be inherited by autosomal dominant or autosomal recessive means. They 
are characterised by the primary loss in cone receptors followed by degeneration in 
the rod photoreceptors. The course of cone rod blindness is normally more severe                                                                                                Chapter 1 Introduction                                   
 
  35
and rapid than that of RP, this leads to younger cases of blindness. RIM1 is one 
such gene responsible for type 7, CORD7 which is a subtype of CRDs (Johnson et 
al., 2003).  
 
1.7.2 Leber congenital amaurosis 
Leber congenital amaurosis (LCA) causes blindness or severe visual impairment at 
or within a few months of birth (Wang et al., 2005). It is a highly heterogeneous 
disorder with several genes implicated; including the recently identified LCA5 gene 
(denHollander et al., 2007). So far 8 genes and 3 loci have been associated with 
autosomal  recessive  LCA.  The  genes  identified  are  all  involved  in  a  variety  of 
physiological pathways, making clinical predictions difficult.  
 
1.7.3 Stargardt’s disease 
This is also known as fundus flavimaculatus. In this condition there is atrophy of 
the macula with the appearance of yellow flecks. Mutations in the ABCA4 gene 
encoding a photoreceptor-specific, ATP-binding cassette transporter are responsible 
for the disease (Reinhard et al., 2007).   
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1.8 Human genome project 
Molecular genetics has contributed immensely to our knowledge and understanding of 
inherited  ocular  genetics  disease.  Preceding  the  development  of  recombinant  DNA 
technology,  the  scientific  field  was  limited  to  phenotypic  classifications  based  on 
biochemistry.  Each  human  genome  contains  between  20,000  and  25,000  genes 
(Abdellah et al., 2004). The human genome project (HGP) was developed to identify 
all of these genes, along with determining the sequences of the 3 billion base pairs of 
DNA and storing this data (Venter et al., 2001). The publication of the full genome was 
completed in April 2003 (Collins et al., 2003). The HGP, the database collections and 
the advances for disease identification are immense. The powerful combination of the 
information generated by the Human Genome Project and technical advances such as 
microarrays enables attempts to identify genes responsible for inherited disorders more 
possible  than  ever  before.  Starting  with  even  modest  pedigrees  of  only  a  few 
individuals,  or  even  single  individuals,  it  is  now  possible  to  identify  the  gene(s) 
involved in the inherited disease.  
 
1.9 Disease gene identification 
There  is  no  single  pathway  to  guarantee  success  in  identifying  a  causative  gene. 
Disease causing genes may be identified by two methods; whole genome candidate 
gene  approach  and  by  linkage  analysis.  Whole  genome  candidate  gene  analysis 
involves  selecting  possible  causative  genes  across  the  genome.  By  applying  this 
approach, it is possible to identify genes and gene variants that have not previously                                                                                                Chapter 1 Introduction                                   
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been associated with a particular disease. Disease causing genes may, on
 one hand, be 
identified  based  on  functional  information  about
 the  disease  and/or  on  genetic  map 
information obtained by linkage
 analysis. A drawback to this is that it can only be used 
on known or previously identified genes, however linkage analysis is the most common 
and conventional way to identify a disease causing gene.  
 
1.9.1 Linkage analysis 
Linkage disequilibrium occurs where alleles at two or more loci appear together in the 
same individual more often than would be expected by chance (LaFramboise et al., 
2009) In this approach, the aim is to find out the approximate location of the gene 
relative to another DNA sequence called a genetic marker, which already has a known 
location on the chromosome. The principals of linkage are simple, in that we inherit 
maternal and paternal alleles, in which there are sequence variants. When this involves 
a disease allele, it should be easy to distinguish from the normal allele by searching for 
incidents of disease in the family tree. 
 
1.9.2 Genetic markers 
Genetic markers are DNA sequences that show a physical location on a chromosome 
and whose inheritance can be followed. A marker can be a gene, or it can be some 
section of DNA with no known function (Smith and Ebrahim 2004). Because DNA 
segments  that  lie  near  each  other  on  a  chromosome  tend  to  be  inherited  together,                                                                                                Chapter 1 Introduction                                   
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markers are often used as indirect ways of tracking the inheritance pattern of a gene 
that has not yet been identified, but whose approximate location is known.  
Genetic markers first became of use in the 1980’s, when it was discovered that DNA 
polymorphisms  can  be  used  as  a  marker system  due  to  their prevalence  across  the 
human genome. Commonly used genetic markers include RFLPs (restriction fragment 
length polymorphisms), VNTRs (variable number tandem repeats) and SNPs (single 
nucleotide polymorphisms).  
 
 
1.9.3 Single nucleotide polymorphisms (SNPs) 
SNPs are DNA sequence variations that occur when a single nucleotide is altered. For a 
variation to be considered a SNP, it must occur in at least 1% of the population. SNPs 
compose about 90% of all human genetic variation occurring every 100 to 300 bases 
along the 3-billion-base human genome (Chakravarti, 2001). SNPs may occur in both 
coding and non-coding regions of the genome and these changes can have a major 
effect  on  a  person’s  response  to  a  disease,  toxins,  and  chemicals  (McCarthy  and 
Hilfiker  2000).  Until  recently,  the  majority  of  gene-mapping  studies  have  focused 
primarily on SNPs in human disorders. However another type of DNA variation has 
been  recognised  as  an  important  source  of  genetic  variation,  these  are  called  copy 
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1.9.4 Copy Number Variation (CNV) 
Initially it was assumed that the majority of genetic variation in the genome was due to 
SNPs. However over the past number of years there is a growing interest in the study of 
structural genetic variation. Copy number variants (CNVs) are now thought to be a 
prevalent form of common genetic variation and represent a large proportion of genetic 
variability in human populations (Ionita-Laza et al., 2008). A CNV is described as a 
DNA segment that is 1 Kb or larger and present at variable copy number in comparison 
with a reference genome (Redon et al, 2006).  Deletions, insertions, duplications and 
complex  multi-site  variants  are  collectively  called  CNVs  or  copy  number 
polymorphisms  (CNPs)
  (Redon  et  al,  2006).    In  comparison  to  the  well-developed 
resources  for  SNP  analysis,  CNV-association  studies  are  still  in  the  early  stages, 
however the development of statistical tools and databases is anticipated in the coming 
years. 
Since the completion of the mapping of the human genome, an immense amount of 
data has been collected. Vast amounts of data associated with disease causing genes, 
novel SNPs and other information associated with both coding and non coding regions 
of genes has been gathered. All of this data has had to be collected, stored and analysed 
in  depth. This has  encouraged  the  development  of databases  and  has  promoted  the 
development of bioinformatics. 
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1.9.5 Databases and Bioinformatics 
Over the past decade or so, there has been a great increase of genetic databases and 
biobanks, which promise to increase the understanding the way our genes interact with 
the environment. These databases are a crucial resource for identifying disease causing 
genes.  Technologies  such  as  genome-sequencing,  microarrays,  proteomics  and 
structural genomics have provided vital information for many living organisms, and 
researchers are now focusing on how the individual components fit together to build 
systems (Collins et al., 2003). There is an ongoing and growing need to collect, store 
and  interpret  all  of  this  information  in  ways  that  allow  its  efficient  retrieval  and 
utilization. The European Bioinformatics Institute (EMBL-EBI), which is part of the 
European Molecular Biology Laboratory (EMBL), is one of the few places in the world 
that has the resources and expertise to fulfill this important task. Its aim is to develop a 
software  system  that  produces  and  maintains  automatic  annotation  on  eukaryotic 
genomes.  The  use  of  programs such as  Ensembl,  allows  us  to  retrieve data  on  the 
genomes of numerous species. It gives the genetic sequence and structure of thousands 
of genes. Access to such information allows for the interpretation and prediction of 
gene makeup. 
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1.10 Mutation Identification Techniques  
Mutation detection techniques are based on testing DNA samples for changes in or near 
the  relevant  gene.  Currently  the  most  common  means  is  through  automated 
fluorescence sequencing, as it is quick and cheaper than other methods. Alternative 
methods include denaturing high performance liquid chromatography (dHPLC), single 
strand confirmation polymorphism (SSCP) and quantitative PCR. Direct sequencing 
has surpassed these methods due to its efficiency and accuracy in mutation detection 
(Han et al., 2004). Methods such as SSCP are based on heteroduplex analysis, which 
uses electrophoretic mobility in gels to identify abnormalities.  
 
1.10.1 Identifying and confirming disease causing mutations 
A  very  important  factor  when  determining  a  disease  gene  is  to  confirm  that  the 
pathogenic  change  segregates  with  the  disease  phenotype  within  a  pedigree.  This 
change  must  be  tested  in  a  control  panel  of  unrelated  ethnically  matching  control 
individuals.  A  mutation  can  also  be  tested  using  a  restriction  digest,  which  is  an 
enzymatic technique used to cleave DNA at specific sites yielding fragments of specific 
sizes (Botstein et al., 1980). A mutation can either create or delete specific restriction 
fragment sites. Other methods such as direct sequencing analysis and SSCP can also be 
used to test this segregation. Once a gene has been identified as being implicated in a 
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how  it  changes  when  it  possesses  a  mutation.  Sometimes  there  is  a  wealth  of 
information  available  in  relation  to  the  gene  and  the  genes  function,  however, 
occasionally the identified gene is novel and its structure and expression have to be 
established. Characterisation of a novel gene involves determining the full coding and 
non coding regions, along with 5’ and 3’ untranslated regions (UTRs).  
 
1.11 Further Analysis of a Novel Gene 
1.11.1 Protein Structure Identification 
Protein structure is also an important feature to identify the proposed function of the 
gene implicated in a disorder. Domains identified in the protein are compared with 
domains of characterised proteins to predict the function of this new protein. A protein 
domain  is  the  part  of  the  protein  structure  that  can  evolve,  exist  and  function 
independently of the rest of the protein (Jain et al., 2009). Each domain in a protein 
forms  a  three-dimensional  structure  and  can  be  often  independently  folded.  It  is 
common  for  proteins  to  have  several  structural  domains  and  vary  in  length  from 
between 25 amino acids up to 500 amino acids and are evolutionary conserved. This 
conservation is essential when identifying the structure and function of a novel protein. 
If  homology  is  identified  between  the  protein  structure  of  the  novel  protein  and  a 
previously characterised protein, then the function of this new gene can be speculated.  
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1.11.2 Functional analysis of a novel protein 
Antibody production is the primary step in the investigation of the functional study of a 
gene of interest. Antibodies are tools to demonstrate both the presence and the sub 
cellular  localisation  of  a  protein  through  the  antigenic  epitopes  in  the  polypeptide. 
Studies to investigate the function of a novel gene include studies of the normal gene in 
living  cells  and  tissue.  Immunohistochemical  and  immunocytochemical  techniques 
utilise the antibody that targets the specific protein through the use of other labeled 
antibodies or markers (Ramos-vara, 2005). Other experiments involve examining the 
same normal gene in animal models such as mice, rats or fruit-flies. Similar studies to 
those performed for the normal gene must also be executed on the mutated copy of the 
gene, to investigate how the changes alter the function of the protein that the gene 
encodes. 
 
 
1.12 RP25 Locus and refinement of Locus 
1.12.1 Background 
The RP25 gene is the 26
th gene to be identified for arRP (Abd El-Aziz et al., 2008). 
The  locus  for  RP25  was  originally  established  through  homozygosity  mapping  by 
targeting functional candidate genes. Four Spanish families with arRP were initially                                                                                                Chapter 1 Introduction                                   
 
  44
linked  to  a  region  on  chromosome  6q  between  microsatellite  markers  D6S257  and 
D6S1644  (Ruiz  et  al.,  1998).  The  linkage  was  further  refined  when  another  three 
families were linked to the interval (Figure 1.7).The region flanked by microsatellite 
markers spans ~ 34 Mb in size and has approximately 110 genes mapped in between 
these  markers.  The  clinical  data  for  five  of  these  families  is  depicted  in  table  1.2. 
Candidate genes were initially selected based on their known function of expression 
patterns and other genetic data available on the genes. Several genes such as GlcAT-S 
(Marcos et al., 2002) and RAB23 (Marcos et al., 2003) were selected as good candidate 
genes  based  on  their  expression  profiles.  GlcAT-S  was  selected  due  to  its  high 
expression level in the retina and RAB23 was selected because proteins belonging to the 
Rab family had previously been implicated in retinal degenerations. Several more genes 
were  also  selected  and  excluded  as  causative  genes  for  RP25,  these  included 
KHDRBS2, PTP4A1, KIAA1411, OGFRL1 and FAM46A (Abd El-Aziz et al., 2005) 
(Barragan et al., 2008). Further information on candidate gene selection is found in 
section 3.1. A strategy was also undertaken to divide the interval into 4 regions, A, B, C 
and D (Section 3.1) based on the linkage of another family of Pakistani origin which 
mapped  north  of  the  RP25  interval  (Figure  1.8),  three  Chinese  families  were  also 
mapped to the RP25 interval (Abd El- Aziz et al., 2007).  
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1.12.2 Families of other ethic origin linked to RP25 
1.12.2.1 Pakistani family 
 
Further to the linkage of Spanish families, in 1999 Khaliq and colleagues mapped a 
Pakistani family to the same interval. In the study 20 members of a consanguineous 
family who displayed features of autosomal recessive retinitis pigmentosa were used. 
Such  features  included  night  blindness  commencing  at  approximately  25  years  and 
deterioration of central vision at ~30  years of age. All 12 affected members of the 
family were  analysed.  Genomic  DNA  from each individual was  collected  and  they 
were genotyped for microsatellite markers for all the known arRP loci. When linkage 
was discovered on 6q, further polymorphic markers from this region were analysed to 
determine whether analysis of recombinant individuals within the family would permit 
further refinement of the published disease interval (Figure 1.8).  
 
1.11.2.2 Chinese families linked to the RP25 interval 
 
Three non-consanguineous Chinese families were also linked to the RP25 interval and 
were linked using a 10K GeneChip. This was undertaken to detect regions of shared 
haplotypes between the affected members in each family. The three Chinese families 
were annotated RP10, RP112 and RP116 respectively (Figure 1.8).  
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Table 1.2 Clinical Characteristics of RP25 patients: 
Family      Age        Age of onset       Symptoms          Visual fields     Fundus          ERG 
 
RP5          56    15                 N,VFC,VAR       CC IN BE       BS & POD     NR BE 
RP73        36           20                    N,VFC,VAR       CC in BE        BS & POD     NR BE 
RP167      57           38                    N,VFC,VAR       CC in BE        BS & POD     NR BE 
RP214      37           30                    N,VFC                CC in BE        BS & POD      NR BE 
RP299      38           15                    N,VFC                CC in BE        BS & POD      NR BE 
 
N: Nyctalopia                                 VFC: Visual field constriction 
VAR: Visual acuity reduction        CC: Concentric constriction 
BE: Both eyes                                 BS: Bone spicules 
POD: Pale optic disc                       NR: Not recordable  
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Figure 1.7 Seven Spanish families linked to the RP25 interval. The arrows denote which members of the 
family were first affected with RP. The families which are consanguineous are RP5 and RP167, and 
nonconsanguineous are RP235, RP260, RP73, RP214 and RP299. The arrows denote which members of 
the families were first identified as having arRP symptoms. The asterisk corresponds to the DNA of 
members we had available for use in the screening process. 
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Figure  1.8  Overview  of  the  arRP  Spanish  affected  families,  along  with  the  Pakistani  and  Chinese 
families whom have been linked to the RP25 interval. The Pakistani family has been linked to an interval 
of 8.61 Mb spanning from microsatellite marker D6S257 to D6S1053. The combined Chinese families 
span an interval of 16.1 Mb, from microsatellite marker D6S257 toD6S421. 
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1.12.3 Chromosome 6q an important interval for retinal degenerations 
Another  important  aspect  of  this  study  is  that  chromosome  6q  is  a  central  genetic 
interval  for  several  other  retinal  degenerations.  These  include,  cone  rod  dystrophy 
(CORD7),  leber  congenital  amarousis  (LCA5),  dominant  drusen  (DD)  and  several 
others  (Figure  1.9).  The  occurrence  of  multiple  loci  so  closely  mapped  in  this 
chromosomal  region  could  indicate  the  presence  of  a  number  of  retinal  genes  in 
continuum, since the phenotype of all these retinal dystrophies, their ophthalmologic 
appearance, age at onset, and the extent and pattern of visual loss are varied (Dharmaraj 
et al., 2000). The other theory was that one single large gene in this region would be 
the cause of numerous retinal degenerations, as in the case of ABCR. Mutations in this 
gene cause numerous retinal degenerations including arRP (Martinez-Mir et al., 1998) 
cone-rod dystrophy (Cremers et al., 1998) and recessive Stargardt disease (Kaplan et 
al., 1993).   
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Figure 1.9 Depiction of chromosome 6 and of the corresponding retinal disease associated genes and 
loci. Note the location of the RP25 locus (red) between microsatellite markers D6S257 and D6S1644. 
Disorders include Cone-rod dystrophy (CORD7), Stargardt disease (STGD3), Dominant drusen (DD), 
Leber Congenital Amaroursis (LCA5), Benign concentriannular macular dystrophy (BCAMD), North 
Carolina  Macualr  degeneration  (MCDR1).  The  colours  of  the  genes  correspond  to  the  same  colour 
disorder. 
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1.13 Aim of Project 
 
The  aims  of  this  project  include  systematically  selecting  and  sequencing  candidate 
RP25 genes in the RP25 interval. Alternative methods to identify mutations including 
CNV analysis is also incorporated into the study. Further aims of the project include 
recruitment of more RP25 affected families to narrow down the RP25 interval. The 
overall goal of the project is to identify the RP25 gene and to determine the possible 
function of this disease causing gene.  
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                       Chapter 2 
               Materials and Methods 
2.1 PCR 
The  polymerase  chain  reaction  (PCR)  is  a  biochemical  and  molecular  biological 
technique. It is used to isolate and amplify specific fragments of DNA exponentially. 
PCR is a relatively recent invention, only created in 1983 by Kary Mullis and is a 
commonly  used  technique  in  biological  research.  It  can  be  used  to  clone  genomic 
sequences with great efficiency, directly sequence genomic and mitochondrial DNA, 
and  also  to  analyse  nucleotide  sequences  (Bartlett  and  Stiling  2008).  The  overall 
purpose of PCR is to generate a large number of copies of a particular sequence; which 
is crucial in generating enough starting template to enable downstream applications. 
 
2.1.1 The cycling reactions 
There are three major steps in PCR, which are repeated for 30 or 40 cycles. This is 
done on an automated cycler, which can heat and cool the reaction mixture in a very 
short time. These include  
1: Denaturation at 94°C during which, the double stranded DNA melts open to single 
stranded DNA, all enzymatic reactions stop. Initial denaturation is at 94°C for 3 min, 
35 cycles of denaturation at 94°C for 30 seconds.  
2: Annealing at 55-68°C. In this step, the primers are moved around; hydrogen bonds 
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stranded template. This is known as the annealing stage and occurs at 55°-68°C for 30 
seconds (depending on the required annealing temperature). 
3: Extension at 72°C: The temperature in this step is ideal for the polymerase to work. 
The bases (complementary to the template) are coupled to the primer on the 3'  side (the 
polymerase adds dNTPs from 5 '  to 3 ' , reading the template from 3 '  to 5 '  side; bases 
are added complementary to the template). Extension at 72°C for 30 seconds (time 
depends on the size of the amplicon), final extension step of 72°C for 5 min. 
2.1.2 Taq polymerase 
The  enzyme  used  in  the  PCR  reaction  is  called  Taq  polymerase.  It  is  a  highly 
thermostable DNA polymerase from the thermophilic bacterium Thermus aquaticus. 
The enzyme catalyzes template-dependent polymerization of nucleotides into duplex 
DNA  in  the  5  ' =>3  '   direction.  Taq  DNA  Polymerase  exhibits  deoxynucleotidyl 
transferase activity, which frequently results in the addition of extra adenines at the 3 ' -
end of PCR products (Peake, 1989).  
 
2.1.3 Parameters for PCR 
All PCR reactions carried out in this study were performed in 25￿l reaction volume 
containing 1X buffer (10X NH4 buffer, Bioline, UK), MgCl2 (1.5, 2.5 and 3.5 mM, 
Bioline,  UK),  0.2  mM  deoxynucleoside  triphosphate  (dNTPs:  dATP,  dCTP,  dGTP, 
dTTP, Promega, UK), 10 pmoles of each primer, 0.5 unit of taq polymerase (Bioline,                                                                                 Chapter 2 Materials and Methods 
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UK) and ~100ng of DNA. Amplification reactions were performed using a Thermal 
Cycler equipped with heated lids. The amplification conditions are as above. 
 
2.1.4 Special parameters 
For  GC  rich  areas,  buffer  3  (containing  22.5  mM  MgCl2;  supplied  by  Boehringer 
Manheim GmbH-Germany) together with dimethyl sulphoxide DMSO  5% or  ready 
mix (AB-0975; ABgene, UK) were used. 
 
2.1.5 Annealing temperature and primer design 
Both  primer  length  and  annealing  temperature  are  fundamental  components  when 
preparing  a successful  PCR reaction. The  melting temperature of  a duplex reaction 
increases both with its length, and with increasing (G+C) content. There is a simple 
formula to calculate the melting temperature (Tm): Tm=4(G+C) +2(A+T)ºC 
The annealing temperature was dependent on length and nucleotide composition of the 
primers. The length of primers would generally be between 18 and 27 nucleotides, the 
difference between Tm of both primers should be no greater than 4°C.  There should 
also be a random base distribution, 40-60% GC within the primer designed. Along with 
these rules, it is also necessary to ensure low complementary of each primer to each 
other, to avoid the formation of primer dimmers. In this project, the software program 
Primer 3 Output (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) was used 
to  design  primers,  commercially  synthesised  primers  were  purchased  from  Sigma                                                                                 Chapter 2 Materials and Methods 
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Aldrich  (http://www.sigmaaldrich.com/united-kingdom.html).  See  appendix  for  table 
of primers used in this thesis. 
2.2  Agarose Gel Electrophoresis 
Gel electrophoresis is a method used to separate DNA and RNA molecules based on 
size. Separation was performed by an electrical current supplied to the gel tank. To 
prepare the gel for the separation a substance called agarose was used. Agarose comes 
from a family of polysaccharides called agars that are obtained from algae such as 
seaweed  and  structurally  it  is  a  galactan  (galactose  polymer)  (Yaphe  1984).  It  is 
purified  from  agar  and  different  purities  are  available  with  varying  melting 
temperatures.  
Depending on the concentration of the gel and the purpose of its use (whether RNA or 
DNA analysis) a quantity of agarose was weighed in a clean conical flask. A relative 
amount of 1X TAE buffer was added to the agarose powder and was mixed gently. The 
mixture was heated in a microwave to allow the agarose to dissolve. Once the mixture 
had  cooled  to  approximately  50°C,  ethidium  bromide  was  added.  This  is  an 
intercalating intercalating agent which allows staining of nucleic acids (Biggiogera and 
Biggiogera 1989). A sealed loading tray with a set number of combs was prepared. The 
cooled  agarose  gel  was  poured  into  this  tray  and  left  to  set.  Once  the  gel  was 
polymerised,  the  combs  and  seals  were  removed  and  the  gel  was  placed  in  the 
electrophoresis  tank  (Gel  electrophoresis  apparatus  GNA-200,  Pharmacia,  Sweden) 
which contains 1X TAE buffer. An electrical current was run through the tank from                                                                                 Chapter 2 Materials and Methods 
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positive to negative. In the tank, the DNA samples mixed with the loading dye were 
added to each lane of approximately 10￿l. A suitable DNA ladder was also loaded to 
detect the size of each band. Electrophoresis was performed at 100-120 V for 30 min, 
gels were analysed using a biodoc-it imaging system (UVP). 
2.3 Purification of PCR products 
2.3.1 Montage cleanup purification 
The Montage SEQ96 Sequencing Reaction Cleanup Kit provides the filtration plate and 
the  solution  necessary  to  remove  contaminating  salts  and  unincorporated  dye 
terminators  from  DNA  sequencing  reactions.  It  is  based  on  the  incorporation  of  a 
vacuum  pump  and  the  filtration  plates.  The  vacuum-based  size  separation  platform 
eliminates  the  need  for  gel  filtration  or  bind-wash-elute  columns  that  require 
centrifugation. The protocol can be altered slightly depending on the concentration of 
the PCR products. Initially 80 ￿l dH2O was added to a 20 ￿l of the PCR products. The 
whole volume was transferred to the filtration plate and attached to the vacuum pump; 
which was set to vacuum for 10-15 min. 25 ￿l of dH2O was then added to the plate and 
was vacuumed again for 2-3 min. Finally 20 ￿l of dH2O was added to the plate which 
was left to shake on the vortex at 1000 rpm for 10 min to elute the DNA. The cleaned 
products were then collected; which were directly used for sequencing or were stored in 
the -20°C freezer for future use. 
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2.3.2 ExoSAP IT 
ExoSAP-IT  is  another  efficient  clean-up  system;  it  removes  contaminants  while 
utilising  two  hydrolytic  enzymes,  Exonuclease  I  (SAP,  QAmersham  LifeScience, 
Buckinghamshire, UK) and Shrimp Alkaline Phosphatase (United States Biochemicals, 
Ohio,  USA)  mixed  together  in  a  specially  formulated  buffer,  to  remove  unwanted 
dNTPs  and  primers  from  PCR  products.  Exonuclease  I  removes  residual  single-
stranded primers and any extraneous single-stranded DNA produced in the PCR; while 
Shrimp Alkaline Phosphatase removes the remaining dNTPs from the PCR mixture 
To set up the exosap reaction, 1 ￿l of the amplified PCR product was mixed with 
16.5￿l  of  dH2O  along  with  the  enzyme  mix  exoSAP  IT.  This  combination  was 
incubated at 37°C for 15 min followed by 80°C for another 15 min to deactivate the 
enzyme. The product was used for the following sequencing reaction.  
2.4 Automated DNA sequencing 
Automated DNA sequencing uses a fluorescent dye to label nucleotides rather than 
using  a  radioactive  isotope.  Fluorescent  dye  can  be  used  without  any  special 
requirements or reagents that hazardous to use in any way. Rather than using X-ray 
film  to  analyses  the  sequence,  a  laser  is  used  to  stimulate  the  florescent  dye.  The 
emissions are collected and the wavelengths are determined. In this study, the ABI 
3100 sequencer was used to analyse sequences. For ExoSAP the following protocol 
was used: the product (18￿l) was mixed with 0.5￿l Big Dye and 0.5￿l of forward or                                                                                 Chapter 2 Materials and Methods 
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reverse sequence specific primers and 2.5￿l sequencing buffer (Applied Biosystems). 
Cycle sequencing reactions were performed in the thermal Cycler and the temperature 
cycling profile consisted of initial denaturation at 96°C for 3 min followed by 25 cycles 
of denaturation at 95°C for 10 seconds, annealing at 50°C for 5 seconds and then 4 min 
at 60°C, and finally a further extension at 4°C for 2 min. After completion of the cycle 
sequencing  reaction  the  DNA  was  precipitated  using  sephadex  clean  up  protocol. 
Sephadex powder (Sigma, UK) was put into a Millipore multiscreen plate. 350￿l of 
dH2O was added to each well. A collection plate was placed underneath the multiscreen 
plate, and the plate was spun for 5 min at 900 rpm. 100 ￿l of dH2O was then added to 
each well. The plate was again spun for 5 min at 900 rpm. Finally the DNA samples 
were added to the plate and the final spin was run for 5 min at 900 rpm. 10￿l of dH2O 
was added to each well of the collection plate and the DNA samples were read by the 
automated DNA sequencer. Sequences were analysed using Seqman software package. 
2.5 Restriction Enzyme Digest Analysis 
Restriction digests were performed on PCR products to identify if a mutation is present 
in a selected patient or panel of control DNA samples. For PCR product digests, a total 
volume of 20￿l containing  2￿l 10X buffer 2, 0.2￿l 1X Bovine serum Albumin (BSA) 
to  enhance  the  enzymatic  activity,  10￿l  PCR  product,  0.5-1.0￿l  of  the  appropriate 
enzyme (1 units) and 7.3￿l dH2O was used. The reactions were then incubated for at 
least 2 hrs or overnight at the specified temperature for the enzyme (usually 37°C). 
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gel  electrophoresis  (see  previously  section  2.2).  Enzymes  were  obtained  from  New 
England BioLabs (UK) or Promega, UK. 
 
2.6 SMART RACE cDNA Amplification 
The SMART RACE cDNA Amplification Kit (Clontech, France) provides a method 
for performing both 5`- and 3`- rapid amplification of cDNA ends (RACE). This kit 
integrates  the  Marthon  cDNA  Amplification  Kit  with  the  SMART  (Switching 
Mechanism At 5` end of RNA Transcript) cDNA synthesis technology. This powerful 
combination allows isolation of the complete 5` sequence of the target transcript. The 
SMART RACE Kit includes recent advances in the PCR technology that both increases 
the sensitivity and reduces the background of the RACE reactions. SMART technology 
provides  a  mechanism  for  generating  full-length  cDNAs  in  reverse  transcription 
reactions (Zhu et al, 2001)  
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Figure 2.1 Overview of RACE protocol. Adapted from Roche website.  
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2.6.1 Primer Design 
Gene specific primers (GSPs) are for the 5` and 3` RACE reactions. These must be 
between 23 and 28 base pairs in length, must have a GC content over 50%, and a Tm > 
70°C.  
 
First-strand cDNA synthesis 
To prepare cDNA for 5` and 3` RACE , 1- 3￿l of the RNA sample was added to a 
cDNA specific primer (CDS primer A) and 1￿l SMART II A oligonucleotide. Sterile 
H2O was added to each tube to make up a volume of 5￿l for each reaction. Contents 
were spun briefly in a centrifuge, and incubated at 70° for 2 min. Tubes were cooled on 
ice for 2 min, and again spun briefly. The following were added to each tube: 2￿l of 5X 
first-strand  buffer,  1￿l      DTT  (20mM),  1￿l      dNTPs  (10mM),  1￿l        PowerScript 
Reverse Transcritase to make a total volume of 10 ￿l. The contents were again spun 
down and incubated at 42°C for 1.5 hr in a thermal cycler. The products were diluted 
with 250 ￿l of tricine-EDTA buffer, the samples were heated at 72°C for 7 min. The 
samples were stored at -20°C for up to 3 months.  
 
Positive Control RACE experiment 
Prior to performing RACE with our own template, a positive control RACE experiment 
was performed using the control Human Placental Total RNA provided with the kit. A 
master mix was prepared. For each 25 ￿l PCR reaction, the following reagents were 
added:17.25 ￿l PCR-grade water, 2.5 ￿l  10x Advantage 2 PCR Buffer, 0.5l ￿l dNTP 
Mix, 0.5l ￿l 50X Advantage 2 Polymerase Mix to make to a total of 20.75 ￿l.                                                                                  Chapter 2 Materials and Methods 
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To prepare for a PCR the below table outlines the order and the components of each 
tube 
 
Table 2.1 PCR preparation for the 5`-RACE and 3`-RACE reactions: 
 
Component 
 
5`  RACE 
control 
3`RACE 
control 
Internal 
Control  (5`-
cDNA) 
Internal  Control 
(3`-cDNA) 
Control  5`  RACE 
Ready cDNA 
1.25 ￿l    _______  1.25 ￿l  ________ 
Control  3`-RACE 
Ready cDNA 
______  1.25 ￿l  ____________  1.25 ￿l 
5`-RACE  TFR 
Primer (10 M) 
0.5 ￿l  _______  0.5 ￿l  0.5  ￿l 
3`-RACE  TFR 
Primer (10 M) 
______  0.5  ￿l  0.5 ￿l  0.5  ￿l 
UPM (10X)  2.5 ￿l  2.5 ￿l  _________  ________ 
Master Mix  20.75 ￿l   20.75 ￿l  20.75 ￿l  20.75  ￿l 
Final Volume  25 ￿l   25 ￿l  25 ￿l  25 ￿l 
 Footnote  
 TFR-gene specific primer for transferrin 
 UPM: Universal Primer Mix. 
 
Thermal cycling was undertaken using the following touchdown PCR program. The 
following reaction was set up: 5 cycles at 94°C for 30 seconds, then at 72°C  for 3 min.  
This was followed by another 5 cycles at 94°C 30 seconds, followed by 70°C for 30 
seconds, and at 72°C for 3 min. The final set of cycles consisted of 27 cycles at 94°C 
for 30 seconds, 68°C for 30 seconds and 72°C for 3 min. Finally, it was possible to 
generate the 5`-RACE and 3`-RACE PCR fragments. PCR Master mixes were made up 
for each reaction: 17.25 ￿l   PCR-grade water, 2.5 ￿l, 10x Advantage 2 PCR Buffer, 0.5 
￿l dNTP Mix, 0.5 ￿l 50X Advantage 2 Polymerase Mix to make a total volume of                                                                                 Chapter 2 Materials and Methods 
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20.75  ￿l.  These  were  mixed  well  by  vortexing.  The  following  tables  depicts  the 
preparation for the 5`-RACE and 3`-RACE. 
         Table 2.2 Preparation for the 5`-RACE and 3`-RACE reactions. 
 
 
 
 
 
 
 
 
 
 
           Footnote: 
           GSP-gene specific primer 
 
2.6.2 Alternative cDNA synthesis protocol 
cDNA  was  prepared  from  RNA  using  SuperScript™  II  Reverse  Transcriptase 
(Invitrogen, UK). 1mg of RNA was added to RNase free tube and was made up to 4ml 
with RNase free water. These tubes were then placed in a water bath at 65°C for 10 
min. The tubes were put on ice immediately and were then spun down and a reaction 
mix made of the following components: 5ml of 5x First Strand buffer, 2ml of 0.1 M 
Component   1: 5`/3`-
RACE 
sample 
2: 5`/3`-
TFR (+ 
Control) 
3: GSP 1 
+ 2 (+ 
Control) 
4: UPM 
only (- 
Control) 
5: GSP1 
only (-
Control) 
5`/3`-RACE-
Ready 
cDNA 
1.25 ￿l  1.25 ￿l  1.25 ￿l  1.25 ￿l  1.25 ￿l 
UPM (10X)  2.5 ￿l  2.5 ￿l  _______
_ 
2.5 ￿l  _______ 
GSP1 (10 M)  0.5 ￿l  _______  0.5 ￿l  _______  0.5  ￿l 
GSP2 (10 M)  ______  _______  0.5 ￿l  _______  _______ 
Control 
5`/3`-RACE 
TFR  Primer 
(10  M) 
         
_______           
 
0.5 ￿l 
 
_______ 
 
_______ 
 
_______ 
H2O  _______  _______  2  ￿l  0.5 ￿l  2.5  ￿l 
Master Mix  20.75 ￿l  20.75 ￿l  20.75 ￿l  20.75 ￿l  20.75 ￿l 
Final 
Volume 
25 ￿l  25 ￿l  25 ￿l  25 ￿l  25 ￿l                                                                                 Chapter 2 Materials and Methods 
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DTT (Dithiothreitol), SuperScript™ II Reverse Transcriptase (Invitrogen, UK), 2 ml of 
dNTP mix (Promega, UK), 1ml RNasin
Ò Plus RNase Inhibitor (Promega, UK), 1ml of 
pd (N6) random hexamers (Amersham Biosciences, UK) and was added and the total 
volume  made  up  to  16  ml  with  RNase  free  water.  This  was  added  to  the  cDNA 
synthesised and was kept at 37°C for 2 hrs. The samples were then stored at -20°C. 1ml 
of these samples were then subjected to the Quantitect Probe RT-PCR reaction. 
2.7 RT-PCR 
The principles of RT-PCR are straight forward and the protocol included three main 
steps. 1-RNA was reverse transcribed to cDNA using a reverse transcriptase enzyme 
and primers. This is also known as the reverse transcription step. 2- The dsDNA was 
denatured at a high temperature so the two strands separated and the primers can bind 
at a lower temperature and start a new reaction. 3- The DNA extension step involved 
using thermostable Taq DNA polymerase at 72°C. This is a highly sensitive technique, 
even detecting very low copy numbers of RNA. 
2.8 Immunohistochemistry (IHC) 
 
Immunohistochemistry is the demonstration of antigens within tissue sections by means 
of specific antibodies and the binding of antigen-antibody is demonstrated through a 
coloured histochemical reaction visible by light microscopy or fluorochromes with UV 
(Ramos-Vara 2005). There are numerous immunohistochemical methods that may be 
used  to  localise  antigens.  The  selection  of  a  suitable  method  should  be  based  on                                                                                 Chapter 2 Materials and Methods 
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parameters  such  as  the  type  of  specimen  under  investigation  and  the  degree  of 
sensitivity required.  
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Figure 2.2 Overview of immunohistochemical protocol. The target protein (pink) is targeted using a 
specific antibody raised against a peptide in this protein. The antibody (red) attaches to the protein of 
interest. A secondary antibody (green) is added. This is usually fluorescently tagged. This binds to the 
primary antibody and emits a signal.  
 
 
 
 
Target 
Protein 
Primary 
Antibody 
Secondary 
Antibody 
Fluorescent 
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2.8.1 Preparation of eye pieces 
Porcine eyes were sourced from a local abattoir, where boars or sows were sacrificed in 
the morning and the eyes extracted within 1 hr of slaughter. The eyes were immediately 
transported to the laboratory; the retina was extracted and instantly transferred into a 
fixative solution. On the first day, the pig was sacrificed; the eye was removed with 2-3 
mm of the optic nerve. The cornea and lens were carefully removed so as not to cause 
retinal detachment. The eye was cut into pieces using sterile instruments and is left in 
4% paraformaldehyde (PFA) in the fridge overnight. The next day, the eye piece was 
rinsed with 1xPBS 3 times each for 15 min consistently on a shaker. The piece was 
then  placed  in  5%  sucrose  solution  diluted  in  1x  PBS  and  left  to  shake  at  room 
temperature  for  30’.  The eye  piece  was  methodically transferred  into  a  gradient  of 
sucrose diluted solutions. The sucrose gradients were as follows: 2/3 5% sucrose and 
1/3 20% sucrose, ½ 5% sucrose and ½ 20% sucrose, 1/3 5% sucrose and 2/3 20% 
sucrose, all for 30’ shaking at room temperature. Finally, the eye piece was left in 20% 
sucrose at 4°C. The next day, it was placed in 2/3 20% sucrose and 1/3 OCT (freezing 
medium, Thermos biolabs UK) and was left to shake slowly at room temperature for 
30’. The eye piece was then placed in a cylinder of OCT only at room temperature for 
30’. Using a forceps the eye piece was orientated in a small plastic cylinder of OCT. A 
plastic beaker filled with 2-Methlybutane was dipped into a flask of liquid nitrogen. 
The plastic container with the eye was then placed into the 2-Methlybutane until the 
OCT freezes completely. The eye piece was then stored at -80°C. 
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2.8.2 Cryosectioning of eye pieces 
The eye pieces were removed from the -80°C freezer and placed inside a cryostat. The 
cryostat was prepared in the following way, a blade was placed inside the cryostat, and 
the eye piece embedded in OCT was removed from its plastic holder. This was then 
placed in fresh OCT and was left to set inside the cold cryostat. Once set, it was placed 
horizontally from the blade and sections were cut and disposed of. Once the eye piece 
was clearly visible, the cryostat was set to 10µm and sections were cut one at a time. 
These were then placed carefully on the surface of superfrost ultra plus slides (Thermo 
Scientific, UK). The slides were labelled; kept cold until all are collected, and are then 
stored in the -80°C freezer. 
2.8.3 Immunohistochemical Protocol and parameters 
IHC experiments have many parameters by which they may success of fail by. One of 
the major parameters is the production of a good antibody. Another is the quality of 
tissue being used. The tissue must be relatively fresh and be stored adequately. Tissue 
is usually stored in PFA, as this is found to be a very good tissue structure preserver. In 
many  instances,  an  antigen  signal  many  be  difficult  to  obtain.  In  such  cases  pre-
treatment solutions are required; these include using sodium borohydride, TRIS citrate 
and citrate acid. For pig retina sections the most successful pre-treatment was sodium 
borohydride.  
 
                                                                                 Chapter 2 Materials and Methods 
 
  69
2.8.3.1 Pre-treatments 
 
In  the  event  of  unmasking  an  antigen  signal, pretreatment  solutions  such  as  Sudan 
black  and  sodium  borohydride  (Sigma  Aldrich,  UK)  are  often  integrated  into  the 
immunohistochemical protocol. Sudan black B is a fat soluble dye used for staining 
neutral  triglycerides  and  lipids  on  frozen  sections.  Sodium  borohydride  is  a  white 
powder that is soluble in water. It is recognised as a successful treatment to unmask 
antigens,  particularly  in  glutaraldehyde  fixed  tissue  by  reducing  glutaraldehyde 
linkages (Robinson, 2001). For these experiments the most successful pretreatment was 
sodium borohydride. 
 
 
1:Pretreatment with Sodium borohydride 
Frozen sections were removed from the -80°C freezer, and were placed in a slide tank 
of 0.1% sodium borohydride. The sections were left in solution for 30 min, after which 
they were transferred to another slide tank with of 1% tris buffer saline (TBS). The 
sections were left to shake for 10 min. 
 
2:Immunolabelling for Cryo-sections (Standard) 
A hydrophobic pen was used to outline a small area around the retinal section on the 
slide and the sections were blocked for one hr at room temperature, in 0.1% normal 
goat serum (NGS) in 0.1% triton-X with phosphate buffer saline (PBS solution) (PBS-
triton) in a humidity chamber. The slides were washed three times in PBS-triton for 10                                                                                 Chapter 2 Materials and Methods 
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min  each,  and  incubated  with  the  primary  antibody  (diluted  according  to  the 
manufacturer’s recommendation or in serial or different dilutions for novel antibodies, 
in  2%  NGS  in  PBS-triton)  for  one  hr  at  room  temperature  or  alternatively  at  4˚C 
overnight. The slides were washed three times  in PBS-triton for 10  min each. The 
corresponding secondary antibody was diluted 1:300 in 2% NGS in PBS-triton and the 
slides incubated at room temperature for an hr in the dark. The slides were washed 
twice in PBS-triton for 10 min each. The third wash included bisbenzamide (Sigma-
Aldrich, UK) (diluted according to the  manufacturer’s recommendation) which was 
incubated with the slides for 5 min. The slides were mounted with coverslips using 
ProLong Gold Antifade Mounting Medium (Invitrogen).  
 
3.Alternative immunostaining method: 
The slides were left to air dry for several hours. They were then washed with 1XPBS, 3 
times at 5 min each Block with 5% Normal Donkey Serum in 0.3% Triton X-100 in 
PBS,  incubated  for  1  hr  at  room  temperature.  Primary  antibody,  diluting  with  1% 
Normal Donkey Serum in 0.3% Triton X-100 in PBS was then prepared and these were 
washed briefly. The primary antibody was applied and left to incubate overnight at 
room temperature. They were then washed with 1XPBS, 3 times at 5 min each. The 
secondary antibody was then applied and incubated for 1 hr at room temperature. The 
slides were washed 1X PBS, 3 times for 5 min each. Apply DAPI, 1:5000 dilutions in 
PBS and incubate for 1 minute in the dark. Wash with 1X PBS, 3 times for 5 min each. 
They were again washed 1X TBS, 3 times at 5 min each, mounted with Vectashield, 
covered with a coverslip and sealed.                                                                                 Chapter 2 Materials and Methods 
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2.9 Immunocytochemistry (ICC) 
 
Immunocytochemistry is a universal laboratory practice used to stain cells with specific 
antibodies raised to identify antigens. There are a wide variety of fixatives commonly 
used. It allows for identification of expression of antigens in particular cell types.  
2.9.1 Methanol Fixation 
Methanol precipitates proteins, which preserve cytoskeletal proteins well, but not the 
morphology of the cell. Ice cold methanol (-20˚C) was added to each well (0.5ml per 
well) and the plate was transferred immediately to -20˚C and incubated for 5 min. The 
methanol was discarded and the cells rehydrated with 1X PBS buffer for 5 min at room 
temperature. The cells were then blocked with 1X PBS – 0.5% BSA – 20mM glycine – 
0.1% NaN3 for at least 15 min before proceeding with staining, or stored at 4˚C. 
2.9.2 PFA/Triton X-100 Fixation 
Paraformaldehyde  forms  cross-links  between  proteins  and  thereby  preserves  the 
morphology of the cell. Cells were fixed for 20 min in 3% PFA in 1X PBS, at room 
temperature. The cells were permeabilised using 1X PBA – 0.3% Triton X-100 – 0.3% 
BSA, (300￿l per well) and incubated for 5 min at room temperature. The cells were 
washed twice with 1X PBS – 0.5% BSA – 20mM glycine – 0.1% NaN3, and incubated 
for at least 15 min before proceeding with staining or stored at 4˚C. 
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2.9.3 Immunofluorescent Staining 
2.9.3.1 Cell Line-Y79 
 
Media was vacuumed off and cells were washed 3 times in 1X PBS. The cells were 
fixed  in  4%  PFA  in  PBS  for  15  min,  and  washed  3  times  in  PBS.  Cells  were 
permeabilised in 0.05% triton X 100 (Sigma, UK) for 10 min. Cells were then washed 
3 times in PBS.  5% BSA (bovine serum albumin) in PBS was used as a blocking 
reagent,  blocking  for  30  min.  Primary  antibodies  were  diluted  according  to  the 
manufacturer’s instructions in blocking solution (1% BSA in PBS). Cover-slips were 
incubated with the primary antibody at room temperature for 1 hr. Cover-slips were 
washed  3  times  in  blocking  solution  before  incubation  with  the  corresponding 
secondary antibody (diluted 1:300 in blocking solution) for 45 min at room temperature 
in the dark.  The cover-slips were washed 3 times in blocking solution and briefly 
stored in PBS before mounting onto slides using ProLong Gold Antifade Mounting 
Medium (Invitrogen). 
2.9.3.2 General Growth  
 
Cells  were  grown  in  T10  flasks  or  6-well  cell  culture  plates.  Cells  were  grown  in 
RPM1, supplemented with 20% heat inactivated stock fetal calf serum (First link UK 
Ltd)  and  5ml  penicillin/streptomycin  antibiotic  mixture.  Media  was  changed 
approximately twice a week. Cells were passaged according to confluence/density. All 
work was carried out under sterile conditions, under a fume hood                                                                                 Chapter 2 Materials and Methods 
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2.9.3.4 Cell Passage 
 
The media was aspirated and cells were washed once in sterile1X PBS. A mixture of 
trypsin/EDTA  was  used  to  detach  the  cells  from  flask;  3ml  of  pre-warmed 
trypsin/EDTA (37˚C) was added on top of the cells and left for 2-3 min at 37˚C to 
ensure that all the cells had detached. Fresh media (19ml, pre-warmed to 37˚C) was 
added to a fresh cell culture flask, and 10ml to the old (containing trypsinised cells) – 
the addition of fetal calf serum helping to quench the trypsin activity. Of the cells 
resuspended in media, up to 1ml was then transferred the new media and left at 37˚C. 
The old cell/media suspension was removed by suction.  
2.9.3.5 Freezing Cells 
 
Cells were pelleted by  centrifugation at 800
min-1 rpm for 5 min and  resuspended in 
freezing medium (Gibco). The cells were then aliquoted into 1ml cryotubes and frozen 
slowly to avoid the formation of ice crystals; and placed at -80˚C. When frozen, they 
were moved to liquid nitrogen storage. 
 
 
2.10 Zeiss LSM 510 Protocol 
The Zeiss LSM 510 has 3 single photon lasers (Ar, HeNe 543, HeNe 633) which allow 
the  user  to  select  lines  of  458,  488,  514,  543,  568,  and  633  nm.  The  Zeiss  LSM 
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2D/3D (stereo, projection) functions, digital processing of voxels and 3D measurement 
functions and parameters. 
 
2.10.1 Turning on the lasers 
ACQUIRE – LASER was selected this opens a laser control window with a list of 
available lasers. The laser needed to excite the dye of the labelled eye piece was turned 
on. When laser was set to “ready”, the output intensity was turned at 75%. 
 
2.10.2 Viewing specimen through eyepieces 
2.10.2.1Send light to microscope 
The ACQUIRE button was switched on in the toolbar of the main menu. The VIS 
button  was  then  switched  to  on.  The  specimen  was  placed  on  the  stage  with  the 
coverslip facing down and is held in place by two clamps.  
2.10.3 View your specimen under transmitted light 
The  MICRO  button  was  clicked  and  the  Axiovert  Control  window  appeared.  The 
reflector turret position was turned to “none” and the transmitted light was switched 
“On”.  An  objective  was  selected  in  the  objective  panel.  The  intensity  switch  was 
moved  in  front  of  the  microscope  until  LED  above  the  condenser  read  2-3V.  The 
specimen was found in XY. To find in Z focus, the large focusing and small focusing 
knob was used.  
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The transmitted light in Axiovert Control was unchecked. Filter sets were selected for 
DAPI = Fset01. FITC = Fset09. Rho/Cy3 = Fset15. Once the appropriate field was 
selected, the Axiovert Control window was closed and the LSM button was changed 
for confocol scanning.  
2.10.3 Scanning an Image 
2.10.3.1 To collect an xy section (Scan control) 
The acquire button was selected and scanning began. Under channel setting, various 
channels were selected based on the fluorophores used.  
 
2.10.3.2 To acquire a Z-series stack 
The  Z-STACK  button  collects  a  series  of  XY-images  along  the  Z  axis.  The  Z-stack 
button was pressed to open the Z-settings window. The First/Last tab was selected. The 
CONT button was selected to start continuous scanning. While scanning, the manual 
focusing knobs were used to focus on one edge of the specimen. The MARK FIRST 
button was selected to set the limit of the stack. Focus in the opposite direction until the 
other end of the specimen was reached. The MARK LAST button was selected to set 
the end limit. The STOP button was used to cancel fast scans.  
 
2.10.3.3 To collect a Time Series  
Either a single or Z-series collection in Scan Control were set up. TIMESERIES was 
then selected, under which a series of time points were entered.  
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2.11 Electron Microcopy (EM) 
The electron microscope is a high powered microscope using a beam of electrons to 
give a high magnification image of a specimen. This procedure was undertaken with 
the guidance and help of Dr. Peter Munro, Institute of Ophthalmology, UCL, London. 
Sections were cut and prepared by Dr. Munro. EM uses beams of highly energetic 
electrons to examine objects on a very fine scale. 
2.11.1 Preparation of Tissue for EM sectioning 
2.11.1.1 Fixation of tissue for immunogold labeling 
Three fixatives are commonly used when fast (high pressure) freezing is not an option. 
These are 2-4% PFA, 0.1-1% glutaraldehyde (GLA) or a mixture of the two. Tissue 
was fixed in appropriate fixative – 1h minimum, 24h at 4ºC ideal with 4% PFA. Pieces 
were cut no larger than 3mm with a clean alcohol rinsed razor blade. Pieces were kept 
in storage solution until required. 
2.11.1.2 Gelatin embedding 
 
Tissue processing procedure involves the perfusion fixation with 4% paraformaldehyde 
in 0.08M sodium phosphate/cacodylate pH 7.4 for 2h at room temperature. Pieces were 
washed x3 in 0.08M sodium cacodylate + 50mM glycine. Pieces were embedded in 
10%  gelatine  in  Phosphate  buffer  +  5%  sucrose  and  infiltrated  in  2.3M  sucrose 
overnight at 4°C.Mount and freeze. 
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Mesh hexagonal  EM  grids  were  cleaned  by  placing  them in  a  200-mL  glass flask, 
rinsing them with 2% aqueous acetic acid. They were three times with dry acetone and 
dried the grids by placing the flask on a warm plate. A microscope slide was briefly 
immersed in dry ethanol and left to dry. The dry slide is dipped into a solution of 2% 
Formvar in chloroform and withdrawn carefully, to ensure a thick Formvar layer. The 
slide is left to dry by propping it vertically in a clean environment. A deep dish is filled 
with  distilled  water  and  left  to  stand  below  a  diffuse  light  source  so  that  the  light 
reflects off the water surface. The water is cleaned by passing a lens tissue over the 
surface. A razor blade is used to score around the edge of the slide. The formvar-coated 
slide is used at a 45 angle at the edge of the glass dish and touched the bottom of the 
slide to the water surface. The glass slide was slowly and carefully put into the water 
while maintaining a 45 angle. The Formvar film started to detach from the glass surface 
and float onto the water surface. The glass slide was removed from the water when the 
Formvar film has completely detached from the glass surface. The floating film was 
examined for dirt particles. The cleaned EM grids were placed onto the floating film 
using a clean, sharp fine forceps. The grids were placed so that the shiny surface of the 
grid is facing up and the dull side is on the film. The glass slide were dried and used for 
casting the film and stick a 1-inch by 2.5 –inch white address label on its surface. The 
glass slide was held vertically over one edge of the floating film and pushed into the 
water so that the film floated on the water surface stuck to the address label on the glass 
side. Once the glass slide had been totally immersed, it was removed from the water 
making sure the grids remain attached and left to dry. The grids were coated with a thin                                                                                 Chapter 2 Materials and Methods 
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layer  of  carbon  using  a  vacuum  evaporator.  The  final  carbon  layer  should  be  thin 
enough to form a light gray coating on a sheet of white paper. 
2.11.1.4 Cryoprotection and Freezing 
Cubes  of  tissue  pellets  were  transferred  to  1mL  of  2.3  M  sucrose  in  PBS  in  an 
eppendorf  tube  sealed  and  left  overnight  on  a  rotating  mixing  wheel  at  4°C.  The 
sucrose solution infiltrated through the specimen. Each infiltrated specimen block was 
transferred onto a clean metal specimen pin, excess sucrose was removed with a damp 
filter  paper  and  the  specimen  was  immersed  in  liquid  nitrogen  until  freezing  was 
complete. 
2.11.1.5 Specimen transfer to precooled cryochamber 
The  cryochamber  of  the  ultramicrotome  was  precooled  to  -80  °C.  The  diamond 
cryotrim tool was inserted and allowed the chamber to reach equilibration temperature. 
Any tools inserted into the cryochamber must be pre-cooled in liquid nitrogen. The 
specimen pin was placed into the specimen holder and locked in place using minimal 
force.  
2.11.1.6 Trimming the Specimen Block 
The antistatic line was turned on to full power. The front of the trim tool was advanced 
to  the  surface  of  the  block  until  it  was  just  touching  the  front  of  the  block.  The 
ultramicrotome was set to cut sections of 500 nm and the machine was left to section at 
the maximum speed setting. Once a substantial portion of the block had been smoothed 
away, sectioning stopped. This is known as “facing off”. The edge of the trim tool was                                                                                 Chapter 2 Materials and Methods 
 
  79
used to shape the sides of the block into a “mesa” protruding approx 1 mm wide and 2 
mm long. Each side of the block was cut until a protruding mesa was formed with 
smooth sides.  
2.11.1.7 Sectioning 
The diamond knife was mounted in its holder, placed in the cryochamber and left to 
cool down and equilibrate at -120°C. The trimmed block was moved to the knife edge 
and cutting window set so that the section stroke started just above the knife and ended 
just  below  the  knife.  The  antistatic  line  was  set  to  50%  power  or  less.  The 
ultramicrotome was set to cut 80-nm thick sections. The rough advance was used to 
move the knife close to the block. The knife continued moving to the block using the 
fine advance control until the two were almost touching. When it looked like the block 
and knife were almost touching, automatic sectioning began and sections to appear on 
the knife. The cutting speed was set to between 0.6 mm/s and 2 mm/s. The antistatic 
line was turned off. The sections were pulled from the edge of the knife with a clean 
eyelash probe and arranged in groups on the knife surface. 
2.11.1.8 Section Retrieval 
A 2-mm diameter loop was dipped in a mixture of one part 2% methyl cellulose: one 
part 2.3 M sucrose and lifted a drop out on the loop. The methyl cellulose/sucrose 
mixture  was  kept  in  a  small  tube  on  ice.  The  loop  containing  the  sucrose/methyl 
cellulose drop was transferred to the cryochamber and maneuvered so the loop is just 
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liquid and immediately the loop is removed from the cryochamber. Sections adhered to 
the bottom surface of the drop of sucrose/methyl cellulose in the loop. 
The liquid in the loop is thawed and placed, section side down, onto a Formvar/carbon 
coated EM grid at room temperature. The drop is then left to dry on the grid until it is 
ready for labeling. 
2.11.1.9 Storing Sections 
After the sections were placed onto the grids, they were stored for a short period of 
time by placing upside down onto 2% aqueous gelatin. The gelatin was first solidified 
by cooling to 4°C and the grids were placed, section side down onto a solid gelatin 
surface. To remove the grids for immunolabeling, the gelatin was warmed to 37°C for 
30 min and taken off the grids with a wire loop. Long-term storage of sections can be 
achieved by leaving the grids attached to the glass slide.  
 
 
2.11.2 Protein A gold procedure 
Grids were transferred face down to 2% gelatin-PBS gels on ice – then warmed to 
37°C. Grids were placed through 4x 3mins of PM+0.15M glycine (100ul) droplets.  
Grids were washed 2 x 5 mins with PBS+1% BSA. They were then incubated with 
primary antibody and diluted with PBS+1%BSA.Grids were washed 4 x 2mins with 
PB/0.15Mglycine. Grids were washed 5 x mins with PBS/0.1%BSA and incubated for 
20 min on 10ul drops of Protein A diluted in PBS/BSA. Grids were washed 7 x 2 mins                                                                                 Chapter 2 Materials and Methods 
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with PBS+0.1% BSA and fixed for 5mins with PBS+1% glutaraldehyde. Grids were 
then washed 7 x 2mins with ultrapure water.  
 
 
 
 
PROTOCOLS UNDERTAKEN BY COLLABORATORS 
2.12 Comparative genome hybridization 
 
Comparative genomic hybridization (CGH) is a comprehensive molecular-cytogenetic 
method for the analysis of copy number changes (gains/losses) in the DNA content of 
cells (Carter 2007). Genomic DNA from the tissue of investigation and normal DNA 
(reference tissue) are differentially labeled and simultaneously hybridised to normal 
metaphase  chromosomes.  The  tested  DNA  is  labeled  with  biotin  and  the  reference 
DNA  is  labeled  with  fluorescein  isothiocyanate.  CGH  detects  only  unbalanced 
chromosomal  changes.  However,  structural  aberrations  such  as  balanced  reciprocal 
translocations or inversions cannot be detected, as they do not change the copy number. 
CGH is also capable of detecting gain, loss and amplification of the copy number at the 
level of chromosomes. Detection of amplification is sensitive down to less than 1 Mb 
(Carter,  2007).  One  must  take  into  consideration  that  while  CGH  is  sensitive  to 
amplification, it is an order of magnitude less sensitive to loss (Reference). The Sanger 
centre undertook this experiment using the Whole Genomic TilePath (WGTP) array.                                                                                  Chapter 2 Materials and Methods 
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2.12.1 Agilent Human Genome CGH Array 
The Agilent Human Genome CGH Microarray Kit 244A is a high-resolution tool for 
genome-wide  DNA  variation  profiling  without  amplification  loss.  Sufficient  probe 
coverage spans both coding and noncoding regions. Probe design and selection have 
been  carefully  optimised  and  validated  for  maximal  sensitivity  and  specificity.  The 
enhanced detection resolution enabled through the high-density microarrays carry out 
the highest accuracy in mapping chromosome breakpoints and identification of micro-
variations that are not detected by other arrays. 
 
Protocols for WGTP and 224k are similar apart from a few minor adjustments: 
2.12.2 WGTP array hybridization /244k array 
Test  and  reference  DNA  samples  were  differentially  labeled  using  the  Bioprime 
labeling kit (Invitrogen Carlsberg, CA, USA) with modifications of the nucleotide mix. 
Briefly, a 260 ￿l reaction is set up containing 300 ng of DNA and 120￿l for WGTP or 
60 ￿l for 224k array of 2.5x random primer solution. After denaturing the DNA for 10 
min at 100°C, 30 ￿l (WGTP) or 15 ￿l (244k) of 10x dNTP mix (1 mM dCTP, 2 mM 
dATP, 2 mM dGTP, and 2 mM dTTP in TE buffer), 3 ￿l (WGTP) or 1.5 ￿l (244k) of 1 
mM  Cy5-dCTP  or  Cy3-dCTP  (NEN  Life  Science  Products),  and  6  ￿l  of  Klenow 
fragment were added on ice to a final reaction volume of 300￿l (WGTP) or 150 ￿l  
(244k). The reaction is incubated at 37°C overnight and stopped by adding 30 ￿l of stop                                                                                 Chapter 2 Materials and Methods 
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buffer supplied in the kit. Unincorporated nucleotides are removed by use of Microcon 
YM-300 Filter Devices (Millipore Co.), according to the suppliers’ instructions.  
 
Hybridisations were carried out on a Tecan HSTM Hybridization Station (Tecan Group 
Ltd.)  using  63x20  mm  chambers.  Cy3  and  Cy5  labeled  DNAs  were  combined, 
precipitated together with 270 ￿g of human Cot1 DNA (Roche Diagnostics Ltd., UK) 
and resuspended in 165 ￿l of hybridisation buffer (50% formamide, 5% dextran sulfate, 
0.1% Tween 20, 2x SSC and 10 mM Tris/HCl, pH 7.4, 10 mM Cysteamine). Pre-
hybridisation solution was prepared simultaneously by precipitating 100 ￿l of herring 
sperm  DNA  (10  mg/ml,  Sigma  Aldrich,  UK)  and  resuspending  in  165  ￿l  of 
hybridisation buffer.  
 
The prehybridisation and hybridisation solutions were then denatured for 10 min at 
72°C. The prehybridisation solution was injected into the Tecan chamber following 
instructions displayed on the station. During prehybridisation (45 min at 37 ºC), the 
hybridisation solution was incubated at 37°C. Hybridisation was carried out for 21 hrs 
at  37ºC  with  medium  agitation  frequency.  Slides  were  washed  with  PBS/Tween 
20/2mM cysteamine (wash time 0.30 min, soak time 0.30 min, 15 Cycles at 37ºC), 0.1 
x  SSC  (wash  time  1.00  min,  soak  time  2.00  min,  5  Cycles  at  54ºC),  PBS/Tween 
20/2mM cysteamine (wash time 0.30 min, soak time 0.30 min, 10Cycles at 23ºC) and 
HPLC water (wash time 0.30, soak time 0.00, 1 Cycle at 23ºC) before drying for 2.30 
min  using  nitrogen  gas.  All  experiments  were  performed  in  duplicate  with  DNA 
labelling color reversal (dye swap).                                                                                  Chapter 2 Materials and Methods 
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2.12.3 WGTP data analysis  
Array  images  were  acquired  using  an  Agilent  laser  scanner  (Agilent  Technologies, 
UK).  Fluorescence  intensities  and  log2  ratio  values  were  extracted  using  Bluefuse 
software (Bluegnome Ltd). Spots with low signal intensities ("amplitude"<100 in both 
channels) or inconsistent fluorescence patterns ("confidence" < 0.5 or "quality" = 0) 
were excluded before normalising all log2 ratio values by blocks (sub-arrays).  
Fusion of dye-swap results and subsequent analyses were performed using custom Perl 
scripts. The median of all ratio values was calculated chromosome by chromosome for 
each individual hybridisation. Each ratio was then normalised by the corresponding 
chromosomal median. The ratios of each clone in the two dye swap hybridisations were 
then averaged if replicate ratios differed by less than 50% (i.e. less than a difference of 
0.585 on the log2 scale).  
The 68.2th percentile of the absolute values for all combined ratios was then calculated 
chromosome by chromosome as an estimation of the standard deviation (SDe). The 
68.2th percentile of absolute dye swap rations for each chromosome is calculated as an 
estimated  standard  deviation.  The  mean  of  these  give  global  rp68,  which  give  an 
indication of quality (Carter, 2007). Clones reporting replicates different by more than 
eight times the SDe were excluded from further analysis.  
Dye-swap experiments were accepted for CNV calling only if the following criteria 
were fulfilled: (1) Global SDe < 0.06; (2) Global clone exclusion at 23ºC) and HPLC 
water (wash time 0.30, soak time 0.00, 1 Cycle at 23ºC) before drying for 2.30 min                                                                                 Chapter 2 Materials and Methods 
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using nitrogen gas. All experiments were performed in duplicate with DNA labeling 
color reversal (dye swap). 
 
 
2.13 MLPA reaction 
This was undertaken in our collaborators laboratory in Seville, Spain. Genomic DNA 
was isolated from leucocytes using standard  methods. MLPA Kit reagent EK1 was 
obtained  from  MRC  Holland  (Amsterdam,  Netherlands),  using  a  PTC-100  thermal 
cycler (MJ research, Waltham, Massachusetts, USA). 100 ng of DNA were diluted in 4 
ul dH2O and denatured at 98 ºC for 5 min before adding the MLPA buffer and the 
synthetic probe mixes. The reaction mixture was denatured for 1 min and incubated at 
60 ºC overnight (16 hr). Ligation was performed at 54º C and incubated for 15 min. In a 
following step, the ligase enzyme was inactivated by heating up to 98º C for 5 min. 
PCR amplification of the ligation products was carried out in a 33 cycles program (30 s 
at 95ºC, 30 s at 60ºC, and 60 s at 72ºC). The products were separated on an ABI model 
3730 DNA analyser (Applied Biosystems) using the GeneScan-500 LIZ size standards 
(Applied  Biosystems)  and  analysed  by  using  the  GeneMarker  version  1.6 
(Softgenetics). 
2.13.1.1 Probe design 
 
Polymorphisms  particularly  across  the  ligation  site  were  compared  with  the  SNP 
database at NCBI and UCSC. The probes of 60 or fewer bases were synthesized to a 
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than 60 bases were manufactured to the scale of 0.02 mmol with the 3` half-probes 
including a 5` phosphate group for ligation purposes (Operon Biotechnologies GmbH 
(Cologne, Germany).  
 
 
 
 
2.14 Bioinformatics Tools 
This  area  of  research  was  undertaken  by  Professor  Chris  Ponting  and  Doctor  Leo 
Goodstadt of Oxford.  
2.14.1 BLAST  
BLAST (Basic Local Alignment Search Tool) is a set of similarity search programs 
designed to explore all of the available sequence databases regardless of whether the 
query  is  protein  or  DNA.  Using  BLAST  at  the  website  at 
http://blast.ncbi.nlm.nih.gov/Blast.cgi the RP25 genomic interval was used as a query 
to search protein and translated nucleic acid sequence databases for homologs.  
 
2.14.2 ExPASY 
ExPASY found at http://www.expasy.ch/tools/ was another tool used to further analyse 
the protein sequence of RP25. ExPASY is a database server containing access to many 
bioinformatics  databases  and  molecular  biology  analytical  tools.  Such  tools  in  the 
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SWISS-PROT-  protein  sequence  database  that  gives  annotations  such  as  protein 
domain structure and post translational modifications. 
PROSITE-  this  also  gives  details  on  various  protein  domains  and  families.  It  has 
detailed profiles which help to identify to which known protein family a new sequence 
belongs to. Both of the above bioinformatics tools were used in this study to reveal the 
protein  structure  of  the  RP25  gene.  The  Molecular  Biology  Server  (BCM)  Search 
Launcher was also used in this instance. This is an integrated set of World Wide Web 
(WWW)  s  that  organizes  molecular  biology-related  search  and  analysis  services 
available on the WWW by function, and provides a single point of entry for related 
searches. 
 
BLAT  (Blast-like  alignment  tool)  is  a  sequence  alignment  server  and  is  used  for 
sequence  comparisons  against  an  entire  genome.  BLAT  is  found  at 
http://genome.ucsc.edu.  In  this case  it  incorporated the  genomes  of  species  such  as 
rhesus monkey, dog, cat and mouse. 
 
 
2.14.3 Conserved Domains Tools 
The  domain  architecture  of  what  was  predicted  using  tools  including  SMART  and 
hmmsearch. 
2.14.3.1 SMART protein domain database server 
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SMART  (a  Simple  Modular  Architecture  Research  Tool)  (http://smart.embl-
heidelberg.de/)  allows  the  identification  and  annotation  of  genetic  domains  and  the 
analysis  of  domain  structure.  More  than  400  domain  families  found  in  signaling, 
extracellular  and  chromatin-associated  proteins  are  detectable.  These  domains  are 
extensively annotated with respect to phyletic distributions, functional class, tertiary 
structures and functionally important residues (Schultz et al., 2000).  
2.14.3.2 HMMsearch 
 
HMMsearch  is  a  suite  of  programs  that  uses  Hidden  Markov  Models  (HMMs)  to 
describe the profile of a multiple sequence alignment. HMM is a finite set of states, 
each  of  which  is  associated  with  a  probability  distribution.  In  a  particular  state  an 
outcome  or  observation  can  be  generated,  according  to  the  associated  probability 
distribution. It is only the outcome, not the state visible to an external observer and 
therefore states are ``hidden' '  to the outside; hence the name Hidden Markov Model. 
HMMsearch  profiles  can  in  turn  be  used  to  perform  incredibly  sensitive  database 
searches and to merge evermore distantly related sequences into the original alignment. 
One  can  also  search  a  protein  sequence  against  a  profile  library  to  detect  known 
domains. 
2.14.4 Orthology and phylogenetic tree 
Homologs  of  the  RP25  protein  were  identified  using  BLASTP 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins&PROGRAM=blastp&BLAST
_PROGRAMS=blastp&PAGE_TYPE=BlastSearch&SHOW_DEFAULTS=on).  This                                                                                 Chapter 2 Materials and Methods 
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simply compares the protein sequence to the protein database available. The domain 
sequences were manually aligned and the protein distances were calculated. 
The protein distances were calculated using prodist from PHYLIP. Prodist uses protein 
sequences to compute a distance matrix, under three different models of amino acid 
replacement. The distance for each pair of species estimates the total branch length 
between  the  two  species.  The  distance  matrix  programs  used  in  this  case  were 
neighbour and consensus.  
The first step to constructing a phylogenetic tree is to calculate distance matrices for the 
multiple sequence alignment. The neighbour-joining tree from the distance matrix is 
calculated. Inspect the tree by viewing with an outtree file, once tree is satisfactory, 
calculate the bootstrap values. Bootstrap values are a computer-based technique for 
assessing the accuracy of almost any statistical estimate (Efron et al., 1996). 
 
 
 
 
 
 
 
 
 
 
                                                                                 Chapter 2 Materials and Methods 
 
  90
Summary of Materials 
 
Item(s)  Company 
 
1X TAE  Invitrogen 
10X Loading Buffer, Bromophenol Blue  Sigma-Aldrich 
10X NH4 PCR buffer  Bioline 
10X TRIS + glycine +SDS  National Diagnostics 
Acrylamide   National Diagnostics 
Agarose  Sigma-Aldrich UK 
Ampicillin  Sigma-Aldrich UK 
BigDye® Terminator v3.1 Cycle Sequencing Kit  Applied Biosystems 
Bovine Serum Albumin, BSA  Sigma-Aldrich UK 
Bromophenol blue  Sigma-Aldrich UK 
CACO2 Cells  Personal communication 
Calf Intestinal Phosphatase  Roche Diagnostics GmbH 
cDNA  Clontech, UK; made in-house
Chloroform 
DEPC 
BDH-Analar UK 
Difco Laboratories 
Demethyl Sulfoxide, DMSO  Sigma-Aldrich UK 
D-MEM Liquid Medium  Gibco BRL 
D-MEM/F12 
Dnase 
Gibco BRL 
Ambion 
dNTPs  Promega UK 
EDTA  Affymetrix 
Ethanol  BDH-Analar UK 
Ethidium Bromide  Sigma-Aldrich UK 
Fetal Calf Serum 
Formvar 
First Link UK Ltd 
AppliedChem  
Freezing medium  Gibco BRL                                                                                 Chapter 2 Materials and Methods 
 
  91
         Gelatine 
Glutaraldehyde 
Glycerol 
Sigma-Aldrich UK 
Sigma-Aldrich UK 
Sigma-Aldrich UK 
Glycine 
Glycogen 
ICN Biomedicals, Inc 
 
Hydrochloric acid   
Isopropanol  BDH-Analar 
Kanamycin  Sigma-Aldrich UK 
KOD Hot Start DNA Polymerase Kit  Toyobo Novagen 
Methanol 
Methly cellulose 
BDH-Analar 
Sigma Aldrich UK 
Magnesium Chloride, MgCl2  Bioline 
Normal Goat Serum, NGS  Sigma-Aldrich UK 
Paraformaldehyde  Sigma-Aldrich UK 
Penicillin/Streptomycin  Gibco BRL 
Phenol  Sigma-Aldrich UK 
Phosphate Buffered Saline tablets  Oxoid UK 
Precision Plus Protein dual color standards  Bio-Rad Laboratories 
Primers  Sigma-Genosys 
Prolong Gold anti-fade reagent for mounting  Invitrogen 
QIAquick PCR Purification Kit  QIAgen 
Restriction Enzymes & buffers  Promega, New England 
Biolabs 
RPMI-1640 Medium 
RNasin 
Gibco BRL 
Ambion 
Sodium azide 
Sodium cacodylate 
Sigma-Aldrich UK 
Sigma-Aldrich UK 
Sodium dodecylsulfate, SDS  Sigma-Aldrich UK 
Secondary Antibodies  Jackson Immunoresearch 
Labs Ltd USA                                                                                 Chapter 2 Materials and Methods 
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SmartLadder - Molecular Weight Marker  Eurogentec 
S.O.C. Medium Liquid   Invitrogen 
Sodium Chloride, NaCl 
Sodium phosphate 
Fischer Scientific 
Sigma-Aldrich UK 
Sucrose  Sigma-Aldrich UK 
Taq polymerase   Bioline 
Trizma Base  Sigma-Aldrich UK 
Triton X-100 
Trizol                                                                               
Sigma-Aldrich UK 
Invitrogen, UK 
Trypsin/EDTA  Gibco BRL 
Tryptone  Merck 
Tween-20  Sigma-Aldrich UK 
Vectashield mounting medium with DAPI   Vector Laboratories 
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CHAPTER 3 
 
Candidate gene exclusion and       
identification of the RP25 gene 
 
3.1 Background of screening candidate genes in the RP25 interval 
Prior to commencing my PhD studies, 37 of the 110 genes in the RP25 interval (34 Mb) 
were screened by my colleague in London and by our collaborating group in Seville, 
Spain. This, together with previous reports excluded 54 genes within the RP25 interval. 
All screened genes were thus excluded as disease causing for RP25 leaving 56 genes as 
possible  candidates. Details  on  the RP25  locus  and linked Spanish  families  can  be 
found in section 1.12. Selection of candidate genes to screen was based on known gene 
function, tissue expression pattern and/or the genetic data published on the genes. Two 
main approaches were used to prioritise candidate genes for mutation screening; which 
are detailed below. 
 
3.1.1 Functional candidate gene approach 
The  initial  essential stage  in identifying  candidate  genes  was the  selection  process. 
Genes in the interval may already be implicated in a role related to retinitis pigmentosa 
or may be highly expressed in retinal tissue. For this approach, an interactive database               Chapter 3 Candidate gene exclusion and identification of the RP25 gene 
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called  EysSAGE  (Serial  Analysis  of  Gene  Expression)  was  used  to  identify  tissue 
expression of various genes within the RP25 interval. This database queries human 
retina and RPE  gene expression. Some of the 54  genes that were selected as  good 
candidate genes using this approach are as follows: GABRR1 and GABRR2, which are 
both expressed in the retina and encode rho1 and rho2 subunits of the C type receptor 
for  the  ã-aminobutyric  acid  (GABAc  receptor)  (Marcos  et  al.,  2000).  ELOVL4  is 
another gene selected based on its composition and expression in photoreceptor cells 
(Li et al., 2001) (Leonard et al., 2000); which has also been previously implicated as 
the  causative  gene  for  STGD3  and  ADMD  (Zhang  et  al.,  2001).  SMAP1  (stromal 
membrane associated protein 1) is another example of a gene that is located within the 
RP25 locus and is expressed in the retina. Similarly, GLULD1, glutamate-ammonia 
ligase (glutamine synthase) domain containing 1, plays a key role in the uptake and 
metabolism  of  glutamate  in  the  retina  (Barragan  et  al.,  2005).  RIM1,  encoding  a 
presynaptic  protein  involved  in  the  glutamate  neurotransmission,  is  the  gene 
responsible  for  autosomal  dominant  cone-rod  dystrophy  CORD7,  whose  locus 
overlapped partially with the RP25 locus (Barragan et al., 2005).  
 
 
3.1.2 Positional candidate gene 
A positional candidate gene list was produced based on the genetic data obtained from 
the Spanish families and other ethnic families linked to the interval (section 1.12). The 
interval flanked by markers D6S282 to D6S1976 was divided into four regions (Figure               Chapter 3 Candidate gene exclusion and identification of the RP25 gene 
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3.1). All four regions were thought of as being important and so to devise a strategy 
plan, a thorough analysis of known functions and expression patterns of the genes had 
to be explored. This involved performing a functional candidate gene approach. The 
four regions analysed were as follows: 
(1) Region A is where the Spanish families and the Pakistani family overlap and is 
between microsatellite markers D6S257 and D6S1053, spanning approximately 8 Mb 
and has 15 genes mapped to the region. 
(2) Region B is where six Spanish families are genetically linked to the region between 
microsatellite markers D6S1053 and D6S1557 spanning approximately 6 Mb and has 
11 genes.  
(3)  Region  C  is  where  all  Spanish  families  map,  between  microsatellite  markers 
D6S1557 and D6S421 spans approximately 1 Mb and has 7 genes. 
(4)  Finally,  region  D  is  where  the  Spanish  families  overlap  with  the  LCA5  (Leber 
congenetial amarousis 5) locus, between microsatellite markers D6S421 and D6S1644 
spans ~ 18 Mb and contains 79 genes. 
 
Up to the point of project commencement, no  gene had been identified for  LCA5, 
which is also in the same chromosomal region (section 1.12). This led to the possibility 
that the same gene could be causative for both RP25 and LCA5. This has previously 
been reported with genes such as CRB1 (Richard et al., 2006), ABCA4 (Allikmets et al., 
1997) and RPE65 (Redmond et al., 1998) which were reported to cause both LCA and 
RP phenotypes. In total, 54 genes had been screened in all four regions, including all of 
the genes referred to in section 3.1.1. Fourteen genes in region A had been selected as               Chapter 3 Candidate gene exclusion and identification of the RP25 gene 
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possible candidates and then screened for mutations. In region B, five genes were also 
selected as possible candidates and further discounted once they were screened, leaving 
seven uncharacterised gene transcripts to be screened in the region. Seven genes were 
selected as good candidate genes and subsequently discounted from region C once all 
exons in these genes were sequenced. In region D, the largest region, 28 genes were 
selected as possible RP25 causing genes and disregarded as the causative RP25 gene 
after full exonic sequencing.  
 
3.2 Sequencing and screening of genes 
 
Initial screening began with the completion of genes which contained exons that were 
difficult to sequence. Numerous genes including those described in table 3.1 had exons 
which proved difficult to amplify. Many new primers for these exons were designed, as 
well  as  using  alternative  temperatures  and  magnesium  concentrations  during  PCR 
amplification. It is extremely important that every exon is completely screened in order 
for  the  gene  to  be  excluded  as  a  possible  disease  gene.  Once  these  genes  were 
completely screened, the next stage of the project was to select candidate genes for 
sequencing.  
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Gene/gene 
description 
Gene  size 
(Kb)/Position 
and  region 
location 
No.of 
exons 
UniGene  Published  information  on 
gene 
ZNF451-Zinc 
finger protein 451 
80.27/57.06-
57.14/Region A 
14  HS.485628  Co  activator  for  steroid 
receptors. 
COL19A1/NM_0
01858/Collagen, 
type XIX, alpha 1 
345.71/70.63-
70.97/Region B 
51  HS. 444842  COL19A1 and COL9A1 were 
duplicated  from  the  same 
ancestral  gene  of  the  FACIT 
family  (Khaleduzzman  et  al., 
1997). 
COL9A1/Collage
n,  type  IX,  alpha 
1. 
87.03/70.98-
71.06. 
38  HS.590892.  A  mutation  in  the  COL9A1 
gene was reported in a family 
with  multiple  epiphyseal 
dysplasia (Czarny-Ratajczak et 
al.,  2001).  A  homozygous 
mutation was also reported in a 
recessive  form  of  Stickler 
syndrome  (Van  Camp  et  al., 
2006). 
 
SH3BGRL2- SH3 
domain  binding 
glutamic acid-rich 
protein like 2. 
72.37/80.39-
80.47/Region C 
4  HS.232772.  Reported  as  a  novel  human 
homolog  of  the  SH3  binding 
glutamic acid-rich establishing 
a  new  family  of  highly 
conserved  proteins  related  to 
Thioredoxin  Superfamily 
(Mazzocco et al., 2002). 
 
TTK-TTK protein 
kinase  Dual 
specificity protein 
kinase 
37.88/80.77-
80.80/Region C 
22  HS.169840  Has  dual  specificity  protein 
kinase  (tyrosine  and 
serine/threonine  residues) 
(Lindberg  et  al.,  1993)  Is 
required  for  centrosome 
duplication and for the normal 
progression of mitosis (Fisk et 
al., 2003). 
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3.3 Screening genes in region D 
Once incomplete genes were completely screened, genes in region D of the RP25 locus 
were  analysed.  Seventy  nine  genes  were  identified  between  microsatellite  markers 
D6S421 and D6S1644, region D (Figure 3.2) with 28 genes being previously screened 
and excluded as potential disease causing genes for RP25. In total, six candidate genes 
were selected for mutation screening (Section 3.2.1) (Table 3.2). These candidate genes 
were selected at random as all good candidate genes had been completely screened 
previously. Primer pairs, (Sigma Aldrich, UK) were designed for all 99 exons of the six 
genes (see appendix for primer design). Several novel SNPs were identified, along with 
previously annotated SNPs in these candidate genes (Section 3.2.2). 
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Figure 3.1 The RP25 interval on chromosome 6. An overview of where the seven Spanish families lie in 
the interval and the corresponding microsatellite markers. The RP25 interval was divided into four 
separate regions A-D. The genes been screened in this instance lay in region D between microsatellite 
markers D6S421 and D6S1644. Adapted from Abd El-Aziz et al., 2008. 
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Table 3.2 Genes screened for mutations 
 
Gene Description  No. of exons   Position  Expression data 
DPPA5 
(Developmental 
pluripotency 
associated 5) 
3  74.11-74.12  None 
MTO1 
(Mitochondrial 
translation 
optimisation 1 
homolog) 
13  74.22-74.26  Ubiquitously expressed 
SENP6 
(SUMO1/sentrin 
specific peptidase 6) 
24  76.36-76.48  Ubiquitously expressed
ME1 
(Malic enzyme 1) 
14  83.97-84.19  Ubiquitously expressed
CYB5R4  
(Cytochrome b5 
reductase 4) 
16  84.62-84.72  Ubiquitously expressed
SNX14 
(Sorting nexin 14) 
29  86.27-86.36  Ubiquitously expressed
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3.3.1 Information on genes screened 
DPPA5  (developmental  pluripotency  associated  5)  is  also  known  as  ESG1 
(PH34/ECAT2).  This  gene  has  been  reported  to  have  an  important  role  in  human 
embryonic stem and germ cells and also can be used as a marker of pluripotent stem 
cells (Kim et al., 2005). MTO1 (Mitochondrial translation optimization 1) has been 
proposed as a candidate gene to modulate the effects of nonsyndromic sensorineural 
deafness  mutation  A1555G  (Bykhovskaya  et  al.,  2004).  It  is  also  suggested  to  be 
involved in the process of mitochondrial RNA modification, which is an important 
regulatory  pathway  for  nonsyndromic  sensorineural  deafness.  SENP6  encodes  an 
ubiquitin-like molecule (UBL), SUMO-1 UBLs are small proteins that are covalently 
conjugated to target proteins with important functional consequences such as protein 
degradation and/or change in localisation (Matic et al., 2008). SENP6 (SUMO1) mainly 
modifies  nuclear  proteins,  and  participates  in  the  modulation  of  ER-mediated 
corticotrophin-releasing hormone (CRH). This may be important for the regulation of 
the stress response (Zhu et al., 2008). It is reported to be highly expressed in organs, 
such as testis, ovary and prostate suggesting it may play a role in reproduction (Kim et 
al.,  2000).  ME1  encodes  a  cytosolic  NADP+-dependent  enzyme  involved  in  the 
regeneration of pyruvate from malate back to the mitochondria, forming a link between 
the glycolytic pathway and the citric acid cycle. By assisting the release of acetyl–
coenzyme A (CoA) and NADPH from the mitochondria into the cytosol, it makes these 
compounds available for de novo fatty acid biosynthesis and other metabolic processes. 
ME1 is considered lipogenic. Recently, it was identified as a primary candidate gene 
underlying  a  porcine  quantitive  trait  loci  (QTL)  associated  with  back  fat  thickness               Chapter 3 Candidate gene exclusion and identification of the RP25 gene 
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(Yang et al., 2009). SNX14 is a G-protein signaling intracellular trafficking gene and is 
mainly  expressed  in  neurons  (Carroll  et  al.,  2001).  CYB5R4  (NCB5OR)  is  a 
flavohemoprotein that contains functional domains found in both cytochromoe b5 and 
CYB5 reductase. It is a single 58 kDa polypeptide composed of two well characterized 
domains tethered by a unique 90-residue hinge (Larade et al., 2008). 
 
3.3.2 SNPs identified in screened genes 
In DPPA5, one novel SNP was identified in an affected member of the RP5 family c. 
297-30 G>A. Since this synonymous SNP did not lead to an amino acid change, there 
was  no  requirement  to  check  the  allelic  frequency  (Figure  3.3).  Several  already 
annotated SNPs were also identified in members of all linked families. Three novel 
SNPs were identified in MTO1, along with several members having numerous already 
known SNPs. Both affected and unaffected members of family RP214 and the affected 
member of RP5 and RP73 all had individual novel SNPs (Figure 3.4). These were 
found at positions a) c. 879–46 A>G, b) c. 1201–59 C>G and c) c. 1409 + 14 T>A. All 
three novel SNPs were identified in the intronic regions therefore do not lead to any 
amino acid changes. However, these changes may be involved in modifying the normal 
splicing  of  the  relevant  candidate  gene  or  by  affecting  expression  levels  through 
changes to putative regulatory elements. 
              Three novel SNPs were identified in SENP6 in individuals of several families 
(Figure  3.5).  The  SNPs  were  as  follows  c.  1129  A>G  –  now  a  known  SNP 
(rs16886792), c. 420 + 453G>T, c. 637–135 G>C. The first SNP was found in the 
affected member of RP73. The second SNP was identified in unaffected and affected               Chapter 3 Candidate gene exclusion and identification of the RP25 gene 
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members of RP299. The final SNP was identified in both affected members of RP5 and 
RP73 respectively. Again all three SNPs were not pathogenic. Several SNPs, already 
identified, were found in all members screened. One Novel SNP in ME1; c. 302 + 
21A>C (Figure 3.6) was identified in all members of RP5 which is now an annotated 
SNP (RS4706990) found on Ensembl. No novel SNPs or mutations were identified in 
either SNX14 or CYB5R4, only several known SNPs. Therefore all of these genes were 
ruled out as possible candidate genes for the RP25 locus.  
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Figure 3.3: Electropherograms of the novel SNP c.297-30 G>A identified in affected member of RP5 in 
the gene DPPA5 (See Automated Sequencing Section 2.4) 
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Figure 3.4:  Electropherograms of SNPs identified in MTO1 A) Novel SNP c.879-46 A>G identified in 
unaffected members of RP5 B) Novel SNP c.1201-59 C>G. C) Novel SNP c.1409 +14 T>A identified in 
affected and unaffected members of RP5 and RP73. 
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A: Novel                                                                WT 
 
 B: Novel                                                                  WT 
 
C: Novel                                                                 WT 
 
 
Figure 3.5: Electropherograms of SNPs in SENP6. A) Novel SNP c. 637-135 G>C identified in several 
families, including RP5, RP299 and RP167.B) Novel SNP c.420 +453 G>T identified on all members of 
RP5. C) SNP c.1129 A>G now a known SNP (rs16886792 ) 
 
         
 
                   
 
                  
 
                  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Electropherogram of SNP RS4706990 identified in ME1 in RP167, RP214, and RP299. 
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3.4 Identification of the RP25 gene 
3.4.1 Copy Number Variation (CNV) and Comparative Genome Hybridisation 
(CGH) arrays 
In the previously analysed genes in the RP25 interval, all identified SNPs segregated 
with the genetic data of each of the families. However, one gene, PRIM2A came to 
attention when heterozygous SNPs were observed within a stretch of homozygosity in 
the affected members of two consanguineous families (RP5 and RP214). This did not 
correlate with the linkage data of these families and so it was postulated that a second 
copy of this gene existed in the same interval. This is also known as copy number 
variation  (CNV),  which  would  mean  that  amplification  of  two  copies  of  the  gene 
occurred at the same time. In addition to this, it would also be possible that in one of 
the copies of PRIM2A at a specified position, a sequence of dinucleotide AA would 
exist, and in the other copy a sequence of TT would exist. Through amplification of 
both  copies,  the two  strands of  DNA  would  lead  to  the  existence  of  the  identified 
heterozygous  SNPs  in  the  consanguineous  families.  These  observations  led  us  to 
undertake the CNV study.                                     
 
In  collaboration with Sanger Centre, Cambridge, six samples belonging to the RP5 
family  were  subjected  to  a  whole  genome  tilepath  array  analysis.  This  molecular-
cytogenetic technique used for the analysis of copy number changes in DNA, detects 
only unbalanced chromosomal changes and identify abnormal regions in the affected 
genome. The results from this study revealed that a clone within the RP25 locus was 
deleted in all affected members of this family. A whole genome tilepath array was               Chapter 3 Candidate gene exclusion and identification of the RP25 gene 
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undertaken on each of the members and as a result a deleted clone was identified in the 
affected members (Figure 3.7 and 3.8).  The deleted clone was also identified in the 
carriers  of  this  family  but  at  a  higher  ratio  than  that  off  the  affected  members 
demonstrating that this mutation is present as a single copy, all unaffected members 
read with normal ratios for this deletion. A clone is called as having a copy number 
difference in the test compared to the reference. If the ration is >6x rp68 (Section 2.13) 
for an isolated clone or > 4x rp68 for a consecutive clone.  
 
3.4.2 The deleted clone 
The deleted clone, chr6tp-19C7 is located at 65.7 Mb within the 6q12 interval in all 
affected members of family RP5. A 95 Kb region of sequence proximal to Chr6tp-
19C7 was not covered by the array used in this experiment. Hence, it was not possible 
to delineate the proximal breakpoints of the deletion since there is a gap in the clone 
coverage. The proximal clone Chr6tp-10D10 reports with a normal ratio, suggesting it 
is not affected by the deletion. The deleted clone does however overlap with a distal 
clone Chr6tp-10G7. The overlap with this clone spans 40 Kb, and also reports a normal 
ratio (Figure 3.9). This deletion is novel as it had not been previously reported as a 
known CNV and is a large deletion of 100 Kb in size. This deleted clone could pinpoint 
the gene responsible for RP25 as it segregates with the disease phenotype in the RP5 
family.  
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A 244k Agilent array (Figure 3.10) and a Nimblegen data array were performed on the 
affected members to verify the segregation of this copy number variation in the RP5 
family (Figure 3.11).The breakpoints for this deletion were identified later (Section 
4.10) in the study using both MLPA (multiplex ligation probe dependent assay) and a 
244k Agilent array. The most interesting aspect of the identification of this deleted 
clone  was  the  precise  mapping  within  the  RP25  interval.  The  corresponding  genes 
mapped in this region were a cluster of uncharacterised gene transcripts in region B of 
the RP25 interval (Figure 3.9).  
 
3.5 Mutation screening of genes in region B 
In parallel to CGH analysis, PCR amplification and sequencing of candidate genes in 
the RP25 locus continued. In the meantime, our Spanish collaborators had collected 
five more unrelated Spanish families who were linked to the RP25 locus (Barragan et 
al., 2008). In addition to the originally linked families (RP5, RP73, RP167, RP214 and 
RP299), these  five new  families  (RP328,  RP349,  RP355,  RP377  and  RP351)  were 
incorporated  into  the  study  (Figure  3.12),  with  three  of  the  ten  families  being 
consanguineous (RP5, RP167 and RP377). This further confirmed the high prevalence 
of RP25 in the Spanish population. The linkage of these new families also refined the 
RP25 interval from 16.1 cM down to 2.67 cM.  
 
Based on the CGH array results and the mapping of five more Spanish families to the 
RP25 interval, sequencing of candidate genes moved from region D to B. Genes which               Chapter 3 Candidate gene exclusion and identification of the RP25 gene 
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had been screened and previously excluded in region B are COL19AL, EGFL11, BAI3 
and  LMPRD1  (Table  3.3).  Seven  uncharacterised  gene  transcripts  were  left  to  be 
analysed,  they  are  as  follows Q5T669,  Q5T1H1,  Q9H557_human,  Q5TEL3_human, 
Q5TEL4_human,  Q5VVG4_human,  and  Q5T3C8.  Six  of  these  transcripts  share  a 
common epidermal growth factor (EGF-like) domain; however none were identified as 
having full length transcripts or had defined translation start or stop codons. All seven 
transcripts mapped in very close approximation to one another in the region of interest 
(Figure 3.13).  
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Figure  3.7  Whole  Genome  Tilepath  Array  data  run  on  the  father  of  the  RP5  family.  Each  profile 
represents a single chromosome. The points in red highlight significant copy number variation (CNV), 
light blue represents regions of CNV variants in less than 1% of the population, blue represents regions 
of CNV variants in more than 1% of the population, and the points in green have no hapmap information. 
A deleted clone identified in father (carrier) has a ratio of -0.201 in chromosome 6 as depicted by the red 
arrow. Experiment was undertaken by Sanger Centre, Cambridge.   
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Figure 3.8 Whole genome tilepath array run on one affected son from family RP5, attention was on 
chromosome 6 where the RP25 locus maps and where a variation in CNV was identified. A copy number 
plot (red) is identified in chromosome 6  of this affected member of RP5; this deleted clone in this 
affected member has a ratio of -0.307. 
 
 
 
 
RP5 3039 130307 2137-53 & 54; rp68 0.044, 98.86% retention Build 36 
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Figure 3.9 Identification of a deleted clone, Chr6tp-19C7 in an affected member of family RP5. This 
clone spans over 100Kb. A 95 Kb region of sequence proximal to Chr6tp-19C7 was not covered by the 
array used in this experiment. The nearest clone Chr6tp-10D10 reports with a normal ratio, suggesting it 
is not affected by the deletion. The deleted clone does overlap; however, with a distal clone Chr6tp-
10G7. The overlap spans 40 Kb, and also reports a normal ratio (Adapted from Abd-El Aziz et al., 2008) 
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Fig
ure 
3.10 
An 
Agil
ent 
arra
y 
dem
onst
rati
ng the region where the deletion lies in the RP5 family. The height of the peak in the affected son of this 
family  highlights  the  deletion  of  a  clone  in  this  interval.  The  heights  of  the  peaks  in  both  parents 
highlights  that  both  parents have  one  allele  with the same  deletion.  Experiment  was  undertaken  by 
Sanger Centre, Cambridge.  
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Figure 3.11 Depiction of Nimblegen data array run of RP5 family. The array shows the nimblegen array 
run on chromosome 6. This was designed to cover a 2 Mb interval from 64753791 and 66753791 Mb. 
The deletion is identified as a noisy signal. The Mother and Father both exhibit a run of chaotic peaks 
from approximately 6560000 to 6578000 Mb; both parents are carriers of this deletion. Both affected 
sons and affected daughter have a run of large chaotic peaks, as the deletion appears as a duplicate. 
Finally, the unaffected daughter of the RP5 family ran as normal with no chaotic peaks. Experiment 
undertaken by Sanger Centre, Cambridge.  
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Figure 3.12 Haplotypes of the newly recruited Spanish RP25 families, RP328, RP349, RP351, RP355 
and  RP377.  Microsatellite  markers  on  chromosome  6p12.1-q12  were  used  in  this  instance. 
Recombination events between markers D6S272 and D6S1557 occurred in families RP351 and RP328 
respectively (Barragan et al., 2008). 
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Gene Annotation  Location 
(Mb) 
Gene 
size/Exon 
number 
Expression info  Published info 
on gene 
Q5T669_human 
Fragment gene 
65.38-
65.39 
8.87 Kb/2  None   Contains EGF-like 
domain. 
Q5T1H1 
Fragment gene 
65.57-
65.58 
9.55Kb/3  Expression identified in 
tissues including eye, 
brain, lung and blood 
Similar to 
Neurogenic locus 
Notch protein 
precursor. 
Q9H557_human 
Fragment gene 
65.65-
65.67 
26.05Kb/4  None  Contains EGF-like 
domain. 
Q5TEL3_human 
Fragment gene 
65.76-
65.76 
0.123Kb/1  None  Contains EGF-like 
domain. 
Q5TEL4_human 
Fragment gene 
65.77-
65.77 
0.075Kb/1  None  Contains EGF-like 
domain. 
Q5VVG4_human 
Fragment gene 
65.82-
65.82 
0.111Kb/1  None  Contains EGF-like 
domain. 
Q5T3C8 
Fragment gene 
66.062-
66.063 
0.255Kb/1  None  Contains EGF-like 
domain. 
EGFL11 
EGF-like domain, 
multiple 11 
66.10-
66.26 
161.09Kb/9  Expressed in several 
tissue lines, but mainly 
in eye and ovary. 
Contains EGF-like 
domains 
BAI3 
Brain specific 
angiogenesis 
Inhibitor 3 
69.40-
70.15 
750.22Kb/30  Ubiquitously expressed  BAI3 may participate 
in the early phases of 
ischemia-induced 
brain angiogenesis 
and in brain tumor 
progression. (Kee et 
al., 2002). 
LMPRD1/C6orf209 
LMBR1 domain 
containing 1 
70.44-
70.56 
21.03Kb/16  None  None 
COL19A1 
Collagen, type XIX, 
alpha 1 
70.63-
70.97 
345.71Kb/51  Expressed in several 
tissue lines but 
predominantly blood. 
Unlike all other 
tissues, expression of 
Col19a1 in the 
central nervous 
system gradually 
increases after birth. 
(Sumiyoshi et al., 
2001). 
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Figure 3.13 Ensembl view (version 43: April 2007) of the arrangement of the gene transcripts being 
sequenced. The common feature of all of the transcripts in the interval is an epidermal growth factor 
like domains.  
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3.5.1 IDENTIFICATION OF A SECOND DELETION 
While screening the four exons of Q9H557_human, a novel change was identified. This 
was a 17 base pair frameshift deletion in exon 2 and was detected in both affected 
members of family RP214. This deletion was not identified in the unaffected member 
of the family (Figure 3.14) and was also absent in any of the other Spanish RP families 
screened. This frameshift deletion causes a change in the reading frame of the amino 
acids and would ultimately lead to a truncated protein.  
 
To further prove the phenotypic segregation of this 17 base pair deletion in family 
RP214, a restriction enzyme digest was performed on all members of the family. The 
digest was performed using the restriction enzyme Tsp45I (5’...GTSAC...3’) (Promega, 
UK). Exon two of Q9H557 was digested with 1 unit of TSP451 and products were 
analysed on a 2% agarose gel. Segregation was revealed in this family as none of the 
affected members of RP214 demonstrated cleavage of the enzyme (Figure 3.15). The 
restriction digest was also performed on a control Spanish population of 96 members, 
to verify this is a novel, possible disease causing mutation (Figure 3.16). All members 
of the panel, 80 of which are demonstrated in figure 3.16 segregate normally when 
cleaved with restriction enzyme Tsp45I, demonstrating that this deletion is unique and 
is absent from the normal Spanish control population.  
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RP214 Parent 
 
 
RP214 Affected 
 
 
 
Figure 3.14 PCR amplification of exon 2 of Q9H557. A RP214 parent with normal coding transcript. B 
RP214 affected member with a 17 base pair deletion in exon 2 leading to a frameshift deletion that may 
lead to a truncated protein.  
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Figure 3.15 Restriction enzyme digest performed on all members of family RP214, using restriction 
enzyme Tsp451 in the 17 base pair region of exon 2 of Q9H557. Affected members (6 and 10) have a 
deletion where the restriction enzyme cuts, with neither allele been cleaved by the enzyme (855bp). 
Carriers for the mutation (1, 2, and 4) have one allele cleaved with this enzyme, as they have one 
wildtype allele (600bp and 272bp) and one affected allele (855bp). Non-affected members (3, 5, 7, 8 and 
9) have both alleles cleaved (600bp and 272bp). Segregation of this deletion is in accordance with the 17 
bp deletion identified by sequencing. 
 
 
 
 
   M         1          2         3           4           5          6          7            8           9        10     M 
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Figure  3.16  Restriction  digest  using  restriction  enzyme  Tsp451,  displaying  80  members  of  the  96 
Spanish control population. Marker represents bands within a 1 Kb size range; lane 1 in each row is an 
affected member of RP5 family (872bp) where there is no digestion. All control members amplified 
normally and all were cleaved with the enzyme. 
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3.6 Extension of RP25 transcript 
To reiterate,  two  independent  deletions in  two  unrelated  RP affected  families  were 
identified in a region where a cluster of seven incomplete gene transcripts map to. As 
the 17bp deletion was identified in Q9H557 and this is an incomplete  transcript, a 
methodical bioinformatics investigation was performed to identify if further exons of 
this  transcript  existed.  Using  bioinformatics  databases  such  as  Ensembl 
(http://www.ensembl.org/index.html),  the  predicted  size  of  this  gene  transcript 
increased from four to 14 exons. Eight of these newly predicted exons correlated to the 
exons of previously annotated transcripts which include, downstream of Q9H557:  
 
Q5T3C8: one exon (66,062,478-66,062,732) 
Q5VVG4: one exon (65,824,229-65,824,339) 
Q5TEL4: one exon (65,771,073-65,771,147) 
Upstream of Q9H557 
Q5T1H1: three exons (65,579,997-65,589,548) 
Q5T669: two exons (65,384,020-65,392,891) (Figure 3.12) 
 
Two novel exons were also predicted as being part of this 14 exon novel transcript and 
the exons of Q9H557 (1-4) were renumbered as exons 7-10. Using 5` and 3` RACE 
PCR, primers were designed in these exons to “walk” from exon to exon using human 
retinal cDNA (Clontech, France), a method also known as exon collection. Primers 
were  designed  flanking  all  14  exons  and  PCR  amplification  was  performed  using               Chapter 3 Candidate gene exclusion and identification of the RP25 gene 
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genomic DNA of all affected families and amplification of the full-length gene was 
possible. It is imperative to highlight that no translation start and stop codons were 
identified,  and  further  RACE  and  bioinformatics  predictions  were  required  to  fully 
characterise this gene.  
 
3.6.1 Deletion in RP5 family  
Once  the  extended  transcript  of  Q9H557  was  identified,  PCR  amplification  of  all 
members  of  the  affected  families  was  performed.  From  this  amplification  it  was 
possible to correlate with which exons the deletion in the affected members of family 
RP5 occurred in. Amplification of the affected members of RP5 failed for exons 6 
through to 10 (previously exon 1 of Q5TEL4 and exon 1-4 of Q9H557) of this newly 
predicted  14  exon  transcript.  Exon  amplification  was  successful  in  the  unaffected 
members of this family (Figure 3.17) supporting the phenotypic segregation of this 
mutation in the RP5 family. This result reaffirms the deletion identified through the 
CGH  array  on  the  RP5  family,  however  to  reveal  the  breakpoints  of  this  deletion 
further MLPA assay analysis would be necessary.  
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Figure  3.17  Amplification  of  exons  6-10  of  RP5  members  of  the  extended  gene  for  RP25.  a) 
Corresponds to exon 6 (previously exon 1 of Q5TEL3) which is 367 bp in size. b) Represents exon 7 
(previously  exon  1  of  Q9H557)  which is  532  bp in size.  c)  Corresponds to  exon  8  and  9 together 
(previously exon 2 and 3 of Q9H557) (805bp), and d) corresponds to exon 10 (previously exon 4 of 
Q9H557) (433bp). Please note amplification failure of all 5 exons in each of the three affected family 
members.  
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3.7 Conclusion of Chapter 3 
A functional candidate  gene  approach  was undertaken  to  select  genes  for  mutation 
screening in RP25 affected families. Highly efficient genetic databases were utilised to 
identify good candidate genes. 54 genes had been previously collectively screened and 
excluded as possible causative genes. Six genes were selected as possible candidate 
genes and were subsequently excluded as possible disease causing genes for RP25. Due 
to heterozygous SNPs being identified in a stretch of homozygosity in gene PRIM2A in 
affected  members of two families (RP5 and RP214), a CNV study  was performed. 
From the array analysis undertaken by collaborators in Sanger Centre, Cambridge, a 
deleted clone was identified in the RP25 interval in the RP5 family. 
 
Logical and intensive mutation screening of genes in the RP25 interval in parallel with 
CGH array analysis on all members of an affected family revealed the causative RP25 
gene. Initial genome tilepath results revealed a deletion of a clone in the RP25 region of 
the affected members of the RP5 family. Based on the linkage of a further five Spanish 
families  to  the  locus,  the  RP25  interval  was  narrowed  down  to  2.67  cM.  Gene 
transcripts in region B of RP25 then became the focus of mutation screening as this is 
where the deleted clone mapped to. Seven incomplete transcripts (Q5T669, Q5T1H1, 
Q9H557_human, Q5TEL3_human, Q5TEL4_human, Q5VVG4_human, and Q5T3C8) 
were all screened for possible mutations.  
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One of these transcripts, Q9H557 which has 4 exons, revealed a 17 base pair deletion in 
affected  members  of  the  RP214  family.  A  restriction  enzyme  digest  concluded  the 
segregation of this deletion in the family. A bioinformatics study determined that this 
gene Q9H557, along with the surrounding gene transcripts may all belong to one larger 
gene.  5´  and  3´  RACE  and  PCR  amplification  confirmed  that  these  transcripts  do 
belong to one larger gene; we postulated that this gene is 14 exons in size, identifying 2 
novel exons confirmed through PCR amplification.  
 
It is imperative to highlight that no translation initiation or termination site had been 
identified therefore suggesting this gene is larger in size. To verify the validity of the 
CGH clone deletion, a PCR analysis was performed on all members of the RP5 family 
using primers designed across the 14 exon transcript. The deletion corresponded to 5 
exons  of  this  14  exon  transcript  and  segregated  in  the  RP5  family;  however  the 
breakpoints of this deletion had yet to be identified.               Chapter 4 Characterisation and mutation screening of RP25 gene : EYS 
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Chapter 4 
Characterisation and Mutation Screening of 
RP25 gene: EYS 
4.1 Identification of full length RP25 gene 
Following the preliminary identification of the extended RP25 transcript, subsequent 
experiments were performed to identify the full length RP25 gene. 
 
4.1.1 Identification of new exons of RP25 transcript         
In Chapter 3 it was established that the RP25 transcript spans 14 exons, however the 
transcription  start  site  and  translation  initiation  and  stop  codons  remained  to  be 
determined.  Through  further  RACE  experiments  and  intensive  bioinformatics 
analysis  (with  the  assistance  of  Professor  Chris  Ponting  and  Dr.  Leo  Goodstadt, 
University of Oxford), it was possible to generate primers to sequence the coding 
region bi-directionally of the 14 exon transcript.  
 
Initially, first-strand retinal cDNA synthesis was performed, prior to 5´ and 3´-RACE 
PCR analysis. Gene specific primers (GSPs) were primarily designed in exons 1 and 
4 of Q9H557 (exon 7-10 of the 14 exon transcript). Subsequently, several GSPs were 
designed upstream and downstream of the first primer pair, once a novel exon was              Chapter 4 Characterisation and mutation screening of the RP25 gene: EYS 
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identified, new primers were designed for the adjacent exon and a chromosome (or 
transcript) walking technique was employed using human retinal cDNA. Sequence 
analysis of the various PCR products was then performed bi-directionally, followed 
by alignment of the multiple contigs to identify the transcript structure of this novel 
gene  (Figure  4.1).  Interestingly,  it  was  determined  that  EGFL11,  a  previously 
characterised and annotated gene formed part of this novel transcript. 
 
The EGFL11 segment of the RP25 gene formed the 5´ end; with the translation start 
site positioned in exon 4, as exons 1-3 were identified as non-coding. Subsequently, 
incorporating  the  bioinformatics  predictions  of  exons,  further  internal  exons  were 
identified including the previously annotated Q5T1H1. Consequently, the full length 
gene  increased  in  size  from  the  initial  4  exons  of  Q9H557,  to  26  exons,  which 
incorporated the annotated transcripts, Q5VVG4, Q5TEL3 and EGFL11 (Figure 4.2). 
Furthermore, analysis of gene product predicted that several EGF-like repeat domains 
exist in the corresponding protein (Figure 4.2). However, it is imperative to highlight 
that though the translation start site had been identified, the stop codon was yet to be 
established, with further RACE and bioinformatics analysis to be performed. 
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Figure 4.1 Overview of RACE PCR reactions depicted on a 1% agarose gel. M represents the 10 kb 
marker used. 1-5 depict amplicons of varying size. The stepwise  size of each band illustrates the 
increased size of each amplified fragment. 
1-ex2R2 of 14 exon RP25 transcript and EGFL11 ex8F (expected amplicon size of 600bp)                
 2-ex2R1 of 14 exon RP25 transcript and EGFL11 ex6F (900bp) 
3- ex2R2 of 14 exon RP25 transcript and EGFL11 ex4aF (1,170bp)      
4- ex5R of 14 exon RP25 transcript and EGFL11 ex2aF (1,944bp) 
5-Control-ex7F1 and ex10R of RP25 transcript (600bp). 
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Figure 4.2 Initial prediction of the RP25 gene, the transcript spans 26 exons, including 9 exons from 
the previously characterised gene EGFL11. Other exons correspond to previously predicted transcripts 
of Q9H557 and Q5T1H1. Also depicted is the predicted EGF like domain structure of the gene.  
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4.1.2 Full length structure and size of gene 
Once the final rounds of 3´ RACE were complete, determining the full length gene 
sequence was possible (Table 4.1 intron-exon boundaries). The gene encompasses 30 
exons from 9 previously annotated genes including; EGFL11, Q5T3C8, Q5VVG4, 
Q5TEL3,  Q9H557,  Q5T1H1,  Q5T669,  ENSG00000214559,  and  Q9NQ15  (Figure 
4.3). The overall coding region of RP25 is approximately 9 Kb in size and contains 
3,145 amino acids (see supplementary data). The gene consists of 40 coding exons, 
and three non-coding exons. The translation start codon is in exon 4 and translation 
termination codon is at the end of exon 43. RP25 maps on chromosome 6q, spanning 
66,473,990-64,487,835 Mb. The size of the gene spans just over 2 Mb, making it one 
of the largest genes in the human genome, the largest gene being dystrophin which is 
2.5Mb in size (Roberts et al., 1993).  
 
One significant outcome of these RACE experiments was the identification of the 
absence of a 1,238 bp segment spanning the 3´ end of exon 29 from the human online 
genomic  databases. This reaffirms that human  genome databases, although highly 
accurate and reliable, still require traditional molecular techniques to identify novel 
sequences. This 1,238-bp fragment did not alter the reading frame of the previously 
identified coding region. 
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        Table 4.1   Exon and Intron Sizes of Human EYS 
        (See also supplementary data)   
Exon/Intron  Exon size (nt)  Intron Size 
1  43  67,243 
2  115  143,785 
3  135  252 
4  945  3,956 
5  114  85,227 
6  194  2,569 
7  128  17,978 
8  115  30,769 
9  160  9,281 
10  140  8,892 
11  167  38,861 
12  257  238,136 
13  114  59,911 
14  122  51,668 
15  122  33,050 
16  260  9,984 
17  97  184 
18  108  15,271 
19  146  63,875 
20  172  934 
21  79  8,068 
22  200  187,133 
23  125  8,588 
24  116  24,109 
25  193  1,128 
26  1,767  150,871 
27  191  2,897 
28  92  47,334 
29  151  80,403 
30  113  76,146 
31  233  148,590 
32  147  15,365 
33  154  67,155 
34  109  14,472 
35  221  120,025 
36  173  57,814 
37  183  16,966 
38  167  809 
39  145  9,925 
40  175  15,373 
41  173  35,719 
42  162  4,719 
43  1,689   
         EYS total size                                                                                               1,985,847                    Chapter 4 Characerisation and Mutation Screening of RP25 gene: EYS 
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4.2 cDNA Expression and RT-PCR 
4.2.1 cDNA expression profile 
Tissue  expression  analysis  is  a  fundamental  experiment  and  was  performed  to 
identify  in  which  tissue  types  the  RP25  gene  is  expressed.  cDNA  samples  from 
human retina, brain, kidney, liver, heart, skeletal muscle, pancreas, lung and placenta 
(Quick-Clone; Clontech) along with lymphoblast, Y79, ARPE19 and HELA cell lines 
were  all  incorporated  into  the  expression  profile  experiment.  Y79  cells  are  a 
retinoblastoma  cell  line,  representative  of  photoreceptor  cells,  retinal  pigment 
epithelium (RPE) cells are represented by the ARPE19 cell line, while HELA cells 
are an immortal cell line. cDNA specific primers were designed in exon 4 (forward) 
and exon 11 (reverse) (see appendix). The amplicon of this fragment was 1.8 Kb in 
size.  
 
Exons  of  the  ubiquitously  expressed  gene,  PGM1,￿ ￿￿hosphoglucomutase  1) 
(Whitehouse et al., 1992) were amplified in parallel as a positive control (Figure 4.4). 
PCR  products  were  electrophoresed  on  a  2%  agarose  gel  and  visualised  through 
ethidium  bromide  staining.  The  RT-PCR  results  for  the  retina  tissue  (Figure  4.4) 
demonstrates a distinct amplicon that is intensely stained suggesting that the RP25 
transcript  is  retina  specific.  Expression  of  the  fragment  was  also  detected  in  the 
photoreceptor-like Y79 cells. Amplification in all other tissues was unachievable. The 
PGM1 control amplification verified the high quality of all tissue and cell cDNAs                    Chapter 4 Characerisation and Mutation Screening of RP25 gene: EYS 
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used. A further RT-PCR was performed using primers designed in exon 26(F) and 
exon  40  (R),  with  the  same  result  being  produced.  It  is  possible  that  smaller 
transcripts, upstream or downstream of exon 4-40 may exist in other tissues; however 
it can be deduced that the full length transcript of RP25 is retinal specific. This is a 
very significant result, as it can be concluded that the RP25 gene is the largest eye 
specific gene identified in the human genome to date. 
 
4.2.2 Full length RT-PCR  
To  verify  the  predicted  size  of  the  coding  transcript  of  RP25  as  being  accurate,  a 
reverse  transcriptase  PCR  (RT-PCR)  experiment  was  performed.  By  reverse 
transcribing the RNA strand into its DNA complement using reverse transcriptase, the 
resulting cDNA is amplified by PCR. Two cDNA specific primer pairs were designed 
to PCR amplify the coding transcript in two overlapping fragments. The first primer 
pair was designed from exon 4 to exon 26 (4.8 Kb), the second was designed to amplify 
a cDNA fragment from exon 26 to exon 43 (4.1 Kb) (see appendix) with the overlap in 
exon 26.The successful amplification of these two fragments confirms that the retinal 
transcript of the RP25 gene is the predicted size of 9.1 Kb and 3,145 amino acids.  
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Figure 4.4 A cDNA expression profile for the full length gene of RP25. Primers spanning 8 exons 
(exon 4-11) were used to amplify a large coding region. The cDNA amplicon was 1.8 kb in size. A 
retinal specific cell type (Y79) was incorporated in this expression experiment. A band specific for 1.8 
kb was amplified in retinal cDNA and in the Y79 cell line. The control experiment was performed 
using PGM1 primers, which is a ubiquitously expressed gene.  
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Figure 4.5 A RT-PCR experiment performed on two overlapping fragments of the coding transcript of 
the RP25 gene. The first fragment ran from exon 4 to exon 27 this was 4.1kb in size. The second 
fragment incorporated exon 27 to exon 43. The marker used in this experiment was a 10 kb ladder. The 
full length of the transcript stands at 9.1kb. Thus the two overlapping fragments correspond to the full 
length size of the cDNA transcript. 
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4.3   Protein structure and domains 
Protein  structure  prediction  was  carried  out  with  the  expertise  of  Professor  Chris 
Ponting and Dr Leo Goodstadt of Oxford University. The domain architecture of RP25 
was predicted using the SMART (Simple Modular Architecture Research Tool) protein 
domain  database  server.  It  allows  the  identification  and  annotation  of  genetically 
mobile  domains  and  the  analysis  of  domain  architectures  User  interfaces  to  this 
database allow searches for proteins containing specific combinations of domains in 
defined taxa. EGF, Ca
2+-binding EGF and Laminin-G domains were identified as the 
combination of domains in the RP25 protein. EGF-like and Laminin G domains are 
commonly  found  in  extracellular  proteins.  Many  proteins  containing  Laminin  G 
domains are involved in a variety of roles, including signaling, migration and assembly. 
Laminin-1  appears  to  be  a  key  molecule  in  early  embryonic
  basement  membrane 
assembly (Sasaki et al., 2004). EGF-like domains are known to present in a more or 
less conserved form. Proteins with EGF-like domains are often quite large (> 1000 
amino acids) and have multiple copies of this domain in addition to other domains 
known to be involved in specific protein-protein interactions (Nakayama et al., 1998).  
The EGF, Ca
2+-binding EGF and Laminin-G domain predictions were further refined 
manually using seed alignments from SMART and hmmsearch from the HMMER suite 
of programs. Functional EGF domains were found by conservation of the consensus 
cysteines required for disulphide bond formation. EGF- Ca
2+ domains were identified if 
they retain consensus negatively-charged residues. 
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Figure 4.6 Overview of the size and structure of the RP25 gene. RP25 is mapped to chromosome 6q12. 
The genomic size of the gene is over 2 Kb in length. The corresponding previously identified transcripts 
within  the  RP25  gene  with  the  localisation  of  exons  spanning  the  RP25  gene.  The  corresponding 
domains and peptide signal (red) in the RP25 protein, including EGFL, LamininG and Ca
2+ domains is 
demonstrated at the bottom of the figure .  
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4.4  Homolog of human RP25  in Drosophila melanogaster 
Once the domain structure of the RP25 protein was ascertained identity alignments to 
other  characterised  proteins  was  performed.  As  previously  depicted,  the  featured 
regions  of  the  RP25  protein  include  EGF  like,  Ca
2+-  binding  EGF  and  Laminin 
(LamG)  domains.  Based  on  proteins  previously  identified  with  EGF-like  domain 
repeats, the repeat pattern of cysteines in the EGF-like domains of the RP25 protein 
may  be  an  essential  factor  in  its  overall  tertiary  structure.  The  trademark  of 
extracellular  proteins  as  Notch  expressed  in  Drosophila  melanogaster  (D. 
melanogaster) is a run of such EGF-like domain repeats (Weinmaster et al., 1991). 
LamG  is  thought  to  have  a  diverse  role  in  cell  adhesion,  signalling,  migration, 
assembly  and  differentiation  (Beckmann  et  al.,  1998).  BLASTP  was  applied  to 
compare the RP25 protein against all other available sequenced species. Each species 
was aligned against the human protein, through which an interesting alignment to the 
D. melanogaster (fruit fly) genome was determined. All D. melanogaster and human 
orthologs whose sequences contained predicted LamG domains separated by one or 
two  EGF  domains  were  selected.  The  LamG  domain  sequences  were  manually 
aligned and the phylogenetic distances between them calculated using protdist from 
PHYLIP. An ortholog of the human RP25 gene was subsequently discovered in D. 
melanogaster. 
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4.5  RP25 Gene annotation: EYS/(SPAM/SPACEMAKER) 
The N terminus fragment of the RP25 gene (EGFL11_human) was not identified as 
having a homolog in D. melanogaster; however the rest of the gene was established 
to be highly homologous to a previously predicted gene. The ortholog of interest is 
called  eys  (eys  shut)  with  the  protein  name  of  spacemaker/spam.  The  domain 
organisation of eys is comparable to that of the human homolog protein, with 14 
EGF-like and four laminin G-like domains positioned in a similar order (Figure 4.7). 
Based on this breakthrough, the RP25 gene was given the name EYS and the protein 
name of SPAM.  
 
Eys has previously been identified as a gene that is essential for the formation of 
matrix-filled inter-rhabdomeral space in the D. melanogaster eye (Husain et al., 
2006). This inter-rhabdomeral space is an important aspect of the structure of the 
Drosophila eye, as it separates each rhabdomere (photoreceptor) from each other. The 
adult eye consists of approximately 800 hexagonal ommatidia or facets, each 
ommatidium is a structure which contains eight photoreceptor cells, and each 
associated with a photosensitive membrane called a rhabdomere. Photoreceptor cells 
one through six of each ommatidium is placed radically around cells seven and eight. 
Rhabdomeres of cells seven and eight occupy a central position, cell seven above cell 
eight (Figure 4.8). The visual system of the D. melanogaster is built following the                    Chapter 4 Characerisation and Mutation Screening of RP25 gene: EYS 
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principle of neural superposition that is believed to have evolved from an apposition 
compound eye type which is the visual system of most insects (Husain et al., 2006). 
 4.6 SPAM orthologs in the eyes of other insects 
Identification of an ortholog has been determined in D. melanogaster, but what about 
in other insect species? Orthologs of spam have been identified in the eye of other 
insect species with a similar rhabdom system as that in the D. meanogaster such as 
the housefly (Musca domestica Linnaeus). This system is called an “open rhabdom 
system” as each rhabdom is separated by an interrhabdomeral space; it is within this 
space that spam is expressed. Other species such as the honeybee (Apis mellifera), 
rust red flour beetle (Tribolium castaneum) and the mosquito (Anopheles gambiae) 
have an apposition visual system which is a subclass of the compound eye. In these, 
each ommatidium detects a different area in the visual field. All photoreceptor cells 
(PRCs)  within  one  ommatidium  collect  light  from  the  same  area  and  their 
rhabdomeres are not required to be optically individual and instead tightly adhere to 
each other, which is also known as a closed or “fused rhabdom system”. The D. 
melanogaster eye has evolved from an apposition eye in this “open rhabdom” system 
(Figure  4.9).  Interestingly,  orthologs  of  D.  melanogaster  spam  have  not  been 
identified in the genomes of such insects as the honeybee, rust red flour beetle and the 
mosquito, in other terms, species with compound apposition eyes (closed rhabdom 
system). From this it can be concluded that spam is probably restricted to insects that 
acquire an open rhabdomeric visual system.                    Chapter 4 Characerisation and Mutation Screening of RP25 gene: EYS 
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Figure 4.8 A depiction of a Drosophila compound eye. In each eye, there are approximately 800 
ommatidia;  in  each  ommatidium  there  are  8  rhabdomeres.  Each  rod  shaped  rhabdomere  is 
representative of a photoreceptor cell. 
(Taken from http://www.nimr.mrc.ac.uk/molneurobiol/salecker/eyesection/)  
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Figure 4.9 Two types of visual systems in insects. A- “Closed System”- The visual system of honey 
bees, in this system all rhabdomes are fused together. B- “Open System”- Evolved from the closed 
system, in this system all rhabdoms are separated from each other, this is the visual system of the fruit 
fly.  LVF-Long  visual  fibre  photoreceptor.  SVF-Short  visual  fibre  phororeceptor.  R-Rhabdomere. 
Adapted from Osorio, 2007.  
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4.7   EYS and orthologs across species 
 
In order to determine orthologs of EYS in other species, a BLAST search against all 
available sequenced genomes was performed. A phylogenetic tree was constructed by 
Dr. Leo Goodstadt, consisting of a selection of genomes across several phyla’s. The 
phylogenetic tree (figure 4.10) was constructed through BLAST results of exon 43 of 
EYS.  The mutual rate for each species used was then determined. The mutual rate is 
based on the redundant genetic code (dn/ds- number of non synonomous sites over the 
number of synonomous sites in the selected sequence). The mutual rate for conserved 
genes is usually approximately .1%. If this genetic code moves towards 1, the gene is 
becoming redundant in the species (Choi et al., 2005). Resulting from the phylogentic 
tree analysis it was concluded that the EYS gene is found across many mammalian 
species including monotremes (platypus), marsupials (opossum) and chordata including 
the rabbit (Oryctolagus_cuniculus) and the pig (Sus domestica). It is also found with 
high identity in non-mammals such as the chicken (Gallus gallus) and in the zebrafish 
(Danio rario). However, interestingly this gene has somehow been disposed of with, in 
several species  genomes (Figure 4.10) such species include the armadillo (Dasypus 
novemcinctus), little brown bat (Myotis lucifugus) and ruminants (cattle and sheep). 
 
EYS also appears to be severely disrupted in rodents and has gone through more than 
3 reading frame shift disruptions in three rodent species (mouse, rat and guinea pig). 
These frameshift disruptions lead to the pseudogenisation of EYS in these genomes. 
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EYS. Results of this experiment reinforced the phylogenetic tree data, that EYS has 
been disrupted in mice and rats. A short sequence run from EYS is depicted in figure 
4.11.  To  further  confirm  the  accuracy  of  these  predictions,  PCR  amplification  of 
exons belonging to EYS using mouse and rat retina cDNA. Mouse retina cDNA was 
prepared from RNA collected from mice bred in house. Rat RNA was purchased 
(Clontech, France) and cDNA was prepared in house. Amplification of a GAPDH 
exon (see appendix for primers) was incorporated into the experiment as a control and 
cDNA specific primers were designed across several exons of EYS, in exons 14, 26 
and  43.  Failure  of  amplification  of  these  three  amplicons  spanning  across  EYS 
confirms that this gene structure is absent or has become a pseudogene, or is possibly 
assembled differently in mouse and rat genomes (Figure 4.12). 
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Figure 4.10 Phylogenetic tree depicting the independent disruption of eys (spam) in each of the guinea 
pig, rat, sheep, cattle, bat and armadillo lineages (in red). There are no traces of sequence correspondence 
to multiple regions of mouse genomic sequences in this region in the assembled genome which explains 
the absence of eys (spam) in the mouse. The final exon (43) of EYS was used to determine the mutual 
rate of eys across each species (numbers next to each species). This tree was constructed by Dr. Leo 
Goodstadt. 
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Species   Chromosome  & 
nucleotide 
number position 
Sequence 
Homo_sapien  6:66416664 
6:66416547 
CATAGGGCCATGAAATGTCAATTGCAAATGAAATTGTATGATTTT-TCAGTTT- 
GTTTAGAAAAGATTTTGGCCATAAATCTAGAGATACTCATACTAGTTTTGTTG 
GAGGTGATGTTTA 
Canis_familiaris     12:31905674 
12:31905556 
CATAGTGCTACAAAATGTCAATTATAAAATAAATCATATAATGTTCACACTTA 
CTTTTACAAAAGATGTTAATCATAAATCTGGAAATACTTAACCATGG-TTTTTG 
GAAGTGCCTTTTA 
Equus_caballus       20:58311975 
20:58311858 
CATAGTGCAGTGAAATGTCAATTGTGAAAGAAACTGTATAATTGTCACACTTT- 
GTTTACAAAAGATGTTAACCATTAGTCTGGAAATACTTGAACCCAT–TTTTTG 
GAAGGGCCTTTTA 
Mus_musculus                   
                   
_______________ 
……………………………………………………………………………………………… 
……………………………………………………………………………………………… 
Rattus_norvegicus              
 
_______________ 
………………………………………………………………………………………………. 
………………………………………………………………………………………………. 
 
 
 
Figure 4.11 Blast alignment of a short fragment of EYS against several species. This alignment reveals 
an  obvious  absence  of  EYS  in  Mus  musculus  (mouse)  and  Rattus  norvegicus  (rat).  There  is  a  high 
similarity of this particular sequence in Canis familaris (dog) and in Equus cabullus (domestic horse). 
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Figure 4.12 Amplification of EYS exons using human, mouse and rat retinal cDNA.M-1 Kb Smart 
fragment ladder. 1- Human GAPDH (exon 4-322 bp). 2- Amplification of GAPDH exon 4 using mouse 
retinal cDNA. 3- Amplification of GAPDH exon 4 using rat retinal cDNA. Lane 4 represents human 
cDNA amplification of exon 14 (104bp) of EYS. Lanes 5 and 6 demonstrate no amplification of exon 14 
in mouse and rat retinal cDNA. Lane 7 is human exon specific amplification of exon 26 (492 bp), there is 
no amplification of mouse and rat retinal cDNA for this exon (8 and 9). The final three lanes (10, 11 and 
12)  represent  attempted  amplification  of  exon  43a  (552bp),  only  human  cDNA  (10)  amplified 
successfully.  
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4.8 Mutation Screening of EYS 
To  summarise,  two  independent  deletions  have  been  identified  in  two  unrelated 
Spanish RP families (RP5 and RP214). The two changes identified at this stage were a 
deletion of 100 Kb (which spans 5 exons) in family RP5, though the breakpoints of this 
deletion hadn’t been defined and a 17 base pair deletion which was identified in the 
RP214 family.  
 
Through exonic mutation sequencing, our colleagues in Spain identified a heterozygous 
null mutation in the RP73 family, this change was identified in exon 12 which leads to 
a stop codon (Figure 4.13). As RP25 is a recessive disorder, the requirement is for both 
alleles  to  have  a  mutation  in  order  for  a  disease  phenotype  to  prevail.  Since  this 
mutation  was  identified  as  a  heterozygote,  a  further  mutation  is  necessary  to  be 
identified for this change to be considered as disease causing. Exonic sequencing of the 
full  length  of  EYS  was  performed,  however  no  second  mutation  was  identified, 
therefore a CGH array analysis was necessary for this family in order to identify if 
there is a second mutation, this possibly being a large deletion. 
 
My colleagues identified two further unique mutations in two unrelated Spanish RP 
families. In family RP328, a homozygous point deletion of one base pair was identified 
in exon 28 leading to a truncated protein (Figure 4.14). A null mutation causing an 
amino acid change of tryptophan to a stop codon was identified in exon 41 of affected 
members  of  RP349  (Figure  4.15).  In  total,  five  unique  mutations  in  five  unrelated             Chapter 4 Characterisation and mutation screening of the RP25 gene: EYS 
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Spanish RP families had been identified, however significantly a second change was 
necessary  for  the  change  in  family  RP73  to  be  considered  as  disease  causing.  All 
changes identified in the affected Spanish families are summarised in Table 4.2.  
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Figure  4.13  Chromatogram  view  of  the  heterozygous  mutation  c.5857  G>T  in  family  RP73  and 
electrophoresis depiction of the change in the affected members of the family. A restriction digest using 
Hph1 was performed to test the segregation of the change in this family. This experiment was performed 
by collaborators in Seville, Spain. 
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 Figure 4.14 A chromatogram and electrophoresis view of the single bp deletion, c. 1971delT in family 
RP328. A restriction digest (Spe￿) was performed on the family to demonstrate the segregation of the 
deletion  in  all  members  of  the affected  family.  This  experiment  was  performed  by  collaborators  in 
Seville, Spain.             Chapter 4 Characterisation and mutation screening of the RP25 gene: EYS 
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Figure 4.15 A chromatogram and electrophoresis view of the homozygous base pair change c.7919G>A 
in the RP349 family. A restriction digest using enzyme pfIMI was performed on all members of the 
affected  family  to  demonstrate  the  segregation  of  the  mutation.  This  experiment  was  performed  by 
collaborators in Seville, Spain. 
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  Table 4.2  Summary  of  Mutations  identified  in  EYS in  arRP Spanish  families. 
(Table from Abd-El Aziz et al., 2008)   
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4.9 Identification of 2
nd heterozygous change in RP73 
 
Due  to  the  identification  of  a  heterozygous  base  pair  change  identified  in  family 
RP73, collaborators at Sanger Centre performed an Agilent array and a Nimblegen 
chip on members of this family. Since the mother of this family was deceased, only 
the fathers DNA and one affected DNA samples were analysed (See figure 1.7 for 
pedigree of RP73 family). As previously depicted through a restriction enzyme digest 
experiment, the heterozygous point mutation was not identified in either of the alleles 
belong to the father.  It is therefore assumed that if a second change is identified 
through  tilepath  array  analysis  it  should  present  in  the  father  in  a  heterozygous 
manner i.e. only on one allele. Four clones were identified as being absent in the 
affected  members  of  this  family,  these  were  mapped  to  the  same  region  as  the 
deletion of the clone in RP5 (Figure 3.12) suggesting that a second mutation has been 
identified in the RP73 family. This deletion was not identified in the corresponding 
exons of EYS, as full amplification was attainable in all exons in all members of this 
family, leading to the suggestion that this change is the second heterozygote deletion 
in this family. The identification of this change was imperative, as it concluded our 
sixth conclusive mutation in the affected families. It is interesting to note that all five 
families acquired varying types of mutations leading to the RP25 phenotype (Table 
4.2).  
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Figure  4.16  An  ensembl  view  (Version  43:  April  2007)  of  the  clones  of  interest  in  the  region. 
Highlighted in red are the clones identified as being deleted in the affected members of RP73, the clones 
include Chr6tp-10G7, Chr61p-18D9 and Chr61p-9B9. The combined size of these clones is 270 kb. The 
clone highlighted in blue corresponds to the clone deleted in RP5 affected members.  
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Figure 4.17 An Agilent array performed on members of the RP73 family. The above readout is of the 
father and the affected daughter on chromosome 6. The blue line indicates where the deleted clone was 
identified, the high peaks in both members demonstrates that this deletion was in both carrier father and 
affected daughter of this family as this is the 2
nd heterozygous deletion identified. This experiment was 
performed by the Sanger Centre, Cambridge.  
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4.10 Refinement of large deletions using MLPA (Multiplex Ligation 
Probe Dependent) assay and Agilent arrays. 
 
The following experiments were performed by colleagues in Seville, Spain and in the 
Sanger Centre, Cambridge. 
 
Two large  deletions  were  identified  in  families  RP5 and RP73  respectively, whose 
breakpoints had yet to be ascertained. To identify these breakpoints, an MLPA assay 
and an Agilent array were performed, the MLPA assay was designed being performed 
by our Spanish colleagues and the 244k Agilent array was undertaken by the Sanger 
Centre, Cambridge. For the MLPA assay a set of control probes was included in each 
synthetic probe mix in order to provide invariable values. From these experiments, the 
deletion  in  the  RP5  family  was  determined  to  span  from  65581641  to  65783332 
nucleotides on chromosome 6q, being 202 kb in size (Figure 4.18). The deletion in 
RP73 spans 270 kb, from 65816910 to 66087361 nucleotides (Figure 4.19). 
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Figure 4.18 As previously depicted, an Agilent array was performed on RP5 family members. This array 
also narrowed down the interval to identify the deletion size and breakpoint. The deletion ran from 
65581641  to  65783332, the fragment spanning  202 Kb. This  was  performed  by  the  Sanger  Centre, 
Cambridge.  
 
 
 
Mother   Son   Father  
RP5 
65581641 
65630616 
65760938 
65783332 
49 Kb 
22 Kb 
 
Deletion 65581641-65783332 202 Kb              Chapter 4 Characterisation and mutation screening of the RP25 gene: EYS 
 
  163
 
 
 
 
Figure 4.19 As in figure 4.18, an Agilent array was performed on family members of RP73. This array 
identified the exact  breakpoint  and  size of the  deletion  as  being  270 Kb in size,  and  running  from 
65816910 to 66087361 in chromosome 6. This was performed by the Sanger Centre, Cambridge. 
 
 
 
 
 
65816910 
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66067409 
66087361 
 33.8 kb 
 19.9 kb 
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4.11     Mutation screening of arRP panel 
Once the full length EYS gene was identified, a thorough mutation screening of a mixed 
ethnic arRP panel was performed. Patients were British residents of a variety of ethnic 
origin (European Caucasian and Asian from the Indian subcontinent). All 96 patients 
were identified through the retinal dystrophy clinics at Moorfields Eye Hospital using 
standard  techniques.  Informed  consent  for  genetic  studies  in  adherence  to  the 
Declaration  of  Helsinki  was  obtained  by  the  examining  clinicians.  Primers  were 
designed to span approximately 200 base pairs aligning each exon (see appendix). In 
total 47 primer pairs were designed for all 43 exons, three of which are completely non-
coding, a further two having a non coding region. Amplification standards for each 
exon  can  be  found  in  appendix.  Novel  changes  identified  were  compared  with  the 
Ensembl  database  to  confirm  the  prevelence  of  the  change.  Once  a  change  was 
identified to be novel, a control experiment was performed on 96 ethnically matched 
individuals with no personal or family history of retinopathy. These were selected to 
serve as controls. Any change which was not identified in the control population was 
then proposed to be a novel and a possible mutation for RP25. 
 
Many SNPs previously annotated on Ensembl were identified across the gene, several 
novel SNPs were also identified in many members of the arRP panel (Table 4.1). These 
changes, though not identified on Ensembl, were identified through amplification of 
DNA  from  a  control  panel,  therefore  eliminating  them  as  putative  mutations.  Four 
interesting novel changes were identified in specific arRP patients (Figure 4.21); in             Chapter 4 Characterisation and mutation screening of the RP25 gene: EYS 
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exon  36,  a  heterozygous  base  pair  change  G>A,  causing  an  amino  acid  change  of 
arginine (R) to lysine (K). This was only identified in one patient in the panel, patient 
annotated  number  32.  Two  further  heterozygous  changes  were  identified  in  other 
recessive panel members. In patient 28, a heterozygous C>G change was identified 
leading to an amino acid change from tyrosine (Y) to a stop codon (*). In 18 patients of 
the panel a G>C heterozygous change was identified causing an amino acid change of 
valine (V) to alanine (A). Interestingly this change was not identified through screening 
of  the  control  panel.  A  final  change  was  identified  in  exon  40,  this  again  was  a 
heterozygous  change of C>T leading to a change of amino acid of arginine (R) to 
cysteine (C), identified in patient 23 of the 96 recessive panel (Table 4.3). 
 
Since EYS is a recessive gene, it is necessary for both alleles to contain a mutation in 
order for the mutation to be considered as putative. All changes identified in this panel 
have been heterozygous; this does not rule out that these are putative changes; however 
a second change may be necessary in order for the protein to become redundant. It is 
suggested that the second changes in these patients may be large mutations or changes 
in intronic regions. A compound heterozygous change has previously been identified in 
RP73. Also, large mutations were identified in RP5 and RP73, therefore it would be 
suggested that a CGH array analysis be carried out on these patients in order to identify 
further mutations. For these changes to be considered as real is that further control 
panel screening should be performed. If time had prevailed, mutation screening of at 
least  200  members  from  a  mixed  ethnic  population  should  have  been  performed 
allowing for a more accurate statistical analysis.             Chapter 4 Characterisation and mutation screening of the RP25 gene: EYS 
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       Table 4.3 Novel Changes and SNPs identified in arRP panel 
 
 
 
 
 
 
 
 
 
 
Exon   Sequence variation  Amino Acid 
Change  
SNP ID  Patient 
No 
Control  
Panel Screened 
1 
 
c.-508 A>G  
c.-546-81 A> C                   
 - 
 ________ 
rs1490127 
NOVEL 
   
12% allele frequency 
4  c.-359 C>T 
c.- 748+52 T>C 
p. T120M 
_________ 
rs12193967 
NOVEL 
   
18% allele frequency 
5  c.-862+87 T>C    rs4710522     
6  c.-863-22insTT 
c.911 
  rs34154043 
rs34676630 
   
7  c.-1146 T>C  p.N382N  rs974110     
9  c.-1300-3C>T 
c.1459+103C>T                    
  rs1936439 
rs9453265 
   
30  c.6078-4_6078-3delTC             rs35395170     
34  c.8634+61T>G                   -  ENSSNP7485951   
35  c.6835-64C>T    
c. 6977G>A                      
- 
p.R2326Q     
rs1482457 
rs4710457 
   
36  c. 7205 G>A    p. R2402K  NOVEL  32  No allele frequency 
39  c.7723+64T>A    
 
 
c.7666A> T 
 
 
c.7665 C>G       
 
 
c.7658G>C    
                             
_________ 
 
 
p.S2556C     
 
 
p. Y2555* 
 
 
p.V2553A 
NOVEL 
 
 
NOVEL 
 
 
NOVEL 
 
 
NOVEL 
In 3 patients
 
 
In 5 patients
 
 
28 
 
 
In 18 of 96 
30% allele frequency 
 
 
25% allele frequency 
 
 
No allele frequency 
 
 
No allele frequency 
40  c.7796 A>G 
 
 
c.7810 C>T 
p. P2566P 
 
 
p.R2604C 
NOVEL 
 
 
NOVEL 
In 3 patients
 
 
23 
10% allele frequency 
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Figure 4.21 Electropherograms of novel mutations identified in individual patients of an arRP panel. A:  
c. 7205 G>A change identified in exon 36 in patient 32. B: c.7665 C>G change identified in exon 39 in 
patient 28. C: c.7658G>C identified in exon 39 in 18 members of the panel. D: c.7810 C>T in exon 40 in 
patient 23.  
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4.12 Conclusion of Chapter 4        
 
 
The EYS transcript initially spanned 14 exons with no translation start or stop codon 
identified, however through further 5`and 3` RACE the gene expanded to incorporate 
the already characterised EGFL-11 gene making the gene 26 exons in size. At this 
time,  the  translation  start  codon  of  the  RP25  gene  was  identified;  however  the 
translation  stop  codon  was  not  determined.  A  1,238  bp  coding  fragment  was 
identified at the 3` end of exon 29, which did not alter the coding region of the gene; 
this  novel  discovery  had  not  been  previously  annotated  in  the  available  human 
genome database. After several more rounds of 3`RACE and bioinformatics exonic 
predictions,  the final  full length transcript  of  the RP25  gene  was  determined.  On 
assembling all available data, RP25 encompasses 43 exons, 30 exons belonging to 9 
previously predicted genes and 13 newly reported exons, spanning from 64487835 
and 66473839 MB on chromosome 6q12. The RP25 full length transcript is retinal 
specific and is greater than 2.0 MB in size, thus it is the largest eye-specific gene 
found to date. It is also the fifth largest gene in the human genome to date.  
 
Human RP25 was determined to be an ortholog of the fruit fly (D. melanogaster) 
gene eys (Spacemaker), thus RP25 was renamed EYS (SPAM). Orthologs of this gene 
were not identified in insects such as the honeybee, as these insects have a variation 
in their visual system and is not an open rhabdome visual system. An apparently 
intact  EYS  gene  is  found  across  the  mammalian  clade,  including  monotremes             Chapter 4 Characterisation and mutation screening of the RP25 gene: EYS 
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(platypus)  and  marsupials  (opossum).  However,  despite  the  mutations  and  the 
presumed  loss  of  function  associated  with  human  disease,  this  gene  has  been 
dispensed with on at least four separate occasions in the last 100 million years of 
mammalian  evolution,  including  the  armadillo  (Dasypus  novemcinctus),  the  little 
brown  bat  (Myotis  lucifugus)  and  ruminant  (cattle  and  sheep)  lineages.  Eys  has 
acquired many (<3) reading-frame disruptions in three rodents (mouse, rat and guinea 
pig)  representing  two  of  the  three  major  rodent  clades.  RT-PCR  confirmed  the 
absence of eys in mice and rat genomes.  
 
Mutation  screening  analysis  of  the  full  length  EYS  gene  continued  on  all  linked 
Spanish families. Three novel mutations were identified in three unrelated families. In 
RP73, a heterozygous null mutations was identified, later a second large deletion (270 
Kb) was confirmed through CGH analysis. This was the first compound heterozygous 
change revealed thus far in EYS. Two further unique mutations were identified in two 
unrelated families respectively. In family RP328, a homozygous base pair deletion 
was identified causing a frameshift in the gene. In family RP349, a homozygous null 
mutation was identified. The breakpoints of the deletion in the RP5 family were also 
determined to be 202 Kb through MLPA and CGH analysis. In total, five unrelated 
Spanish  arRP  families  with  six  unique  mutations,  one  being  a  compound 
heterozygote, all leading to the RP25 phenotype. 
 
  Once the full length gene was identified, arRP panel mutation screening of EYS 
began. From this, four novel heterozygous mutations were identified. These could be             Chapter 4 Characterisation and mutation screening of the RP25 gene: EYS 
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considered  as  putative  changes,  however  for  these  changes  to  be  considered  as 
disease causing for recessive RP, a second mutation would need to be identified, 
therefore  considering  these  changes  as  compound  heterozygous.                                                                    Chapter 5 Immunolocalisation of SPAM 
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                         CHAPTER 5 
 
Immunolocalisation of SPAM 
 
5.1 Production of SPAM antibody 
 
Once the full length gene and protein structure of SPAM were ascertained an antibody 
was designed against the protein. Antibodies demonstrate both the presence and the sub 
cellular  localisation  of  a  protein  through  the  antigenic  epitopes  present  in  the 
polypeptide. The antibody was selected through the most suitable predictions offered 
by Eurogentec S.A (Belgium). Antigen selection is usually based on hydrophilicity, 
amino acid composition, and certain post-translational modifications (Pow et al., 2008). 
                           
An antigen against the amino-terminus of the human protein was selected as being the 
most suitable; this was done with the expertise of Professor Mike Cheetham, UCL. A 
peptide sequence for the N-terminal sequence of the protein was selected due to the 
amino-  and  carboxyl-termini  being  solvent-exposed  sequences  and  mobile  in 
crystallographic structures of proteins. Rabbit polyclonal antiserum was raised against 
one  peptide  derived  from  the  predicted  amino  acid  sequence  by  Eurogentec.  The                                                                         Chapter 5 Immunolocalisation of SPAM 
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peptide (human N-terminal residues 61-75, GVNTKIDTSGNQAVP) was conjugated to 
hemocyanin through an N-terminal cysteine residue before immunization. The length 
of the chosen peptide is an important factor, as peptides with residues of nine or less 
may  not be effective antigens.  Similarly, peptides longer than 16 amino acids  may 
contain several epitopes; the peptide selected in this instance is assembled of 15 amino 
acids. A final bleed from the immunised rabbit was affinity purified against a peptide 
made from Eurogentec (Double XP program), and the affinity purified serum was used 
in all subsequent experiments. 
 
5.2 Immunocytochemistry with SPAM 
5.2.1 SPAM localisation in Y79 cells 
The existence of EYS in human retinoblastoma cell line Y79 was confirmed in chapter 
4.  To  validate  this  result  and  to  examine  the  specificity  and  quality  of  the  SPAM 
antibody, ICC was attempted using these cells. Y79 cells acquire morphological and 
cytochemical properties typical of human photoreceptors (Tsokos et al., 1986). Because 
these cells are a suspension cell line, additional steps during the ICC protocol were 
required to obtain positive results (Section 2.9).  
 
A gradient of SPAM antibody dilutions were attempted, in this instance, the optimum 
condition for anti-SPAM was a 1:200 dilution with a Cy3 (red) conjugated AffiniPure 
goat  anti rabbit  secondary  antibody  (1:400,  JacksonImmunoResearch  lab).  Negative                                                                         Chapter 5 Immunolocalisation of SPAM 
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control experiments were performed in parallel with cells being stained with the Cy3 
secondary antibody alone with results revealing a positive punctate speckled staining of 
anti-SPAM  in  the  Y79  cells  (Figure  5.1A).  Minimal  background  staining  in  the 
negative control experiment (Figure 5.1B) contributes to the validity of the positive 
anti-SPAM staining in these cells.  
 
To  further  confirm  the  positive  staining  of  SPAM  in  Y79  cells,  a  co-localisation 
experiment was performed with alpha tubulin. Alpha tubulin is an intercellular filament 
structure which makes up cells’ cytoskeleton and exists throughout the cell. In this 
instance, it is used as a marker to identify how abundant the anti-SPAM signal is. Y79 
cells  were  stained  with  anti-SPAM  (1:200)  and  anti-alpha  tubulin  (1:200,  personal 
communication  with  Professor  Matter,  Institute  of  Ophthalmology,  UCL).  SPAM 
staining  (red)  revealed  an  abundant  punctuates  speckled  signal  throughout  the 
cytoplasm of these cells, with alpha tubulin (green) acting as a marker around the cells. 
A yellow signal is indicative of a possible overlap of staining of anti-SPAM and anti-
alpha tubulin (Figure 5.2). All ICC experiments were visualized using a Zeiss LSM510 
laser  scanning  confocal  microscope.  These  results  are  preliminary  and  do  not  give 
comprehensive detail into the precise localisation of SPAM in the cell. One conclusion 
is that there is a high level of SPAM expression in the cytoplasm of Y79 cells. This is 
consistent with the cDNA expression profile which illustrates that EYS mRNA (SPAM 
being the protein) is present in abundance in this retinoblastoma cell line (Figure 4.4).  
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Figure 5.1 ICC staining of Y79 cells with anti-SPAM alone. A anti-SPAM staining (red) highlights a 
prominent speckled staining throughout the cytoplasm of the cell. B A control experiment performed 
using Cy3 secondary antibody alone, only highlighting DAPI (4' , 6-diamidino-2-phenylindole) staining 
of the cell nuclei. 
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Figure 5.2  Immunofluorescent  staining  of  Y79  cells  with  anti-alpha-tubulin  (green) and  anti-SPAM 
(red). A ICC staining for anti-Alpha tubulin (FITC). B A signal for anti-SPAM (Cy3), highlighting a 
speckled staining prominent in the cytoplasm. C Overlay of alpha-tubulin (green), SPAM (red) and 
DAPI (blue) staining. A yellow signal highlights a possible overlap of signal from the SPAM and alpha 
tubulin  antibodies.  D  Enlarged  view  of  a  single  Y79  cell  stained  with  SPAM  and  alpha  tubulin 
antibodies. 
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5.3 Immunohistochemistry (IHC)  
5.3.1 IHC on mouse retina tissue 
The mouse is a key model organism for studying diseases such as retinitis pigmentosa; 
it  has  a  well  characterised  genome  with  most  genes  identified  as  having  human 
orthologs (Huang et al., 2004). As described in chapter 4, SPAM is proposed to be 
dispensed with of in the mouse genome. To validate this assumption further, IHC was 
performed on mouse retina sections. 
 
When  the  epitope  raised  for  SPAM  was  compared  against  the  mouse  genome,  no 
significant similarity was detected; this is proven through IHC experiments on mouse 
retina  tissue.  Co-localisation  staining  experiments  were  performed  using  well 
characterised antibodies such as 1D4, anti-TOPORS (Abnova, UK), anti-RP1 (kindly 
provided by Professor Mike Cheetham, UCL) and PNA (details on all antibodies can be 
found in Section 5.7). All control experiments were performed in parallel. Anti-SPAM 
was  stained  using  a  goat  anti  rabbit  FITC  secondary  antibody.  Numerous  attempts 
using  a  gradient  of  SPAM  antibody  concentrations  were  attempted.  A  prominent 
fluorescent  signal  was  achieved  using  the  control  antibodies  (Figure  5.3);  however 
when performing IHC with the SPAM antibody, no significant signal was achieved. All 
IHC  experiments  were  visualized  using  a  Zeiss  LSM510  laser  scanning  confocal 
microscope. This result further validates the proposal that SPAM is absent from the                                                                         Chapter 5 Immunolocalisation of SPAM 
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mouse genome. However, it may be argued that the lack of signal detection could be 
due to the low similarity between the human SPAM sequence and its corresponding 
ortholog. In this particular case, the lack of signal detection is due to the mouse SPAM 
ortholog being a pseudogene.  
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Figure 5.3 Mouse retina IHC staining with anti-SPAM, RP1, 1D4 and PNA antibodies. A anti-
SPAM staining alone (green). B anti-SPAM (green) co stained with 1D4 (red). C anti-SPAM 
(green) is co stained with anti-RP1 (red). D anti-SPAM (red) co stained with PNA (green). 
There is an obvious lack of signal from the SPAM antibody in all experiments. OS- outer 
segment; IS- inner segment; ONL- outer nuclear layer; INL-inner nuclear layer. 
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5.3.2 IHC on porcine retina tissue 
Based on the prediction that SPAM is absent from the mouse genome, an alternative 
source of retinal tissue had to be chosen. Selection was based on BLAST similarity 
searches across several candidate genomes. BLAST was performed using the epitope 
sequence of the SPAM antibody as a target sequence and BLAST searches were carried 
out on pig (Sus scrofa), chicken (Gallus gallus) and rabbit (Oryctolagus cuniculus). Of 
these,  pig  was  selected  as  the sequence identity  of  the  antibody  epitope.  The  gene 
LOC100153323, similar to EGF-like-domain,  multiple 11 (Sus scrofa) which is the 
ortholog of SPAM in the pig, was identified as having 64% similarity for this peptide 
sequence (Figure 5.4). One of the major parameters which make an antibody successful 
or not is its specificity, even though the ortholog in this instance was 64% it seemed to 
be adequate to detect a signal for SPAM. Initial attempts to detect a signal failed due to 
factors  such  as  autofluorescence  which  was  redeemed  by  using  an  adequate  pre-
treatment protocol (Section 2.8).  
         
 
 
Control experiments are a critical aspect when characterising any antibody. Possible 
cross reactivity is eliminated by performing double labelling experiments using one 
primary antibody against the secondary of the other antibody. Another fundamental 
control experiment is conducted using the antibody in combination with the competing                                                                         Chapter 5 Immunolocalisation of SPAM 
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peptide, which is also known as immunoneutralisation. The purpose of this experiment 
is to ensure the signal identified is authentic and can be blocked when combined with 
the peptide.  
 
Conclusive  results  can  be  assumed  from  these  preliminary  porcine  retina  IHC 
experiments.  Figure  5.5  highlights  a  significant  staining  in  the  photoreceptors  of 
porcine  retina  tissue  using  anti-SPAM  with  a  FITC  secondary  antibody  (green). 
Successful staining was achieved using anti-SPAM in a 1:200 dilution. The lack of 
staining elsewhere in the retina leads to the initial postulation that SPAM is primarily 
located  in  the  photoreceptors.  All  controls  were  successfully  completed,  including 
immunoneutralisation  (Figure  5.6  B),  where  anti-SPAM  staining  appears  as  a  faint 
speckled signal in the tips of the photoreceptors.  
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> ref|XP_001924954.1|   PREDICTED: similar to EGF-like-domain, 
multiple 11 [Sus scrofa] 
Length=294 
 
 GENE ID: 100153323 LOC100153323 | similar to EGF-like-domain, 
multiple 11 
[Sus scrofa] 
 
 Score = 29.5 bits (62), Expect = 0.066 
 Identities = 9/14 (64%), Positives = 10/14 (71%), Gaps = 0/14 (0%) 
 
Query 2  VNTKIDTSGNQAVP 15 
         VN KI+TS N  VP 
Sbjct 63 VNAKINTSENHVVP 76 
 
 
Query- Sus scrofa. 
Sbjct- SPAM peptide. 
 
 
Figure 5.4 BLAST results of the peptide sequence for the SPAM amino-terminal antibody against the 
pig genome. A 64% identity between the porcine ortholgoue and human peptide was observed.  
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Figure 5.5 IHC staining on a porcine retinal section highlighting anti-SPAM (green) staining using FITC 
goat  anti-rabbit  secondary  antibody.  A  strong  signal  is  identified  in  the  photoreceptor  cells.  DAPI 
staining in blue highlights the nuclear layers of the retina. OS-outer segment; IS-inner segment; ONL-
outer nuclear layer; INL-inner nuclear layer; GCL-ganglion cell layer.  
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Figure  5.6  Control  IHC  experiments  on  porcine  retinal  sections.  A  anti-SPAM  staining, 
highlighting  a  strong  signal  for  anti-SPAM.  B  SPAM  peptide  versus  SPAM  antibody, 
demonstrating a speckled appearance, highlighting the blocking of the antibody by the competing 
peptide. C Primary SPAM antibody without a secondary antibody, no signal detected. D FITC goat 
anti-rabbit  secondary  antibody  alone,  without  any  primary  antibody  therefore  no  signal  was 
detected. C and D highlight that there is no background or secondary antibody staining. DAPI 
staining highlighting nuclear cell layers. 
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5.4 Co-localisation of SPAM with other proteins 
5.4.1 SPAM and Rhodopsin 
Immunofluorescence  staining  experiments  are  also  successfully  used  for  labelling 
multiple antigens in the same preparation. This method is particularly successful for the 
co-localisation  of  antigens  in  the  same  site  of  the  tissue  section.  An  initial  co-
localisation staining was performed using an anti-rhodopsin antibody, 1D4. Rhodopsin 
(RHO or RH1) is a well characterised gene and is a major cause of adRP and some 
arRP cases. It is a pigment of the retina that is responsible for both the formation of the 
photoreceptors and is also involved in the perception of light, detecting the levels of 
illumination.  RHO  is  identified  to  be  tightly  packed  in  the  outer  segments  of  rod 
photoreceptor cells (Kisselev, 2005) where it can maximise its photon absorption. 1D4 
is a monoclonal antibody that specifically detects the highly conserved C-terminus of 
rhodopsin molecules from a wide variety of mammalian (and many non-mammalian) 
rod cells. 1D4 was raised in mouse, while anti-SPAM was raised in rabbit. All control 
experiments were performed in parallel. 
 
The result of this experiment is extremely significant as it appears that SPAM and RHO 
completely co-localise producing a strong yellow staining when double labeled, with 
RHO  staining  being  more  prominent  on  the  rim  of  the  outer  segments  of  the 
photoreceptors  (Figure  5.7).  From  this  result  it  is  possible  to  postulate  that  SPAM 
localises specifically to retinal photoreceptors, due to a signal not being detected in any 
other cell layer.                                                                         Chapter 5 Immunolocalisation of SPAM 
 
  185
    
                   
 
 
Figure 5.7 IHC co-localisation of SPAM and RHO antibodies in porcine retina. A IHC staining with 
anti-SPAM (green). B Staining of 1D4 (anti-RHO) (red). C Co-localisation staining of anti-SPAM and 
1D4, with the nuclear layer. The yellow colour depicts the overlap of signal of anti-SPAM and 1D4 in 
the outer segments of photoreceptors. 
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5.3.2 Localisation of SPAM with PNA and WGA 
To  further  speculate  the  precise  localisation  of  SPAM  in  porcine  retina  tissue,  co-
staining  with  labeled  lectins  PNA  (Peanut  agglutinin)  and  WGA  (Wheatgerm 
agglutinin)  streptavidin  conjugates  (ZyMAX  Grade  1:100,  Zymed  laboratories,  San 
Francisco, CA) was performed.  WGA is a lectin from wheat germ that binds to N 
acetylglucosaminyl (Naeem et al., 2007) and PNA is a lectin that specifically binds to 
Gal-beta (1-3)-GalNAc carbohydrates (Krull 2000). Both PNA and WGA are specific 
lectins that bind in the insoluble interphotoreceptor matrix (IPM) of the human retina. 
PNA selectively binds to the cone matrix domains whereas WGA binds to the matrix 
domains surrounding rods (Tien et al., 1992). Antibodies utilised for both lectins were 
performed  with  a  biotinylated  FITC  secondary  antibody  to  ensure  strong  specific 
binding of the streptavidin. IHC staining of porcine retina with anti-SPAM and PNA 
resulted  in  a  lack  of  co-localisation  as  both  the  antibody  and  marker  exhibit 
independent  signals  with  no  overlap  of  staining  (Figure  5.8).  This  leads  to  the 
hypothesis  that  SPAM  is  absent  from  cone  photoreceptors  in  porcine,  alternatively 
SPAM may exist in cones but at a lower expression level in comparison to the strong 
clearly visible staining in rod photoreceptors. Double IHC labelling with WGA reveals 
a strong yellow orange staining concluding the foremost existence of SPAM is in rod 
photoreceptor cells (Figure 5.9). This antibody staining result conclusively exhibits the 
presence of SPAM in rod photoreceptor cells.  
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Figure 5.8 IHC co-staining of SPAM and PNA (stains the rims of cone photoreceptors). A Anti-SPAM 
(red). B PNA (green) staining. C Overlay of both antibodies with DAPI nuclear staining. There is no 
colocalisation of SPAM and PNA. The right hand panels depict an enlarged view of PNA and anti 
SPAM staining.  
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Figure 5.9 IHC staining with anti-SPAM and WGA antibodies. A IHC staining of anti-SPAM (red). B 
WGA (green) staining. C Overlay of SPAM and WGA staining with DAPI. Enlarged view in the right 
hand columns of single photoreceptors stained with WGA and SPAM. The merged image of both 
antibodies (yellow) confirms there is some co localisation of SPAM and WGA. 
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5.4.3 IHC of SPAM, TOPORS and RP1 antibodies 
The localisation of SPAM to photoreceptors can now be concluded, in particular to the 
rod  photoreceptors  of  porcine  retina.  Further  co-staining  IHC  experiments  were 
performed to refine the precise localisation of SPAM in photoreceptor cells. Antibodies 
to TOPORS and RP1 were selected to define this precise localisation. TOPORS is a 
causative gene for adRP which was cloned in our lab (Chakarova et al., 2007) and 
localises to the connecting cilium of photoreceptors. RP1, when a mutated result in 
adRP and like TOPORS is also present in the connecting cilium (Liu et al., 2002). The 
connecting cilium is a non-motile structure that links the inner and outer segments of 
photoreceptors. Through performing these experiments it would be possible to deduce 
whether SPAM localises to the inner segments, outer segments, and the connecting 
cilium or in all three layer, and to observe whether there is any co-localisation between 
SPAM and these connecting ciliary antibodies. 
 
Both experiments were performed in parallel and produced similar results. Co-staining 
of  SPAM  and  TOPORS  antibodies  revealed  an  obvious  distinction  of  where  both 
proteins are localised (Figure 5.10) with no overlap of the two antibody signals. Co-
staining with anti-RP1 revealed a similar result with no overlap of the antibody signals 
(Figure  5.11).  From  these  two  experiments  it  is  evident  that  SPAM  specifically 
localises to the outer segments of photoreceptors in porcine retina.  
                                                                         Chapter 5 Immunolocalisation of SPAM 
 
  190
 
 
                  
 
Figure 5.10 IHC staining of anti-SPAM and anti-TOPORS. A Anti-SPAM staining in green highlighting 
the  outer  segments  of  photoreceptors.  B  Anti-TOPORS  staining  in  red  highlighting  a  signal  in  the 
connecting cilium of photoreceptors. C Overlay of both staining, with no co-localisation of SPAM and 
TOPORS  being  observed.  D  A  schematic  view of  a rod  photoreceptor  with  arrows denoting  where 
SPAM and TOPORS are localised. 
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Figure 5.11 IHC co-localisation staining of anti-RP1 and anti-SPAM. A Anti-SPAM staining alone 
(green). B Anti-RP1 staining alone (red). C Overlay of both RP1 and SPAM staining with DAPI staining 
of the nuclear layers. D Enlarged view of anti-RP1 (red) staining in the connecting cilium and anti-
SPAM (green) staining in the outer segments of photoreceptors.  
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 5.5 Electron Microscopy of SPAM 
Electron microscopy (EM) was performed to confirm the previous results identified in 
the IHC experiments and to reaffirm the existence of the signal detected for anti-SPAM 
in the outer segments of photoreceptors. Porcine retinal sections were cryofixed and 
sectioned to slices of approx 60 nm thick. Anti-SPAM was labeled with gold particles 
and sections were scanned on a transmission electron microscope. High magnification 
images of the rod outer segments (ROS) of porcine  retina depict  a signal for anti-
SPAM, the signal displayed as black speckles (gold particles) reaffirms the expression 
of SPAM in ROS (Figure 5.12). In an attempt to further refine the precise location of 
SPAM expression in ROS a co staining EM was performed using the 1D4 antibody. A 
control experiment using the secondary antibodies alone were performed in parallel 
(Figure 5.14 A). 
 
1D4 is specific towards the C terminus of rhodopsin (Molday and MacKenzie., 1983) 
and localises to the cytoplasmic surface of native photoreceptor discs (Liang et al., 
2003). Double gold particle staining was performed using antibodies specific to SPAM 
and RHO. Anti-SPAM  was labeled with  gold  particles of 10 nm in size; 1D4 was 
labeled  with  gold  particles  of  5  nm.  Figure  5.13  demonstrates  labelling  of  both 
antibodies  in  the  outer  segment  of  porcine  rod  photoreceptors.  1D4  staining  has 
previously been observed at the periphery of a burst photoreceptor disc (Liang et al., 
2003). Double staining of a burst disc demonstrates anti-SPAM and 1D4 staining at the                                                                         Chapter 5 Immunolocalisation of SPAM 
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periphery of the disc (Figure 5.14). This labelling may also be due to the design of the 
antibody, if the antibody was designed to the C terminus of SPAM then this expression 
may have been across the full surface of the disc membranes. An example depicting 
this occurrence is from  two antibodies designed for RHO; these are 1D4, designed 
against the C terminus and 4D2, designed against the N terminus (Liang et al., 2003). 
As previously depicted, 1D4 localises to the periphery of the disc, however 4D2 has 
even distribution across the surface of the disc. Though it can be concluded that SPAM 
in this instance, localises to the periphery of rod discs it does not exclude localisation of 
the protein across the surface of the disc membrane.  
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Figure 5.12 EM micrographs of outer segments of porcine photoreceptors. Retinal sections were labeled 
with  the  SPAM  antibody  and  secondary  donkey  anti-rabbit  antibody  conjugated  with  10-nm  gold 
particles. A An individual rod outer segment (ROS), arrows denotes the gold labelling of the SPAM 
antibody localisation. B Enlarged view of ROS captured in A. 
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Figure 5.13 EM micrographs of SPAM and 1D4 in the retina of porcine. A Retinal ROS double labeled 
with SPAM and 1D4 antibodies, conjugated with 10-nm and 5-nm gold particles respectively. Blue circle 
highlights 1D4 gold particle staining, red circle highlighting SPAM gold particle staining. B Enlarged 
view of EM micrograph observed in A.  
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Figure 5.14 A Control experiment of ROS with secondary gold particle staining only. B Membrane from 
burst disc exposing the extracellular surface. Section was incubated with 1D4 and SPAM. Gold particles 
for SPAM and 1D4 are observed at the periphery of the disc.  
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5.6 Conclusion of Chapter 5 
An antibody was designed and raised against the amino-terminus of the SPAM protein. 
ICC  was  performed  using  this  antibody  on  retinoblastoma  cells  (Y79s),  which  had 
previously been used in a cDNA expression analysis of SPAM. Prominent expression 
of SPAM was determined in these cells with a strong punctuate signal being detected in 
the cytoplasm. This result does not exclude nuclear signal staining in these or other 
cells, but is a preliminary result reinforcing the expression data from chapter 4. 
            To reiterate the  prediction  that  SPAM is  absent  in  the  mouse genome,  IHC 
staining was performed on mouse retinal tissue with the conclusive result that detection 
of  SPAM  is  unattainable  through  using  this  antibody.  Bioinformatics  predictions 
selected the porcine genome as having an ortholog to SPAM with a high similarity 
(64%) to the peptide to which the antigen was raised against. Porcine retinal sections 
were  prepared  and  several  IHC  experiments  performed.  The  initial  indication  of  a 
prominent signal was detected using anti-SPAM at a 1:200 dilution. Since this peptide 
worked at 64% identity to human peptide, it highlights the fact that peptide identity 
need not be 100% and that the amino acids that were identical were enough to detect a 
signal.  Co-localisation  studies  were  then  performed  with  a  RHO  antibody  (1D4). 
Complete  co-localisation  of  the  two  antibodies  revealed  that  SPAM  is  exclusively 
localised  to  the  photoreceptors  of  porcine  retina.  Through  performing  IHC  with 
bioatynulated markers PNA and WGA, a further conclusion was drawn; that SPAM is 
primarily  expressed  in  rod  photoreceptors  in  comparison  to  cone  photoreceptors. 
SPAM expression may still exist in cone photoreceptors however the foremost level of                                                                         Chapter 5 Immunolocalisation of SPAM 
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expression  exists  in  rod  photoreceptors.  Performing  co-localisation  staining 
experiments  with  TOPORS  and  RP1  antibodies  further  refined  the  expression  of 
SPAM. From these experiments, it can now be concluded that SPAM is exclusively 
expressed in the outer segments of the photoreceptor cells. 
 
 
The  expression  of  SPAM  in  the  outer  segments  of  ROS  (rod  outer  segments)  was 
further  affirmed  through  EM  studies  with  a  gold  staining  labelling  reaction,  which 
depicts that SPAM is expressed throughout the outer segment of rod photoreceptors at a 
prominent  level.  Double  gold  particle  staining  with  1D4  reveals  the  expression  of 
SPAM is to the surface of photoreceptor discs suggesting it is localised to the periphery 
of disc membranes, however this result could be biased based on the design of the 
antibody and possible SPAM expression may be detected across the full surface of disc 
membranes.  
 
Despite the identification of many genes for recessive RP, the combined frequency of 
mutations from all identified genes accounts for only a third of arRP patients, with 
individual genes contributing to 1-5% of disease (Abd-El Aziz et al., 2008) this implies 
that causes of arRP are as yet unidentified in the vast majority of patients.  
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                         CHAPTER 6 
                           Discussion 
Recessive RP consists of a group of disorders that include juvenile or early-onset forms 
of  RP  and  overlap clinically  with  Leber' s congenital  amaurosis  (LCA).  Despite  the 
identification of many genes for recessive RP (section 1.12), the combined frequency of 
mutations from all identified genes accounts for only a third of arRP patients, with 
individual  genes  contributing  to  1-5%  of  disease  (Abd-El  Aziz  et  al.,  2008)    This 
implies  that  the  causative  gene  for  the  majority  of  arRP  patients  has  yet  to  be 
discovered. 
                          
Genes  that  cause  arRP  encode  proteins  that  have  a  range  of  functions  in  various 
pathways in the retina. These include being involved in the phototransduction cascade; 
PDE6A (Huang et al., 1995), RHO (Dryja et al., 1990) and RGR (Chen et al., 1996) or 
have a role in Vitamin A metabolism; ABCA4 (Allikmets et al., 1997), LRAT (Ruiz et 
al., 1999) and RPE65 (Redmond et al., 1998). Some proteins have a structural role, 
such as RP1 (Bowne et al., 1999) and TULP1 (Banerjee et al., 1998). NR2E3 (Haider et 
al.,  2000)  and  NRL  (Bessant  et  al.,  1999)  play  a  role  in  transcriptional  regulation,                                                            Chapter 6 Discussion and future work 
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whereas MERTK (Gal et al., 2000) is involved in the phagocytosis the photoreceptors 
by the RPE.  
 
6.1 Traditional and conventional methods for identifying EYS 
In this project, automated mutation sequencing analysis was performed in an attempt to 
identify the causative gene for RP25. Up to the point of identification, 60 genes had 
been collectively screened for mutations. An alternative method, copy number variation 
(CNV) analysis was then incorporated into the  study based on the identification of 
heterozygous SNPs in a homozygous interval in one arRP affected family. In parallel, 
both copy number variation (CGH) array analysis and mutation screening identified 
mutations in novel transcripts which in turn determined EYS.  
 
In theory, the traditional method of mutation screening was successful; however it is 
imperative  to  highlight  that  the  identification  of  large  deletions  (e.g.  in  the  RP73 
family) would never have been identified through performing this technique alone. This 
reveals the importance and possible application of CGH arrays to identify novel disease 
causing mutations in genes. Another fundamental procedure performed in this project is 
5` and 3` RACE. Through performing PCR analysis with bioinformatics predictions of 
exons alone, the precise composition of EYS would not have been wholly accurate. This 
leads  to  a  very  important  conclusion  that  through  the  combination  of  traditional 
molecular techniques and bioinformatics and chip array analysis allow for the most 
accurate prediction of mutations and novel gene size.                                                            Chapter 6 Discussion and future work 
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6.2 EYS mutations in arRP Spanish families 
Prior to the identification of EYS, all causative genes for arRP accounted for a minority 
of cases, it is suggested that EYS may be the common causative gene for many arRP 
cases. We have previously concluded that 10-25% of all Spanish arRP cases are linked 
to the RP25 interval, the suggestion is that EYS is a causative gene for a proportionate 
number of arRP cases, not only in Spain, but worldwide. This theory is based on the 
linkage of families from different ethnic backgrounds to the RP25 interval and the 
identification of further mutations in a second ethnic population (Collin et al., 2008). 
Unique mutations  that  span across  EYS  (e.g.  exon  17,  exon  28  and  exon  41)  were 
discovered in five unrelated arRP Spanish families. This leads to the opinion that there 
is no one individual region for mutations in EYS, and that the gene as a whole is crucial 
for protein function.  
 
6.3 Further ethnic populations linked to EYS 
 
Initially, primary focus was on the Spanish families linked to the RP25 interval, for 
which  it  was  considered  that  this  gene  is  the  principal  causative  gene  for  arRP. 
However, now a second population with novel mutations has been established, leading 
to the prospect of further populations being linked. To reinforce this, it is important to 
consider that Pakistani and Chinese families were also originally linked to the RP25 
interval (Abd El-Aziz et al., 2007). The affected members of the Chinese families could                                                            Chapter 6 Discussion and future work 
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still possess mutations in the EYS gene and should be further analysed for mutations, 
however linkage of the Pakistani family (Figure 1.10) is outside where EYS has now 
been  identified.  This  data,  along  with  the  fact  that  mutations  have  not  yet  been 
identified in several Spanish families may lead to the possibility that there is a second 
RP25 causative gene in this interval. This occurrence is rare but has previously been 
reported  for  other  disorders  such  as  Griscelli  syndrome,  which  is  a  rare  autosomal 
recessive  disease  characterised  by  albinism  and  immunodeficiency  (Pastural  et  al., 
1999). 
 
A significant result was that from Collin et al., 2008 who linked two unrelated Dutch 
families  and  one  Dutch  individual  to  the  same  RP25  interval.  They  examined  five 
patients from the two families and discovered the same homozygous nonsense mutation 
(p.Tyr3156X), whereas in the individual patient, a homozygous frame-shift mutation 
was  identified  (p.Pro2238ProfsX16).  This,  in  addition  to  the  information  from  our 
studies concludes that there are at least seven novel and independent mutations in the 
RP25  gene.  The  mutations  vary  from  missense  mutations,  large  deletions  and  null 
deletions. Moreover, this further reinforces the suggestion that this gene is a major gene 
for  arRP,  as  a  second  ethnic  population  has  been  linked  to  the  causative  gene 
independently.  
                         
Another interesting aspect of this study is the variation in mutations in different ethnic 
populations,  no  common  mutation  has  yet  been  identified  across  the  two  disease 
associated  populations.  Since  mutations  in  EYS  are  now  not  only  confined  to  the                                                            Chapter 6 Discussion and future work 
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Spanish population, it may be possible that different mutations give rise to the disease 
in different populations? Or possibly the severity and the onset of the disease depend 
on the type and position of the ensuing mutation in EYS. 
 
An intriguing result from this study is the conclusion from data so far is that there is no 
unique specific hotspot for mutation events in EYS, mutations are dispersed across the 
full length of the gene. This result can be correlated with the major causative gene for 
dominant  Retinitis  Pigmentosa,  rhodopsin  (Schuster  et  al.,  2005).  In  the  rhodopsin 
gene, over 200 different mutations across the gene have been identified (Chadderton et 
al., 2009). It is speculated that EYS may be the primary causative gene for arRP, just as 
rhodopsin is for adRP. 
 
6.4 EYS-Largest human eye specific gene 
We determined that EYS is composed of 43 exons and spans 2 MB in size. To date, 
dystrophin is the largest gene in the human genome, covering 2.4 MB and spanning 79 
exons (Roberts et al., 1993), located on chromosome Xp21, it is the causative gene for 
Duchenne Muscular Dystrophy (Hoffman et al., 1987). EYS is consequently one of the 
largest genes identified in the human genome. To discover the molecular function of 
EYS could prove to be a difficult and complicated task due to it being such a large gene. 
The large size of some human disease genes in combination with a large number of 
distinct disease-causing mutations essentially restricts the identification of the specific 
molecular alterations underlying disease phenotypes (Van Orsouw et al., 1996).                                                             Chapter 6 Discussion and future work 
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The full length transcript of EYS is retina specific however, smaller transcripts do exist 
in  other  tissues,  for  example  a  transcript has  been identified  in  human  testis  tissue 
between exons 9 and 12 (Collin et al., 2008). An alternatively spliced exon of 63bp was 
discovered  between  exon  41  and  42  but  does  not  alter  the  reading  frame  of  the 
transcript. Low expressing transcripts were also discovered from exons 41-44 in several 
tissues, including fetal heart and testis; however these transcripts exist at significantly 
low levels. Even though these small transcripts exist, it is still plausible to conclude that 
EYS is retinal specific, since the full length gene transcript exists exclusively in the 
retina.  
6.5 EYS and Drosophila 
The common fruit fly, Drosophila melanogaster, has been a central part of genetic 
research over the past 100 years (Banfi et al, 1997). The Drosophila genome sequence 
was published in 2000 and has since been used as a critical resource for research in 
genetics and medicine. The high degree of conservation of genes from flies through to 
mammals is vast and in particular the high degree of conservation of genes causing 
retinal degeneration in flies and mammals is immense when considering the differences 
in relation to the development and the organization of the eye of flies (Knust 2007) 
(Table 6.1). 
 
Importantly, there seems to be a strong correlation between the function of several 
retinal genes in humans and in Drosophila for example Rhodopsin, which is involved                                                            Chapter 6 Discussion and future work 
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in retinal signal transduction of the Drosophila eye (table 6.1). EYS was determined to 
have  an  ortholog  in  Drosophila,  this  being  eys/eys  shut  with  the  protein  name 
spam/spacemaker. This led to the corresponding human protein name of SPAM. Many 
other  human  genes  identified  as  causative  retinal  degenerative  disease  genes  have 
orthologs  in  Drosophila,  for  example  mutations  in  mammalian  crumbs  (Crb1)  are 
causative  for  RP12-  and  LCA-related  blindness  in  humans  (Knust,  2007).  In 
Drosophila, crumbs is very important for photoreceptor development (Fan et al., 2003). 
Another important retinal degeneration gene is prominin (PROM), mutations in which 
cause arRP and macular degeneration in humans (Maw et al., 2000). In Drosophila, 
prominin, like spam localises in the interhabdomeral space. Mutant prominin flies fail 
to separate their rhabdomeres, leaving them fused together to form a “closed visual 
system” (Zelhof et al., 2006).  
 
Drosophila spacemaker/spam is an extracellular matrix protein that is located in the 
interrhabdomeral space (Collin et al., 2008, Zelhof et al., 2008). The generation of the 
interrhabdomeral space has been a crucial event in the transition of compound eyes 
from closed to open visual systems. Due to the development of the open visual systems 
in fly eyes, they have an improved angular sensitivity, which allows the detection of 
smaller moving objects. Studies have demonstrated that if spam/spacemaker is knocked 
out  of  the  Drosophila  eye,  the  rhabdomeres  fuse  together  leaving  in  place  of  the 
interrhabdomeral space  (Zelhof et al., 2006) (figure 6.1).  As previously  stated, this 
fusion  is  also  associated  with  mutant  Drosophila  prominin  line.  This  leads  to  the 
conclusion that spam binds to prom in forming the open rhabdomere structure (Zelhof                                                            Chapter 6 Discussion and future work 
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et al., 2008). Data from Drosophila studies reinforces the suggested function of spam 
as  being  an  extracellular  matrix  protein  essential  for  rhabdomere  separation  (figure 
6.2).  Spacemaker/spam  distribution  is  linked  to  prominin  in  Drosophila,  while  in 
vertebrates PROMININ localises to the outer segment of rod photoreceptor cells as 
does SPAM as proven through IHC experiments (Cook and Zelhof 2008). Interestingly, 
Drosophila crumbs is expressed at the stalk membrane, this leads to the speculation 
that there is an interaction between spam, prominin and possibly crumbs which may be 
correlated with the human gene orthologues.  
An intriguing aspect of this study demonstrates that mutated spam does not lead to 
retinal degeneration in Drosophila. Apart from Spam being a necessary component in 
the formation of the IRS, it also acts in mechanoreceptor neurons (MRNs) in flies, and 
is an extracellular shield that protects these neurons from environmental stresses (Cook 
et al., 2008). MRNs are essential for functions such as hearing, flight control and touch 
sensing, the aberrant function of these neurons leads to uncoordinated movement in 
flies therefore demonstrating the apparent dual function of Spam in Drosophila.  
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      Table 6.1 Common eye genes of Drosophila and Humans 
Drosophila 
protein 
Human 
Homolo
g 
Retinal 
disorde
r 
Structural characteristics  Function in the eye 
Actin  Yes  Unknow
n 
Secreted protein, Egf-like and Lam A Formation of 
interrhabdomeral space 
Armadilio/￿-
catenin 
Yes  Unknow
n 
￿-catenin like repeats  Cell-cell adhesion 
Bazooka  Yes  Unknow
n 
Scaffolding protein  Polarity of Photoreceptor 
cells (PRCs) 
Chaoptin  Yes  Unknow
n 
Transmembrane protein  Photoreceptor-specific 
adhesion molecule 
Crumbs  Yes  LCA  Transmembrane protein. EGF-like 
and Lam A repeats 
Elongation of the 
PRC/rhadomere 
formation/prevention of 
light-induced degeneration 
DE-Cadherin  Yes  Unknow
n 
Transmembrane protein  Cell-cell adhesion 
DPATJ  Yes  Unknow
n 
Scaffolding protein  Elongation of the 
PRC/rhadomere 
formation/prevention of 
light-induced degeneration 
Prominin  Yes  arRP  Pentaspan membrane glycoprotein  Formation of the 
interrhabdomeral space 
Rhodopsin  Yes  adRP  G protein-coupled receptor with 
seven transmembrane domains 
Signal transduction; 
morphogenesis of 
rhabdomere 
Rab11  Yes  Unknow
n 
Monomeric GTPase  Mediate membrane transport 
to developing rhabdomeres 
Spacemaker/sp
am/Eyes shut  
Yes  arRP  Secreted protein, EGF-like and 
laminin A G-domain-like repeats 
Formation of the 
interrhadomeral space 
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Figure 6.1 Confocal microscopy images of rhabdomeres in a Drosophila eye. A Spam 
wildtype  (pink)  is  evidently  located  in  the  IRS  (interrhabdomeral  space).  B  Spam 
knockout Drosophila. The absence of Spam is clearly visible through the merging of 
the rhabdomeres (Images adapted from Zelhof et al., 2006). 
 
 B 
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Figure 6.2 Overview of important genes in the structure of the eye of Drosophila. Spacemaker/Spam is 
localised  to  the  interrhabdomeral  space.  Genes  such  as  prominin  and  crumbs  are  located  in  the 
neighbouring stalk membrane (Husain et al., 2006) 
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6.6 Orthologues of SPAM                                   
Moving from DNA to protein composition, it is the C-terminus of the SPAM protein 
that is orthologous to spam in Drosophila (figure 4.37). Although the C-terminal amino 
acids of Drosophila spam are not highly conserved in comparison to human SPAM, 
several  residues  of  this  fragment  are  conserved  in  vertebrate  species,  including 
zebrafish. This indicates that during the evolution of the vertebrate eye, the C-termimus 
part of SPAM possibly became essential for proper functioning of the entire protein 
(Collin et al., 2008). However, it is imperative to highlight that the functional antibody 
for SPAM was raised against a fragment of the N terminus of EYS, demonstrating that 
this region of SPAM is also a fundamental and conserved part of the protein. IHC 
experiments established this through signal detection in porcine retinal sections using 
this antibody. 
 
6.7 Absence of SPAM in other species 
Through bioinformatics studies it was determined that SPAM is absent from rodent 
species such as mouse and rat (Section 4.9). Based on the high homology of disease 
genes between humans and mice, the mouse genome is a commonly used animal model 
for countless genetic disorders. Many functional and anatomical similarities exist in the 
eyes of mice and humans, making the mouse an excellent model system for human 
retinal disorders (Bedell et al., 1997). In this instance the mouse model system would                                                            Chapter 6 Discussion and future work 
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not be suitable due to the absence of SPAM in the mouse genome. The loss or absence 
of a gene from humans to mice is a rare occurrence, this is only the fifth human disease 
gene identified as being absent in the mouse genome. The five genes are as follows and 
don’t seem to follow any particular pattern of expression or function. The genes are 
SHOX (Blaschke et al., 1998), CETP (Hogarth et al., 2003), Fuc-t III (Huang et al., 
2004) and Kal1 (Soderland et al., 2002). 
Using  a  recently  developed  phylogenetic  approach,  Church  et  al.,  2009  identified 
15,187 human and mouse genes in 1:1 orthologous relationships, representing 75% of 
mouse and 80% of human genes. Genes that are associated with Mendelian disease in 
humans are assumed to be of great importance and function in other species. Some 
exceptions do occur as in the case of EYS, the disruption of EYS in rodent lineages was 
unexpected. One similar example is the human gene KAL1, the disruption of this gene 
in humans leads to an absence or hypoplasia of olfactory bulbs and tracts in patients 
(Church et al., 2009) however it is absent from the mouse genome. In summary, most 
of the genes that are essential in humans are also essential in mice, re-enforcing the 
value of the mouse model for most human genetic diseases. However, a surprisingly 
high number of  genes that are essential in humans are not identified in mice. This 
suggests that it may not always be easy to draw a parallel between a human disease 
mutation and a mouse mutant phenotype; this is especially true for EYS. 
 
There are several postulations as to why there is no ortholog of EYS in the genome of 
particular species, in the mouse the ortholog is a pseudogene with only very short runs                                                            Chapter 6 Discussion and future work 
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of  nucleotide  sequences  being  identified  through  BLAST  searches.  The  inability  to 
detect  orthologs  in  mice  due  to  rapid  evolutionary  pressure  has  previously  been 
demonstrated  with  the  human  gene  AU022751  and  mouse  EG624310  which  are 
orthologous, but only display nonsignificant sequence similarity in database searches 
(Church et al., 2009). In other species such as cattle and sheep, the absence of EYS may 
be due to incomplete genomic sequencing of the species or the region where the EYS 
ortholog would be mapped to is completely absent.  
 
A  recent  study  by  Bekpen  et  al.,  2009  have  established  that  some  genes  that  are 
essential  in  humans  may  have  undergone  some  sort  of  event  to  render  them  as 
pseudogenes in other species. The IRGM gene, which is an immunity-related GTPase, 
has recently been implicated a as risk factor for Crohn’s disease. The study suggests 
that in the anthropoid ancestors a retrotransposition event occurred disrupting the open 
reading frame to cause a pseudogene. Millions of years later, in the human-great ape 
ancestor, the open reading frame became active again. However, most interestingly is 
that the version of IRGM identified in the monkey contains premature stop codons, 
leading to  a  pseudogene. Also  orangutans,  shared a  premature  stop  codon-inducing 
substitution with monkeys, suggesting ape ancestors once carried a pseudogene similar 
to  that  in  monkeys.  IRGM  could  play  an  important  role  in  humans;  however  it  is 
unclear what led to this gene' s disuse in the monkey-ape ancestor. It is suggested that 
another  immune  mechanism  may  have  evolved  around  the  same  time  that  IRGM 
became a pseudogene, making it redundant and less crucial. This may be correlated to                                                            Chapter 6 Discussion and future work 
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EYS and that possibly another gene had evolved at the same time that EYS became a 
pseudogene in rodents, making it less crucial and possibly redundant in that lineage. 
  6.8 Proposed role of SPAM 
What is the proposed role for SPAM in human eyes? Based on the function of spam in 
Drosophila and the localisation of SPAM in the outer segments of photoreceptors in 
porcine  retina  (Figure  5.8),  the  initial  postulation  would  be  that  SPAM  provides 
structure and support to these outer segments. Since Retinitis Pigmentosa is a late onset 
disorder, that slowly progresses (Tsujikawa et al., 2008), it has been suggested that the 
degeneration observed in the absence of SPAM could be the end result of structural 
abnormalities  of  the  outer  segments  that  accumulate  over  time  (Cook  and  Zelhof, 
2008). What about interaction between the human orthologs of prom, eys  and crb? 
PROM1  is  found  mainly  in  rod  photoreceptors  (Jászai  et  al.,  2007),  and  from  our 
immunolocalisation studies, it can be assumed that SPAM is also mainly localised to 
rod outer segments. Therefore it is proposed that there’s an interaction between PROM 
and SPAM in the rod outer segments, leading to disc morphogenesis (Collin et al., 
2008). EYS may also interact with CRB1 or CRB2 and may have a role in Müller cell–
photoreceptor cell and photoreceptor cell–photoreceptor cell interactions, as CRB1 is 
thought to be required to regulate number and size of Müller glia cell villi (van de 
Pavert et al., 2007). Another possible function of EYS could be that it is restored in the 
extracellular  matrix, also known  as the sub retinal space, between the  (developing) 
photoreceptors and RPE. This proposed function is based on the function of spam in                                                            Chapter 6 Discussion and future work 
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Drosophila eyes, and its importance for the structure of the extracellular matrix in their 
eyes.  
 
Future Work 
The next stage in the investigation of EYS will be to perform an intensive mutation 
screening  analysis  of  EYS  in  arRP  panels.  This  will  determine  the  prevalence  of 
mutations in EYS and its expected that novel mutations will be identified in other ethnic 
arRP populations. Another area of study will be to examine the molecular mechanisms 
underlying RP25. Through in situ cellular and tissue analysis, the localisation of SPAM 
has been presented in Y79 cells and porcine retina sections. An important aspect of the 
future  study  of  SPAM  will  be  to  fully  characterise  the  protein  which  will  involve 
characterising the antibody through western blot analysis and further in-depth IHC and 
ICC.  This  will  reiterate  the  data  confirmed  from  IHC  performed  on  porcine  retina 
sections and gives an indication of the expression level of SPAM in human retina and 
should further confirm the precise localisation of SPAM in human retina. IHC studies 
will also determine whether SPAM is rod specific in humans, or if there is a level of 
expression in cone photoreceptors also. Developmental studies of SPAM will also be a 
critical area of study, through experiments performed on tissue from an early stage 
developmental source and an adult source of the same species it will be possible to 
postulate  whether  SPAM  plays  a  role  in  controlling  or  regulating  development. 
Through parallel examination of early stage developmental retinal and mature retina, it 
will be possible to specify at what stage is SPAM turned on.                                                            Chapter 6 Discussion and future work 
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As  for  protein-protein  interactions,  from  the  Drosophila  data  it  is  expected  that 
PROMININ and CRB1 are the protein interactants in humans, however this must be 
determined using the yeast two hybrid system, through which novel protein interactants 
may also be identified. The concept of the yeast-two-hybrid technique involves using 
the  GAL4  transcription  factor,  which  has  two  domains  (DNA  binding  domain  and 
activation domain); the two must come together for transcription to occur. The ‘bait’ 
(protein of interest) is expressed as a fusion protein in frame with the DNA binding 
domain  of  the  GAL4  transcription  factor.  The  ‘prey’  (potential  interactants)  is 
expressed in frame with the activating domain. If the two domains are brought close to 
one  another,  by  the  interaction  of  the  bait  and  prey,  transcription  is  triggered  of  a 
reporter gene, which allows the yeast to grow in selective media lacking a particular 
nutrient (Coates and Hall, 2003). The function of SPAM will need to be thoroughly 
investigated and examined.  
 
The  secondary  and  tertiary  structure  of  SPAM  will  also  be  required  to  be  studied. 
Motifs of the secondary structure will reveal substructures such as alpha helices and 
identify how many motifs are present in a single protein molecule. This will lead onto 
the identification of the tertiary structure which will reveal how the protein folds and 
will expose the spatial arrangement of the secondary structures.  
 
Another fascinating aspect of the future of this study will be the evolutionary aspect of 
EYS.  Why  has  EYS  been  disposed  of  with  in  particular  species  and  is  crucial  for                                                            Chapter 6 Discussion and future work 
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functional eyes in other species? Is there a correlation or connection between these 
species? Have these genomes been fully sequenced, or has EYS become a pseudogene 
in all non expressing animals? This will require a great amount of effect but should 
reveal some interesting aspects of eye and retinal gene evolution.  
 
Animal models are a crucial component of biomedical research, both to understand the 
pathogenesis of human disease and to provide systems for testing new therapies. The 
mouse  has  been  paramount  in  modeling  human  diseases,  primarily  because  of  the 
striking homology between mammalian genomes and the many similarities in aspects 
spanning  from  anatomy  to  cell  biology  and  physiology.  The  mouse  is  still  a  very 
popular model to use in terms of studying retinal degenerations. Significantly, there are 
several mouse lines that copy different types of human retinal degeneration (Bovolenta
 
and Cisneros 2009), knockout mice that are commonly used for many forms of retinal 
degenerations; include the RDS and rpe65 knockout mice. Knock in mouse models are 
also  commonly  used  for  retinal  degenerations,  the  purpose  of  knock  in  mice  is  to 
determine what the consequences are on the mouse, of having particular mutated genes 
knocked in. One example of such a model used to study retinal degenerations is the 
rhodopsin-GFP fusion knock in mouse model. This particular model has been identified 
to test for arRP and has produced expression patterns that are identical to normal mouse 
rhodopsin  (Chan  et  al.,  2004).  One  knock-in  mouse  model  has  previously  been 
generated in our lab for the Prpf31 gene, the causative gene for RP11. Due to the large 
size of EYS, it is proposed that a smaller more applicable construct (mini gene) be                                                            Chapter 6 Discussion and future work 
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prepared for transfection experiments. It will be imperative that all crucial elements of 
the gene be retained in the miniaturised construct. 
 
Many researchers who are interested in an embryologically and genetically tractable 
disease  model have now turned to zebrafish (Danio rerio) as an alternative animal 
model (Lieschke and Currie 2007). In terms of a knock out model for SPAM, it is 
impossible to utilise the mouse as an animal  model, however it will be feasible to 
construct a knock-in model to determine the effects on the mouse when it possesses the 
mutated gene. The proposed model for SPAM will be the zebrafish. An ortholog to 
SPAM has been identified in zebrafish, and the lifespan of the fish allows good scope 
in terms of retinal degeneration disease models. The symptoms for some arRP cases 
present mostly in mid to late years and based on the lifespan of the zebrafish, being 
approximately five years (Gerhard et al., 2002), it is possible to utilise this model over 
a short period of time. Using zebrafish to model arRP will require a certain level of 
generalisation; however this system has previously been successfully used as a model 
organism for several other retinal degenerations. One example of this is choroideremia, 
which is an X-linked hereditary retinal degeneration caused by mutations in the REP1 
gene.  Zebrafish  rep1  mutants  exhibit  degeneration  of  the  RPE  and  photoreceptors 
(Krock et al., 2007). 
 
Another  method  which  will  be  used  to  investigate  EYS  further  is  through  RNA 
interference  (RNAi),  which  is  a  post-transcriptional  regulatory system  within  living 
cells that helps to control which genes are active and how active they are. Technologies                                                            Chapter 6 Discussion and future work 
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such as RNAi allow for knock down expression of a gene of interest through using 
short interfering RNA (siRNA) oligonucleotides complementary to the gene of interest. 
The  siRNA  duplexes  combine  with  cellular  proteins  to  form  the  RNA-induced 
silencing  complex  (RISC)  which  recognises  and  selectively  binds  complementary 
sequences.  
 
The eye is a prime target organ for gene therapy of both inherited and acquired ocular 
disorders and offers an important model system for gene therapy (Bainbridge et al., 
2006). For inherited disorders like RP, several methods can be performed to replace or 
correct “faulty” genes. In the case of EYS, a corrective gene may be introduced into the 
cell through the use of a recombinant adeno- (adeno-associated) viral vector, in the 
possibility that the virus would deliver the “normal” gene and replace the “disease” 
gene. EYS could perhaps be a prime target gene for gene therapy due to it being a 
recessive gene and recessive genes are easier to target because the transfer of a single 
copy  of  the  gene  may  be  sufficient  to  correct  the  loss  of  function  that  causes  the 
phenotype. The RPE65 gene, which is responsible for cases of LCA and arRP, has 
already been successfully used in gene therapy trials. Trials were first attempted on 
canine models (Acland et al., 2001) but recently Bainbridge et al., 2008, undertook a 
groundbreaking study using a rAAV vector containing human RPE65 human cDNA 
and the human RPE65 promoter on three human patients suffering from LCA. Such 
trials can not be attempted before the function and molecular mechanisms of SPAM are 
fully  understood.  The  future  work  for  SPAM  is  immense  and  very  intriguing.  To 
understand the complex molecular mechanisms of the protein may take years. If SPAM                                                            Chapter 6 Discussion and future work 
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is  similar  to  RHODOPSIN  in  terms  of  numbers  of  mutations,  then  identifying  the 
diverse roles and functions of each component of the protein will take time and effort. 
It  is  likely that  we  have  identified  a  major  gene  for  recessive  RP.  This  is  a novel 
breakthrough as all previously identified causative genes account for only a minority of 
all cases of arRP. Mutations in EYS have been reported in a number of different ethnic 
populations, making it a prime candidate for a major arRP gene. Such a case would be 
immense in terms of patient identification and disease prognosis and prevention. If EYS 
can be incorporated into gene therapy trials the potential for retinal degeneration repair 
is great. Future research on EYS will be an intersting area of study within the retinal 
research  community  and  in  the  general  wider  science  world.  
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Supplementary Data 
EYS cDNA and UTR (OMIM 612424) 
(see also Table 4.1) 
agaaacaaagtgatacacgctaggcatgtccagacattaaccgtaatcagaagcctcctagggttgcaagcctccttggct
ggttgggctttgtgcctcactcttctcttacacctggggagtcaagtctggatcctctgctccatatttatttagcaaataaaaca
ctgatctcaaacagcaacggaacctgtgtacttgagttttaaaggtgttttttgaaaactaatcagaagaggaatgcttatctcc
caagaaaattgaaaccatctgtaaaagaatcttggctgtgctgtgttttgattagattgaagcttggtgtaaagagaaaacaca
aaagaccgcaagaaacaaagtgatacacgctaggcatgtccagacattaaccgttaaccgtaatcagaagcctcctaggg
ttgcaagcctccttggctaatggttgggctttgtgcctcactcttctcttacacctggggagtcaagtctggatcctctgctcca
tatttatttagcaaataaaacactgatctcaaacagcaacggaacctgtgtacttgagttttaaaggtgttttttgaaaactaatc
agaagaggaatgcttatctcccaagaaaattgaaaccatctgtaaaagaatcttggctgtgctgtgttttgattagattgaagc
ttggtgtaaagagaaaacacaaaagaccgcagaatatttacaacatttgaattcctgtttctccatcaaagcacattgtcatca
aagctactttgggtatagaaaaaaggtcaattccaattcccaggaatccttaaccacaactttacttggaaatttccggtaata
cttaaaacaccattttgcagcaattctttatgataaactgtaaaatacagctacccgaaaATGACTGACAAATC
AATCGTCATTCTGAGCCTGATGGTTTTTCACAGCTCTTTCATAAATGGAAA
AACATGTAGACGGCAATTGGTGGAAGAATGGCATCCACAACCCTCATCAT
ATGTGGTAAATTGGACACTAACAGAAAACATCTGCTTGGACTTCTACAGA
GATTGCTGGTTTTTGGGTGTAAACACTAAAATAGATACTTCAGGCAATCA
AGCTGTTCCCCAGATTTGCCCTTTGCAAATTCAATTAGGAGATATCCTTGT
AATTTCTTCTGAACCATCTCTTCAATTTCCAGAAATAAATTTGATGAATGT
TTCTGAAACATCTTTCGTTGGCTGTGTGCAAAATACCACAACGGAAGATC
AGTTACTTTTTGGCTGCAGACTAAAAGGAATGCACACTGTTAATTCTAAG
TGGCTGAGTGTTGGGACACATTATTTTATCACAGTTATGGCAAGTGGTCC
ATCACCTTGTCCACTGGGACTTCGACTAAATGTGACAGTGAAACAGCAGT
TCTGCCAGGAATCTCTGAGTTCAGAATTTTGCTCTGGTCATGGTAAATGTC
TTAGTGAAGCTTGGAGCAAGACATATAGCTGCCATTGCCAGCCTCCATTT
TCTGGAAAATACTGCCAGGAACTTGATGCATGTTCTTTTAAACCATGTAA
AAATAATGGCAGTTGCATTAATAAAAGAGAAAATTGGGATGAGCAAGCA
TATGAATGTGTCTGTCACCCACCATTTACAGGAAAGAATTGCTCAGAAAT
AATTGGCCAGTGTCAACCACATGTCTGTTTCCATGGAAACTGCAGCAATA
TTACTTCAAATAGTTTCATTTGTGAATGTGATGAGCAATTTTCAGGTCCAT
TCTGTGAGGTGTCAGCAAAACCTTGTGTTTCTCTGCTTTTTTGGAAAAGAG
GAATTTGCCCAAATAGCAGTTCTGCTTATACTTATGAATGCCCAAAAGGA
TCTTCCAGCCAAAATGGTGAAACTGATGTCAGTGAGTTTTCATTAGTACC
ATGTCAGAATGGTACTGACTGCATCAAAATATCAAATGATGTTATGTGCA
TCTGTTCACCAATATTTACAGATTTGCTTTGTAAGAGCATTCAAACATCAT
GTGAGTCATTTCCTTTGAGGAATAATGCTACATGTAAGAAATGTGAGAAA
GATTATCCTTGCAGCTGTATATCAGGATTTACTGAAAAAAACTGTGAGAA                                                                                  
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AGCAATTGACCACTGTAAACTGCTCAGCATCAACTGTCTGAATGAAGAAT
GGTGTTTCAATATAATTGGAAGATTCAAATATGTATGCATTCCAGGGTGC
ACAAAAAATCCATGTTGGTTTTTGAAGAATGTTTACCTAATTCATCAACAC
CTCTGCTACTGTGGAGTCACCTTCCATGGTATTTGCCAAGATAAAGGTCCT
GCTCAATTTGAATATGTGTGGCAATTGGGATTTGCAGGATCTGAAGGCGA
AAAGTGCCAAGGGGTTATTGATGCCTATTTCTTTCTGGCTGCAAACTGCAC
TGAAGATGCAACCTATGTGAACGATCCTGAAGATAATAATTCTTCATGTT
GGTTCCCACATGAAGGCACAAAAGAGATTTGTGCAAATGGATGCAGTTGT
TTGAGTGAAGAAGACAGTCAGGAATATCGGTATCTATGTTTTCTCAGATG
GGCTGGCAACATGTATCTGGAAAATACAACTGATGATCAAGAAAATGAG
TGTCAACATGAAGCTGTTTGTAAAGATGAAATTAATAGACCCAGATGCAG
CTGTTCTCTTAGTTACATTGGCAGATTGTGTGTTGTCAATGTTGACTATTG
CTTAGGGAACCACAGTATATCAGTGCATGGCCTCTGCCTGGCCCTTTCGC
ACAATTGTAACTGTAGCGGTCTGCAAAGATATGAAAGGAACATCTGTGAG
ATAGATACTGAAGACTGCAAATCTGCGTCCTGCAAAAATGGAACAACTAG
TACACATTTAAGGGGATATTTCTTCCGCAAGTGTGTCCCAGGATTTAAAG
GTACGCAATGTGAAATTGATATAGATGAGTGTGCTTCACATCCCTGCAAA
AATGGAGCCACCTGCATTGACCAACCTGGTAATTACTTCTGCCAGTGTGT
GCCTCCATTTAAAGTGGTTGATGGCTTTTCCTGCTTATGCAATCCAGGCTA
TGTTGGGATAAGATGTGAACAGGACATTGATGACTGCATCCTGAATGCCT
GTGAGCACAATTCTACCTGCAAAGACCTGCATCTCAGCTACCAGTGTGTG
TGCCTATCTGATTGGGAAGGAAATTTTTGTGAACAAGAATCCAATGAGTG
TAAAATGAATCCTTGCAAGAACAATTCCACCTGTACTGACCTTTACAAAA
GCTATCGATGTGAGTGTACATCTGGATGGACTGGACAGAACTGTAGTGAA
GAAATAAATGAATGCGACTCTGATCCATGCATGAATGGAGGTCTTTGTCA
TGAATCTACCATCCCTGGACAATTTGTATGTCTGTGCCCACCCCTTTATAC
TGGACAATTTTGCCACCAACGCTATAACCTTTGTGACCTACTTCATAACCC
TTGCAGAAACAACTCAACATGCTTAGCTTTGGTAGACGCAAATCAGCATT
GTATTTGTAGAGAAGAATTTGAAGGTAAAAACTGTGAAATTGATGTGAAA
GACTGCCTCTTCCTTTCCTGCCAGGATTATGGTGACTGTGAAGATATGGTC
AACAATTTCAGGTGTATTTGCAGACCTGGGTTTTCTGGATCTCTGTGTGAA
ATTGAAATTAATGAATGTTCCTCTGAACCTTGCAAAAATAATGGAACATG
TGTGGATCTGACAAACAGATTTTTTTGTAATTGTGAACCTGAGTACCATGG
GCCCTTCTGTGAACTTGATGTAAATAAATGTAAAATCTCACCTTGTCTAGA
TGAAGAAAATTGTGTCTACAGGACTGATGGATACAACTGCCTCTGTGCCC
CTGGTTATACAGGCATCAACTGTGAAATAAATCTAGATGAATGCCTATCA
GAGCCCTGTCTCCATGATGGAGTTTGTATCGATGGCATCAATCATTATACC
TGTGACTGCAAGAGTGGGTTTTTTGGAACACACTGTGAAACAAACGCCAA
TGATTGCCTTTCAAATCCTTGTCTACATGGAAGGTGCACAGAACTTATTAA
TGAATATCCATGTTCATGTGATGCAGATGGGACTAGCACACAATGTAAGA
TCAAAATTAATGACTGCACATCAATCCCTTGTATGAATGAAGGCTTCTGTC
AGAAGTCAGCACATGGATTTACTTGCATTTGCCCACGTGGATACACTGGT
GCATACTGTGAAAAAAGCATTGATAATTGTGCTGAGCCTGAACTTAATTC
AGTCATCTGTCTTAATGGAGGGATCTGTGTTGATGGGCCTGGACATACTTT
TGACTGCAGATGTCTTCCTGGATTTTCTGGTCAATTTTGTGAAATTAATAT                                                                                  
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AAATGAATGCTCTTCATCACCATGTCTACATGGTGCAGACTGTGAAGATC
ACATCAATGGATATGTTTGCAAATGCCAACCAGGATGGTCTGGACACCAC
TGTGAGAATGAGCTTGAGTGCATTCCCAACTCATGTGTTCATGAACTCTGC
ATGGAGAATGAACCTGGCTCGACATGTTTATGCACACCTGGATTTATGAC
CTGCTCCATTGGGCTTCTTTGTGGTGATGAAATAAGGAGAATTACCTGTTT
AACTCCCATCTTTCAAAGAACAGATCCCATTTCCACACAGACATATACAA
TTCCCCCTTCTGAGACTTTGGTCAGCAGCTTTCCATCTATAAAGGCTACTA
GAATACCAGCCATAATGGACACTTACCCAGTTGATCAAGGTCCAAAACAG
ACAGGCATTGTCAAGCACGACATTCTCCCAACCACTGGTTTGGCAACATT
AAGAATTAGCACACCCTTGGAAAGCTACTTACTCCAAGAACTGATTGTCA
CTAGAGAGCTTTCAGCAAAACACAGTCTTCTTTCTTCCGCAGATGTTTCCT
CTTCTCGATTCCTGAATTTTGGTATTCGTGACCCAGCACAAATTGTCCAGG
ACAAAACATCGGTATCACATATGCCTATTCGAACTTCAGCAGCCACACTA
GGTTTCTTTTTTCCTGATAGGAGAGCAAGGACCCCATTTATCATGTCTTCC
TTAATGTCAGATTTTATTTTTCCTACACAATCTTTATTATTTGAGAACTGTC
AGACTGTTGCTTTATCTGCTACCCCAACGACTTCAGTAATTAGAAGCATTC
CAGGGGCTGATATTGAGCTAAACAGGCAGTCATTACTCTCCCGTGGATTC
CTGCTTATAGCTGCCTCCATAAGTGCAACTCCAGTTGTCTCTAGGGGGGCT
CAAGAGGATATTGAAGAATATTCAGCTGATTCTTTAATTTCAAGAAGAGA
GCACTGGAGATTGCTCAGCCCCTCGATGTCTCCCATTTTTCCTGCTAAGGT
AATTATATCTAAACAGGTAACCATCTTAAACTCATCAGCTCTGCACCGGTT
CAGTACAAAAGCCTTCAATCCCAGTGAATATCAGGCTATTACTGAGGCTT
CAAGCAACCAGAGACTCACAAACATCAAATCACAGGCTGCTGATTCTTTA
AGAGAATTAAGCCAAACATGTGCAACATGTTCTATGACTGAAATAAAATC
CTCTCGTGAATTCTCAGATCAAGTTTTGCATAGCAAACAGTCCCACTTTTA
TGAGACATTCTGGATGAACTCAGCGATATTAGCCAGCTGGTATGCACTAA
TGGGAGCTCAAACTATCACTTCTGGGCATTCATTTTCTTCTGCTACTGAAA
TAACACCATCAGTGGCATTCACAGAAGTGCCATCTTTATTTCCTTCTAAAA
AGAGTGCAAAAAGAACAATTTTATCCTCATCCTTGGAAGAATCCATTACC
CTATCAAGTAATTTGGATGTTAATTTATGTTTGGATAAGACTTGTTTATCC
ATTGTCCCTTCACAAACTATCTCTTCAGACTTGATGAATTCTGATTTGACT
TCAAAAATGACTACTGATGAACTGTCAGTATCAGAAAACATTTTAAAACT
ATTGAAAATAAGACAATATGGCATAACTATGGGACCCACTGAGGTACTAA
ATCAAGAGAGCTTATTGGACATGGAAAAAAGTAAAGGATCTCATACACT
GTTCAAACTTCACCCAAGTGATAGTTCTCTGGATTTTGAGTTAAACTTACA
AATTTATCCGGATGTTACTTTAAAGACATATTCAGAAATTACACATGCAA
ATGACTTCAAAAATAATCTGCCACCATTGACAGGCTCAGTGCCTGATTTTT
CAGAAGTCACCACCAATGTTGCATTTTATACAGTTTCAGCAACTCCAGCA
CTTTCAATACAGACGTCTTCCTCCATGTCTGTAATTAGGCCAGATTGGCCA
TATTTTACAGATTATATGACCTCTCTTAAAAAAGAGGTCAAGACTTCTTCA
GAATGGTCCAAATGGGAACTTCAGCCTAGTGTGCAATATCAGGAATTTCC
CACTGCAAGCCGGCATCTTCCCTTCACTAGATCTCTTACTTTGTCTTCACT
GGAATCCATTCTGGCACCTCAACGGCTGATGATTTCTGATTTCAGTTGTGT
TCGTTATTATGGAGATTCTTATCTAGAATTTCAGAATGTGGCTTTAAATCC
ACAAAATAACATCTCCCTAGAATTTCAGACCTTCAGCTCCTATGGACTTCT                                                                                  
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GCTGTATGTCAAGCAAGACTCAAATTTAGTAGATGGATTTTTTATTCAATT
GTTTATTGAAAATGGTACTTTAAAGTACCACTTTTACTGTCCTGGTGAAGC
AAAATTTAAAAGCATTAATACTACTGTTAGAGTGGACAACGGGCAAAAGT
ATACACTGCTTATCAGGCAAGAATTGGATCCATGTAACGCTGAGCTGACT
ATTTTAGGGAGGAATACACAAATATGCGAATCTATCAATCATGTACTCGG
AAAACCCCTGCCAAAATCAGGATCTGTCTTCATTGGTGGATTTCCAGACC
TTCATGGGAAAATCCAGATGCCTGTACCAGTCAAGAATTTTACTGGCTGC
ATAGAAGTTATAGAAATAAATAACTGGAGATCTTTCATTCCATCCAAGGC
AGTGAAAAACTATCACATTAACAATTGCAGATCCCAGGGATTTATGCTGT
CTCCAACAGCCTCCTTTGTTGATGCTTCTGATGTGACACAAGGGGTTGATA
CCATGTGGACTTCTGTCAGCCCCTCTGTTGCAGCACCCTCTGTGTGCCAGC
AGGATGTATGCCACAATGGAGGCACATGCCATGCCATCTTCCTCTCCAGT
GGCATAGTGTCATTCCAATGTGACTGTCCACTACATTTCACTGGCCGCTTC
TGTGAAAAAGATGCAGGTTTATTCTTTCCATCTTTCAATGGGAATTCCTAT
TTAGAACTGCCCTTTTTGAAGTTTGTCCTGGAGAAGGAACATAACAGAAC
TGTTACCATCTACTTGACTATAAAAACAAACAGTTTAAATGGAACTATTCT
TTACAGTAATGGGAATAATTGTGGAAAGCAGTTTCTTCATTTATTTCTTGT
GGAAGGAAGGCCATCAGTTAAATATGGGTGTGGAAATTCTCAAAATATTT
TGACTGTTTCTGCTAATTACAGCATTAACACAAATGCATTCACCCCTATCA
CAATACGCTACACAACGCCTGTTGGCAGCCCTGGAGTTGTTTGTATGATT
GAAATGACTGCAGATGGAAAACCTCCAGTACAGAAGAAAGACACAGAGA
TTTCCCATGCCTCTCAGGCATATTTTGAATCAATGTTCCTTGGCCATATTC
CTGCAAATGTTCAAATTCATAAGAAAGCAGGTCCTGTTTATGGGTTCAGG
GGCTGCATTCTAGACCTTCAAGTAAACAACAAAGAATTCTTCATCATCGA
TGAAGCACGACATGGAAAGAATATTGAGAACTGCCACGTCCCTTGGTGTG
CTCATCATCTGTGCCGCAACAATGGCACCTGCATCAGTGATAATGAAAAT
CTGTTTTGTGAGTGTCCAAGGCTGTATTCAGGCAAGCTGTGCCAGTTTGCA
AGTTGTGAAAACAACCCATGTGGAAATGGTGCCACCTGTGTTCCAAAATC
CGGAACAGATATTGTCTGCCTCTGCCCATATGGGAGGTCTGGACCCCTCT
GCACTGATGCTATTAATATTACTCAGCCAAGGTTCAGTGGCACAGATGCC
TTTGGATACACCTCATTCCTGGCTTATTCACGGATCTCAGACATCAGCTTC
CATTATGAATTCCACCTGAAGTTTCAGCTGGCAAACAACCACTCAGCACT
GCAAAATAACTTGATATTTTTTACTGGACAGAAAGGCCATGGGTTGAATG
GCGATGACTTCCTGGCTGTGGGCCTGCTCAATGGCAGTGTGGTTTATAGTT
ATAACCTGGGGTCTGGCATAGCAAGCATCAGGAGCGAGCCCCTCAATCTG
AGCCTTGGAGTCCACACTGTTCATCTGGGCAAGTTCTTCCAAGAGGGCTG
GCTGAAGGTAGATGATCATAAAAATAAATCCATTATCGCCCCAGGAAGAC
TGGTTGGTCTCAATGTCTTCAGTCAGTTTTATGTAGGTGGCTACAGTGAAT
ACACTCCAGATCTCTTACCAAATGGAGCAGATTTTAAAAATGGTTTTCAA
GGCTGTATTTTCACTCTTCAAGTTCGCACTGAGAAGGATGGCCATTTCAGA
GGACTGGGAAATCCTGAGGGCCACCCAAATGCTGGACGCAGTGTTGGCC
AGTGTCATGCTTCTCCCTGCAGTTTAATGAAATGTGGCAATGGTGGGACA
TGCATAGAGAGTGGAACTAGTGTTTACTGCAATTGTACCACTGGGTGGAA
AGGATCATTCTGCACAGAGACAGTTTCTACCTGTGATCCTGAACATGACC
CTCCACACCACTGTAGCAGAGGAGCAACCTGCATTTCATTACCTCATGGA                                                                                  
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TACACCTGTTTCTGTCCTCTAGGAACCACTGGAATCTACTGTGAACAAGCT
TTATCCATAAGTGATCCATCTTTCAGAAGCAATGAGTTATCCTGGATGTCT
TTTGCTTCCTTTCATGTTCGAAAAAAGACACATATTCAATTGCAGTTTCAG
CCTCTCGCTGCAGATGGTATCCTATTTTATGCTGCACAACACTTAAAAGCC
CAATCAGGTGATTTTTTATGCATCTCTTTAGTAAATAGTTCCGTTCAACTT
CGCTACAACCTTGGCGACAGAACTATCATTCTAGAAACTCTCCAAAAAGT
AACTATAAACGGAAGTACTTGGCATATAATAAAAGCAGGAAGAGTTGGT
GCAGAAGGCTACCTGGATCTAGATGGGATAAATGTAACAGAAAAGGCCT
CCACTAAAATGAGTTCTCTGGACACAAATACAGACTTCTATATTGGAGGA
GTATCTTCTTTAAATCTTGTAAATCCCATGGCAATAGAAAATGAACCTGTA
GGTTTTCAAGGCTGTATCCGACAAGTTATCATAAATAATCAAGAATTACA
ATTAACTGAATTTGGAGCAAAAGGTGGCTCAAATGTAGGTGACTGTGATG
GGACAGCCTGTGGGTACAACACATGCAGAAATGGAGGTGAATGTACAGT
AAATGGCACAACTTTTTCTTGCAGATGTTTGCCAGATTGGGCTGGAAATA
CATGTAACCAGTCTGTGTCCTGTTTGAATAATCTTTGCCTCCACCAATCTT
TATGTATACCTGACCAATCATTTTCTTACAGTTGCCTGTGTACTTTGGGTT
GGGTGGGAAGGTATTGTGAAAACAAAACTTCATTTTCAACTGCAAAATTT
ATGGGTAATTCTTACATTAAATACATTGATCCAAATTATAGAATGAGAAA
CCTCCAGTTCACTACTATATCCTTAAATTTCAGTACCACTAAAACAGAAG
GTCTAATTGTATGGATGGGAATAGCTCAAAATGAAGAAAATGATTTTCTG
GCAATTGGTCTCCATAATCAGACCTTGAAAATAGCAGTTAACTTGGGAGA
AAGAATCTCTGTGCCTATGAGCTATAACAATGGCACATTCTGTTGTAATA
AATGGCACCATGTAGTTGTAATTCAAAATCAGACTCTTATCAAGGCCTAC
ATAAATAACAGTCTAATTCTTTCCGAGGATATTGATCCACATAAAAACTTT
GTGGCTCTAAACTATGATGGCATTTGTTATCTAGGGGGCTTTGAATATGGT
AGAAAGGTAAATATCGTTACTCAAGAGATTTTTAAAACCAATTTTGTTGG
CAAAATTAAAGATGTTGTATTTTTTCAGGAACCAAAAAACATTGAACTAA
TTAAATTAGAAGGATACAATGTTTATGATGGAGATGAACAAAATGAGGTT
ACATAAgttaacactagagattttagtacacactatacataaatgcagttattttgatagttatttctttgatacattgcttac
ggggaatcaactgtttactatattacctgaaatagtctaaatgctaacatatctttttgataagattgtaaaatgtcactgaaggtt
ctgattgtttttcctacatctaatttatctgtatatattttgattcatgttttaactccattagttcagtgcttattcacagaatgtgcttat
tcactttgcttattcactttttacctatccctaatgcttacattttaaaatcaacgtgtaaacacaattttaaaaatcaatgtgtaagc
tgaactttaaaatgtttaaaattcagttgggaatgaattagggataggtacaaataagaaaaaaatcaagttattaatcaaagg
aaaaataaaaattatacaaagctaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 
 
 
Alternative colours represent exons, 43 in total. Underlined and lower cases represent 
the 5’and 3’ UTRs.   
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Protein Sequence of SPAM 
  1 MTDKSIVILS LMVFHSSFIN GKTCRRQLVE EWHPQPSSYV VNWTLTENIC 
51 LDFYRDCWFL GVNTKIDTSG NQAVPQICPL QIQLGDILVI SSEPSLQFPE 
101 INLMNVSETS FVGCVQNTTT EDQLLFGCRL KGMHTVNSKW LSVGTHYFIT 
151 VMASGPSPCP LGLRLNVTVK QQFCQESLSS EFCSGHGKCL SEAWSKTYSC 
201 HCQPPFSGKY CQELDACSFK PCKNNGSCIN KRENWDEQAY ECVCHPPFTG 
251 KNCSEIIGQC QPHVCFHGNC SNITSNSFIC ECDEQFSGPF CEVSAKPCVS 
301 LLFWKRGICP NSSSAYTYEC PKGSSSQNGE TDVSEFSLVP CQNGTDCIKI 
351 SNDVMCICSP IFTDLLCKSI QTSCESFPLR NNATCKKCEK DYPCSCISGF 
401 TEKNCEKAID HCKLLSINCL NEEWCFNIIG RFKYVCIPGC TKNPCWFLKN 
451 VYLIHQHLCY CGVTFHGICQ DKGPAQFEYV WQLGFAGSEG EKCQGVIDAY 
501 FFLAANCTED ATYVNDPEDN NSSCWFPHEG TKEICANGCS CLSEEDSQEY 
551 RYLCFLRWAG NMYLENTTDD QENECQHEAV CKDEINRPRC SCSLSYIGRL 
601 CVVNVDYCLG NHSISVHGLC LALSHNCNCS GLQRYERNIC EIDTEDCKSA 
651 SRKNGTTSTH LRGYFFRKCV PGFKGTQCEI DIDECASHPC KNGATCIDQP 
701 GNYFCQCVPP FKVVDGFSCL CNPGYVGIRC EQDIDDCILN ACEHNSTCKD 
751 LHLSYQCVCL SDWEGNFCEQ ESNECKMNPC KNNSTCTDLY KSYRCECTSG 
801 WTGQNCSEEI NECDSDPCMN GGLCHESTIP GQFVCLCPPL YTGQFCHQRY 
851 NLCDLLHNPC RNNSTCLALV DANQHCICRE EFEGKNCEID VKDCLFLSCQ 
901 DYGDCEDMVN NFRCICRPGF SGSLCEIEIN ECSSEPCKNN GTCVDLTNRF 
951 FCNCEPEYHG PFCELDVNKC KISPCLDEEN CVYRTDGYNC LCAPGYTGIN 
1001 CEINLDECLS EPCLHDGVCI DGINHYTCDC KSGFFGTHCE TNANDCLSNP 
1051 CLHGRYTELI NEYPCSCDAD GTSTQCKIKI NDCTSIPCMN EGFCQKSAHG 
1101 FTCICPRGYT GAYCEKSIDN CAEPELNSVI CLNGGICVDG PGHTFDCRCL 
1151 PGFSGQFCEI NINECSSSPC LHGADCEDHI NGHVCKCQPG WSGHHCENEL 
1201 ECIPNSCVHE LCMENEPGST CLCTPGFMTC SIGLLCGDEI RRITCLTPIF 
1251 QRTDPISTQT YTIPPSETLV SSFPSIKATR IPAIMDTYPV DQGPKQTGIV 
1301 KHDILPTTGL ATLRISTPLE SYLLQELIVT RELSAKHSLL SSADVSSSRF 
1351 LNFGIRDPAQ IVQDKTSVSH MPIRTSAATL GFFFPDRRAR TPFIMSSLMS 
1401 DFIFPTQSLL FENCQTVALS ATPTTSVIRS IPGADIELNR QSLLSRGFLL 
1451 IAASISATPV VSRGAQEDIE EYSADSLISR REHWRLLSPS MSPIFPAKVI 
1501 ISKQVTILNS SALHRFSTKA FNPSEYQAIT EASSNQRLTN IKSQAADSLR 
1551 ELSQTCATCS MTEIKSSREF SDQVLHSKQS HFYETFWMNS AILASWYALM 
1601 GAQTITSGHS FSSATEITPS VAFTEVPSLF PSKKSAKRTI LSSSLEESIT 
1651 LSSNLDVNLC LDKTCLSIVP SQTISSDLMN SDLTSKMTTD ELSVSENILK 
1701 LLKIRQYGIT MGPTEVLNQE SLLDMEKSKG SHTLFKLHPS DSSLDFELNL 
1751 QIYPDVTLKT YSEITHANDF KNNLPPLTGS VPDFSEVTTN VAFYTVSATP 
1801 ALSIQTSSSM SVIRPDWPYF TDYMTSLKKE VKTSSEWSKW ELQPSVQYQE 
1851 FPTASRHLPF TRSLTLSSLE SILAPQRLMI SDFSCVRYYG DSYLEFQNVA 
1901 LNPQNNISLE FQTFSSYGLL LHVKQDSNLV DGFFIQLFIE NGTLKYHFYC 
1951 PGEAKFKSIN TTVRVDNGQK YTLLIRQELD PCNAELTILG RNTQICESIN 
2001 HVLGKPLPKS GSVFIGGFPD LHGKIQMPVP VKNFTGCIEV IEINNWRSFI 
2051 PSKAVKNYHI NNCRSQGFML SPTASFVDAS DVTQGVDTMW TSVSPSVAAP 
2101 SVCQQDVCHN GGTCHAIFLS SGIVSFQCDC PLHFTGRFCE KDAGLFFPSF 
2151 NGNSYLELPF LKFVLEKEHN RTVTIYLTIK TNSLNGTILY SNGNNCGKQF 
2201 LHLFLVEGRP SVKYGCGNSQ NILTVSANYS INTNAFTPIT IRYTTPVGSP 
2251 GVVCMIEMTA DGKPPVQKKD TEISHASQAY FESMFLGHIP ANVQIHKKAG 
2301 PVYGFRGCIL DLQVNNKEFF IIDEARHGKN IENCHVPWCA HHLCRNNGTC 
2351 ISDNENLFCE CPRLYSGKLC QFASCENNPC GNGATCVPKS GTDIVCLCPY 
2401 GRSGPLCTDA INITQPRFSG TDAFGYTSFL AYSRISDISF RYEFHLKFQL 
2451 ANNHSALQNN LIFFTEQKGH GLNGDDFLAV GLLNGSVVYS YNLGSGIASI 
2501 RSEPLNLSLG VHTVHLGKFF QEGWLKVDDH KNKSIIAPGR LVGLNVFSQF 
2551 YVGGYSEYTP DLLPNGADFK NGFQGCIFTL QVRTEKDGHF RGLGNPEGHP 
2601 NAGRSVGQCH ASPCSLMKCG NGGTCIESGT SVYCNCTTGW KGSFCTETVS 
2651 TCDPEHDPPH HCSRGATCIS LPHGYTCFCP LGTTGIYCEQ ALILIVILEK 
2701 PKPAERKVKK EALSISDPSF RSNELSWMSF ASFHVRKKTH IQLQFQPLAA 
2751 DGILFYAAQH LKAQSGDFLC ISLVNSSVQL RYNLGDRTII LETLQKVTIN 
2801 GSTWHIIKAG RVGAEGYLDL DGINVTEKAS TKMSSLDTNT DFYIGGVSSL 
2851 NLVNPMAIEN EPVGFQGCIR QVIINNQELQ LTEFGAKGGS NVGDCDGTAC 
2901 GYNTCRNGGE CTVNGTTFSC RCLPDWAGNT CNQSVSCLNN LCLHQSLCIP 
2951 DQSFSYSCLC TLGWVGRYCE NKTSFSTAKF MGNSYIKYID PNYRMRNLQF 
3001 TTISLNFSTT KTEGLIVWMG IAQNEENDFL AIGLHNQTLK IAVNLGERIS 
3051 VPMSYNNGTF CCNKWHHVVV IQNQTLIKAY INNSLILSED IDPHKNFVAL 
3101 NYDGICYLGG FEYGRKVNIV TQEIFKTNFV GKIKDVVFFQ EPKNIELIKL 
3151 EGYNVYDGDE QNEVT   
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        Supplementary Agilent and Nimblegen Data on 
RP5 family  
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    Affymetrix Data on RP5 family members 
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Primers 
 
Primers for Mutation Screening of Candidate genes for RP25: 
 
 
Gene 
 
Exon No 
 
Sequence (5`……  3`) 
 
Produc
t size 
(bp) 
 
MgCl2 
 
Temp 
CYB5R4  Exon 1&2 F 
Exon 1&2 R 
TGTTGACAGCCTCTTAAAACTG 
CACAAGGCATATTTTTGTTAAATTG 
398 
 
1.5 
 
58.5 
 
  Exon 3 F 
Exon 3 R 
CCATGAAAGTGGCAGGTTAAG 
AAGGGCAAATTAAATGAACAGC 
474 
 
1.5 
 
58.5 
 
  Exon 4 F 
Exon 4 R 
TGCAGCCTTTCTATCACACC 
TCGAACTTTTAAGGGAAAGTCAC  448  1.5  58.5 
  Exon 5 F 
Exon 5 R 
TGGTCTGGCAGTCTTCAGAG 
GGCAGGAGAATTGCTTGAAC  437  1.5  63.2 
  Exon 6 F 
Exon 6 R 
GGCCTTTTGGCTAAGATCAAG 
TGGAACAGCTCATTCTCCAAC  393  1.5  60.8 
  Exon 7 F 
Exon 7 R 
GCTGTATAATGAAGAATGTAACATGG 
GCCACTCAGTGTGTAACTTTGG  426  1.5  58.5 
 
  Exon 8 F 
Exon 8 R 
TGAAGGAGAAGAACTGGGTTG 
GTCACACCGCCACTTGCTA  452  1.5  60.8 
  Exon 9 F 
Exon 9 R 
TGTTTTGGTCTTTCAGAACACG 
CACATCTTTGTTTTGCAATGTG  422  2.5  58.5 
  Exon 10F 
Exon 10R 
TCCCACTAATAATCAGTACCATTCA 
CAACACACATTGTCCCTTTCA  399  2.5  60.8 
  Exon 11F 
Exon 11R 
GGCATTTTAGTGAAATTGAAGC 
CACGTTGCAGTCACAAACCT  309  2.5  60.8 
  Exon 12F 
Exon 12R 
TGAAAATTGTTTCGGCACAC 
CCGACTCGAGTTTCCAGATT  572  2.5  58.5 
  Exon 13+14F 
Exon 13+14R 
TTAGGGGCCTAATGAGTATCC 
TGCCTAGATCTTGCCAGACA  940  2.5  58.5 
  Exon 15F 
Exon 15R 
TTAAATTGTTCCTTTAGGGGAGA 
TAATCCTGGCCTCCAACTCA  441  2.5  63.2 
  Exon 16F 
Exon 16R 
TGAGCTAGTTGAAAATTTGAGCA 
TGTGGTACAAAAGAAAGCCAAG  456  2.5  63.2 
ME1  Exon  1 F 
Exon  1 R 
GATGATCTCCTGCCATGACTC 
CTTCTTCCTTCTGCCCACAC  492  1.5  58.5 
  Exon  2 F 
Exon  2 R 
GGCCATGCTTCCAGTGAC 
TGAGCACGCAGTTTAGAAAGC  476  3.5  58.5 
  Exon 3 F 
Exon 3 R 
GGCCAAGACTCTGTCGTAAAG 
TGTATACATGTTTCAGAACATCCTC  479  1.5  58.5 
  Exon 4 F 
Exon 4 R 
GGAAATAATGTCCACCAGTTTGA 
TTCACTAGAAAAGCTAATGAATGC  333  3.5  58.5 
  Exon 5 F 
Exon 5 R 
TTCTTCACCCTATTCTTCCACAA 
TGGGAAAAGGAGAACAGGAG  104  1.5  57.0 
  Exon 6 F 
Exon 6 R 
TTTCTATTTTTGTCCCTTTTATACAGA 
CATTTGTCCATTAACAGTTATGAGG  600  DMSO  58.5 
  Exon 7 F 
Exon 7 R 
TGTTTTCCTATTTCTATGGGCTAA 
AGTATGTGACATCAGCAAGCAT  338  1.5  57.0                                                                                   
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  Exon 8 F 
Exon 8 R 
CGTATGCAAGCATGGGATAA 
CGGCAACATTTGATAATACCAC  483  1.5  57.0 
  Exon 9 F 
Exon 9 R 
TGGCTTAACCTAAATGTGACAAAA 
TGACATGATCATTTGTATTTAATGG  375  1.5  58.5 
  Exon 10 F 
Exon 10 R 
CGAATGAATGAAATAACATTCTGA 
TCTACAGGGTACTGTCGCTTGA  414  1.5  58.5 
  Exon 11 F 
Exon 11 R 
TTGTTGGCATTAACAAACTTGC 
TCCCTCTGATTTGTGTGCTTT  465  1.5  57.0 
  Exon 12 F 
Exon 12 R 
CATCACAAAAGCTTGTCCAGA 
AACATGCTACCCACCCCTTA  492  3.5  60.8 
  Exon 13 F 
Exon 13 R 
TGTTGATAGAAGTGGGGATGAA 
TCAGTGTGCCTCATTTCTCTG  399  1.5  58.5 
  Exon 14 F 
Exon 14 R 
CACACTTTCCTTAGTTGCTGATG 
ACCAGAAGGCAAAGTGAAGC  597  1.5  60.8 
MTO1  Exon 1 F 
Exon 1 R 
ATCACCCATCTCCCTCACC 
CTGATCCTTGCGAGACACTG  559  1.5  60.8 
  Exon 2+3 F 
Exon 2+3 R 
GACACTTTTGCATCCCATTG 
GCAACATATCTCCACACTTTGC  662  1.5  60.8 
  Exon 4 F 
Exon 4 R 
GCTCACGCCTGTAAGTAATCC 
TACTCAAGGGGGTTGAGGTG  910  1.5  60.8 
  Exon 5+6 F 
Exon 5+6 R 
GGGATGTTTATTTTTGGCAAG 
GAGCAAAACTCCGTCTCAAAAC  736  1.5  60.8 
  Exon 7 F 
Exon 7 R 
TGCCCTTCAGTATAAGGTCAGC 
TGAGGTCGGGAGTTTGAGAC  361  1.5  60.8 
  Exon 8 F 
Exon 8 R 
GCATTTAAGGGTAATGCTTGC 
AAAAGCCATCTCCAAACACC  446  1.5  65.0 
  Exon 9 F 
Exon 9 R 
TTAGGGGCAATACTTGCTTTC 
TGCCCAGGCTAGTCCTAAAC  434  1.5  57.0 
  Exon 10 F 
Exon 10 R 
GGCAAGAGGATCACTTGAGG 
TGAAAAGAAGCCAAAAACAAGC  433  1.5  57.0 
  Exon 11 F 
Exon 11 R 
CTACAGTTGATGGGCGACAG 
AGGTGTTGCAATGCTCTTAGC  433  1.5  57.0 
 
  Exon 12 F 
Exon 12 R 
AAGGGAACACCTACCCAACC 
AGAGATGGGGTCTTGCTGTG  467  1.5  57.0 
  Exon 13 F 
Exon 13 R 
CAGATTGTTATTTGGAGGAAAATAG 
AAGGGCTTTGATATTGCTTCC  670  1.5  57.0 
DPPA5  Exon 1+2 F 
Exon 1+2 R 
ACCAGGTGCGAGGCTTTATC 
CCGCCTTTCACCATAGTCTC  585  1.5  57.0 
  Exon 3 F 
Exon 3 R 
CCCCCTTCAGTTTCTTGGAG 
GTTCAGTGCTGCATCTCAGG  492  2.5  58.5 
SNX14  Exon 1 F 
Exon 1 R 
CGAGACGCTAGAGGCTTTG 
CTCCGCACGGTTAAGCAG  491  2.5  58.5 
 
  Exon 2 F 
Exon 2 R 
TGTAGGTGCTTAATGAATGCTTG 
GCAGGCTTTCAAATAATAAACAG  290  1.5  57.0 
  Exon 3+4 F 
Exon 3+4 R 
TGATGGTTTAGTTTAGCCAGTATTATG 
TGCCTCAGAACTGATTTAAGTGAC  546  2.5  65.2 
  Exon 5 F 
Exon 5 R 
CTCCCAAAGTGCTGGGATTA 
ACAGTACTGCCCCCAAAACA  369  2.5  60.8 
  Exon 6 F 
Exon 6 R 
TCGTGTATGTCTGCAAGGAAA 
AACACAAATGATAAATGCTTGAGG  538  1.5  57.0 
  Exon 7 F 
Exon 7 R 
AGGGCCTAACCAAGACCTAC 
AGTTCTGGAGATGGGGAATG  436  1.5  58.5                                                                                   
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  Exon 8/9/10 F 
Exon 8/9/10 R 
GCCCATTTTCACAAAGGTTAAG 
AGTGAAATTCCGCCTCAAAC  807  1.5  58.5 
  Exon 11 F 
Exon 11 R 
AAAACTGGTTGATTGCATTTCTC 
CCAACCAAGCTCTAGTTCTGAC  536  1.5  60.8 
  Exon 12 F 
Exon 12 R 
TGGCTAGCTGCAGTACATGG 
TGGTCTTGAATGCCTGAACTC  548  1.5  60.8 
  Exon 13 F 
Exon 13 R 
TTGCAATATTTTCATCCTTACCC 
TTCAGGCATTTTCAGATCACC  398  2.5  60.8 
  Exon 14 F 
Exon 14 R 
CCGTGTATGAAAACTCCAAAAG 
AATGAAAGAATGAGAAATACAAAGG  451  2.5  62.0 
  Exon 15 F 
Exon 15 R 
CCCCGGCCTATTATATTTTC 
TGTTCTGGACACTTCTCTTTTGG  574  1.5  58.5 
  Exon 16 F 
Exon 16 R 
TTCTGAAGCTTTTAAATTTTGTTTT 
GGCAGTTAATACCACAGTGTTCC  247  1.5  62.0 
  Exon 17 F 
Exon 17 R 
CTTGAAGCTCTCTGGTTTTGTG 
TTGACAAAAATTCATTCTAAAATTCAC  429  1.5  58.5 
  Exon 18 F 
Exon 18 R 
ATGTGGAAGAGCCAGGATTC 
TGACAAATGGCTAGAAGTGACTG  537  1.5  60.8 
  Exon 19+20 F 
Exon 19+20 R 
TTGAAAATTTCCATGGAGTGTG 
ACCGTTCAACTGATTTCCAC  592  1.5  58.5 
 
  Exon 21 F 
Exon 21 R 
CAATTCGGGGCATAAATGG 
AATATGATCAAGGCCAATCG  446  1.5  57.0 
  Exon 22 F 
Exon 22 R 
GATCTTGAGTATTGCCCCATC 
GGAGAGAGCGAGGTTCAGTG  585  1.5  63.0 
  Exon 23 F 
Exon 23 R 
AATATTGATAAATTTTGCTGGATTATG 
CACAATACCCTCTGTATACCGTTC  358  1.5  57.0 
  Exon 24 F 
Exon 24 R 
GGTGATTTTGCTTTATGATCCAG 
AATGTTTAAAATTATATTGCCTTGG  300  3.5  63.0 
  Exon 25 F 
Exon 25 R 
CCCTGCCTTCCCACTTAGAG 
AACCACAGAGAACAGAGACAAGG  278  3.5  63.0 
  Exon 26 F 
Exon 26 R 
CAGAGCTGTCATTAAACGTTGC 
AGAGGCAACCACACAATCAC  807  2.5  62.0 
SENP6  Exon 1 F 
Exon 1 R 
CCTGGCCTGCCTTTGTATAG 
GGCTCGTAGCTCAATCCAC  468  1.5  58.5 
  Exon 2 F 
Exon 2 R 
TGAGCTTCTTTGTGTAGCAAGC 
TTTCTTTCCTTAAAGCGACTGTG  470  1.5  60.8 
  Exon 3 F 
Exon 3 R 
TTGGAACATAGCCACATGTATTG 
CAATTGTGTAACATGGGAGGTG 
490 
  1.5  60.8 
  Exon 4 F 
Exon 4 R 
TTCTTAAATCCATGCCAATGC 
TGCAATGTTTTATTCAGAAACAAG  500  1.5  57.0 
  Exon 5 F 
Exon 5 R 
GGAAATGGAAAACTCCCAAAAG 
TCTCAGTCAAACACTTTCAGGTC  566  1.5  57.0 
  Exon 6+ 7 F 
Exon 6+ 7 R 
TCCTTGATATTGTGTGTATTTGAAG 
CTGTGCAACTGTTCCAGGTATC  673  1.5  57.0 
  Exon 8 F 
Exon 8 R 
CAGGAAGGGCTTCTGTTACC 
TATGTTGCAGGGAAGCACTG  599  1.5  60.8 
  Exon 9 F 
Exon 9 R 
TGATGGTAATGATGGGGAAG 
ACCTGGCCGAAGTCAGAATG  737  1.5  63.2 
  Exon 10 F 
Exon 10 R 
CCAAGTCTTAATGCTTTCTTCAG 
TGGCTTAATGTTCTTCCAAATAATC  606  1.5  65.2 
  Exon 11 F 
Exon 11 R 
ACATTTCTTATATTGGGTCTTTGC 
CGAAGCTGGCATGATAATAAAC 
486 
  1.5  65.2                                                                                   
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  Exon 12+13 F 
Exon 12+13 R 
TGATGGAAGGGATGTGACAA 
TTTCACAAGGTGGCTGTGAC 
975 
  2.5  60.8 
  Exon 14 F 
Exon 14 R 
AATGTGATTCTGGTTCCTTCCAA 
GGAACCAAAAATGCTTCTGAG  670  1.5  68.0 
  Exon 15+16 F 
Exon 15+16 R 
AAAGTGGCCCCTAGTTTTGC 
AAAATGTGCAAAGACAGAAACAG  685  2.5  63.2 
  Exon 17 F 
Exon 17 R 
GGCTGAAGCAGGAGAATCAC 
AACCCATGAAGAATGAAAATGG 
468 
  2.5  63.2 
  Exon 18 F 
Exon 18 R 
TGTCAAACCATTTTATGCAACTG 
CTGCATTAATTCTTGTAAAACAGG  378  2.5  60.8 
  Exon 19 F 
Exon 19 R 
CTCCCAAAGTGCTGGGATTA 
ATTGGGTCTCGCTATGTTGC  814  1.5  67.0 
  Exon 20 F 
Exon 20 R 
AAGGCAGATTTTGTGTTCTTGAC 
TTATGTTGCCCAGGCTGAAC  386  2.5  60.8 
  Exon 21 F 
Exon 21 R 
TGTTGTAGCATTGGATAATTGG 
AACTGGCAAATGGAGGACTG  471  2.5  60.8 
  Exon 22+23 F 
Exon 22+23 R 
CATACAAAGGGGATTTTGAAGG 
TTATGCCTTGAAGGTTCTTCC  600  2.5  63.2 
  Exon 24 F 
Exon 24 R 
AATTTGGTCCACTGGCAAAC 
TGAAAGGCTGTTACTTTGTTCC  961     2.5  60.8 
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Primers for 5`and 3` RACE PCR: 
 
 
 
5` OR 3` 
RACE 
 
 EXON 
 
SEQUENCE (5`………….3`) 
 
GC  
CONTENT 
 
TM 
(MELTING 
TEMPERA
TURE) 
3`  UTR F  CTCCACAGGTCAGGGCATCTGTAC  58.0%  76°C 
3`  UTR R  GTACAGATGCCCTGACCTGTGGAG  58.0%  76°C 
3`  EXON 2R  CTGTAAATGGTGGGTGACAGACAC  50.0%  84°C 
3`  EXON 14F  TGACTGCAGGAAAGCCTGCTTATAC  66.0%  84°C 
3`  EXON 14F    GGA GCCACCTGCA TTGACCAACC TGG        61.5%  84°C 
3`  EXON 16F  GCAG TTCCAGCCCTTGCCTGCATG G  65.0%  82°C 
3`  EXON 17F1  CATCTGGATG GACTGGACAGAACTGTAG          50.0%  84°C 
3`  EXON 17F2  GTCTGTGCC CACCCCTTTA TACTGGAC         55.5%  84°C 
3`  EXON 20R1  CCAGGGGCACAGAGGCAGTTGTATCC  66.0%  84°C 
3`  EXON 23F  GGAGGGATCTGTGTTGATGGGCCTGG  66.0%  84°C 
3`  EXON 25F  CCCCCTTCTGAGACTTTGGTCAG  57.1%  82°C 
3`  EXON 26F1  CCGCAGATGTTTCCTCTTCTCGATTC  64.0%  78°C 
3`  EXON 26F2  GGAGATTGCTCAGCCCCTCGATG  55.0%  72°C 
3`  EXON 32 F  CTTTCCATCTTTCAATGGGAATTCC  50.0%  70°C 
3`  EXON 35F  GGGTTCAGGGGCTGCATTCTAGACC  60.0%  80°C 
3`  EXON 43F  CAACCTTGGCGACAGAACTATC  50.0%  70°C 
5`  EXON 2CR  GTCCCAGTGGACAAGGTGATGGACC  66.0%  84°C 
5`  EXON 3R  CAGACATGTGGTTGACACTGGCC  56.0%  78°C 
5`  EXON 4R  GGTTTTGCTGACACCTCACAGAATGGAC  56.0%  78°C 
5`  EXON 4R1  CCATGCAGGCAAGGGCTGGAACTGC  65.0%  82°C 
5`  EXON 3R  CAGACATGTGGTTGACACTGGCC  56.0%  78°C 
5`  EXON 4R  GGTTTTGCTGACACCTCACAGAATGGAC  56.0%  78°C 
5`  EXON 4R1  CCATGCAGGCAAGGGCTGGAACTGC  65.0%  82°C 
5`  EXON 7R  GGTGACTCCACAGTAGCAGAGGTGTTG  50.0%  72°C 
5`  EXON 8R  CATCAATAACCCCTTGGCACTTTTCGCC  66.0%  84°C 
5`  EXON 9R  CCAGATACATGTTGCCAGCCCATCTGAG  56.0%  78°C 
5`  EXON 10AR  GGGCCAGGCAGAGGCCATGCACTG  54.1%  74°C 
5`  EXON 10BR  GGGACACACTTGCGGAAGAAATATCCC  56.5%  72°C 
5’  EXON 11R  AGCTCATTCTCACAGTGGTGTCC  53.8%  80°C 
5’  EXON 14R  GTGCTCACAGGCATTCAGGATGCAG  52.0%  78°C 
5`  EXON 17R1  CTACAGTTCTGTCCAGTCCATCCAGATG  50.0%  84°C 
5`  EXON 17R2  GTCCAGTATAAAGGGGTGGGCACAGAC          55.5%  84°C 
5’  EXON 18F  CCTGCCAGGATTATGGTGACTGTG    54.0%  74°C 
5’  EXON 18R  CACAGTCACCATAATCCTGGCAGG  54.1%  74°C 
5`  EXON 20R1  CCAGGGGCACAGAGGCAGTTGTATCC  55.0%  84°C 
5`  EXON 20R2  CAGAAGGGCCCATGGTACTCAGGTTCAC  57.1%  88°C 
5`  EXON 22R  CATTGTGTGCTAGTCCCATCTGCATCAC  50.0%  84°C 
5’  EXON 23R  CCAGGCCCATCAACACAGATCCCTCC  55.0%  84°C 
5`  EXON 26R  GGAATTTCCCACTGCAAGCCGGC  50.0%  72°C 
5`  EXON 32R  AGAAGGAACATAACAGAACTGTTACC  50.0%  72°C 
5`  EXON 36R  GGGAGGTCTGGACCCCTCTGCACTG  68.0%  84°C 
5’  EXON 41R  GACCCTCCACACCACTGTAGCAGAG  60.0%  80°C 
5’  EXON 43R  GGGGGCTTTGAATATGGTAGAAAGG  55.0%  82°C                                                                                   
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Primers for amplification of full length RP25 gene 
 
 
 
Exon No 
 
Sequence (5’……  3`) 
 
MgCl2 
 
Temp-
C 
4 F 
 
26 R 
CCAATTCCCAGGAATCCTTAACCACAA
C 
GAATCGAGAAGAGGAAACATCTGCGG 
2.5  57°C 
26 F 
43R 
CCGCAGATGTTTCCTCTTCTCGATTC 
CCCAACCCAAAGTACACAGGCAACTG 
 
2.5  58.5°C 
 
 
 
Primers for expression analysis of cDNA of EYS  
 
Exon No 
 
Sequence (5`……  3`) 
 
MgCl2 
 
Temp-
C 
4F 
11R 
CCAATTCCCAGGAATCCTTAACCACAA
C 
CCAGATACATGTTGCCAGCCCATCTGA
G 
 
1.5  58.5°C 
 
  Primers for MLPA Analysis: 
 
Exon No 
 
5` Probe sequence 
 
3` Probe sequence 
12  TGAAGACTGCAAATCTGCGTCCTG  CAAAAATGGAACAACTAGT
ACACATTTAAGGGGA 
13  TGGAGCCACCTGCATTGACCAACCT  GGTAATTACTTCTGCCAGTG
TGTGCCT 
15  TGTGAACAAGAATCCAATGAGTGTA
AAATGAATCC 
TTGCAAGAACAATTCCACC
TGTACTGACCTTTAC 
16  TACATCTGGATGGACTGGACAGAAC
TGTAGTGAA 
GAAATAAATGAATGCGACT
CTGATCCATGCATGA 
17  TCTCATACTCTTTGCAGAATTTGAAG
GTAAAAACTG 
TGAAATTGATGTGAAAGAC
TGCCTCTTCCT 
18  TGGGTTTTCTGGATCTCTGTGTGAAA
TTGAAATT 
AATGAATGTTCCTCTGAAC
CTTGCAAAAATAATGG 
19  TTGTGAACCTGAGTACCATGGGCCCT
T 
CTGTGAACTTGATGTAAAT
AAATGTAAAATCTCACCTT 
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Primers for SPAM gene: 
 
 
Gene 
 
Exon No 
 
Sequence (5`……  3`) 
 
MgCl2 
 
Temp-C 
EYS  1(nc)F 
1(nc) R 
AGCTCCAGATGGTGATTTGC 
TCCTTAAGCAAATGACAGAGAAAA 
1.5  60.8 
  2(nc)F 
2(nc) R 
GGCAGGATACTGGCTAATCTG 
GCCAAAAACGATAAAACCTGA 
1.5  60.8 
  3(nc)F 
3(nc)R 
CCATCCTCTGGATTATCATAAAAG 
CTTTGGGAAAGAAGGCCAAG 
1.5  60.8 
  4a F 
4a R 
GCTGCTGGTGACACTATCTTTG 
GAAGTCCAAGCAGATGTTTTCTG 
1.5  60.8 
  4b F 
4b R 
GCCTGATGGTTTTTCACAGC 
AAAATGGAGGCTGGCAATG 
1.5  60.8 
  4c F 
4c R 
GCAGTTCTGCCAGGAATCTC 
GTGCTGGGATTACAGGTGTG 
1.5  60.8 
  5 F 
5 R 
TTTCAATTTAAATGCATCATCG 
TGAAAAGCATGTGAACTGTTG 
2.5  57.0 
  6 F 
6 R 
TTTGCAAAAGTTACTGTAGAATTGC 
GACCGTTCTTGTTCGTCTGAG 
1.5  57.0 
  7 F 
7 R 
TGAGATGGGAGATGGTGTTG 
CAACAATTAACCCAAAACATGC 
1.5  57.0 
  8 F 
8 R 
GCTTTTTGGCTAAGATCACAGG 
TGGCTAAGATTAATAAGAGCATTTG 
1.5  57.0 
  9 F 
9 R 
GGCTTTTGAACATGGATATGAC 
TCTCTTGCACCAAGTAGATTTCC 
1.5  57.0 
  10 F 
10 R 
GGAACTTATTTTGTGGCAGATG 
TGATTCTTCAAAATTTTTACTTTCC 
1.5  57.0 
  11. F 
11.R 
CAAGCTTTGAACCCTTGTCC 
CTTCTTCCCTCCTTTTATTGTGC 
1.5  57.0 
  12 F 
12 R 
GCCAAGAATGGACACTTTAT 
CCAAAGAAGCAATCCTATTATTCAA 
1.5  57.0 
  13 F 
13 R 
TGGCATTCTTATCTAATAAATTTGG 
TTGGTTGGTCACTTTAGAAGC 
1.5  57.0 
  14 F 
14 R 
TTGGTTAAAAGTGAACTACATAAATG
A TGCTTGAGTTTCTGTTTTCTAACC 
1.5  57.0 
  15 F 
15 R 
GAGATATCAAAATGGCCAGGAG 
ATGATTGCGACACCATCTTG 
2.5  60.0 
  16 F  
16 R 
TCACAGGAAATTAGGCAAACAA 
GGATTTTTCCAACCCATTTT 
2.5  60.8 
  17+18 F 
17+18R 
CTGGCATGTTTTTATGCACAC 
CATTTTGCTCAGGCACACAT 
2.5  58.0 
  19 F 
19 R 
AAAATTTTGCAAGGAGAATTGC 
ATTTTTGCCCTGTTTGCATC 
2.5  58.0 
  20 F 
20 R 
TGTGCTTTGTTTTTGTCATTCAC 
AACTGGCAGCATCTGTCATC 
1.5  57.0 
  21 F 
21 R 
TTTCACCTGAACTAGGAAAGAAAAG 
CAACAAGAGACAAAGAAAGAAAAG
G 
1.5  57.0                                                                                   
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  22 F 
22 R 
GAGGAAGGAAATGTCAAACAAG 
TTGCAGAGTGCATTACTAGTGG 
1.5  57.0 
  23 F 
23 R 
GTTGGAGCTCTGAAAACACG 
TAGTATTGGTGGAGTGGATTGTC 
1.5  58.0 
  24 F 
24 R 
CCACGGATAAGAGCTGAGAC 
AGAGAAGGAGAGATGCGCTG 
1.5  57.0 
  25 F 
25 R 
TGTCTATGGAAATGCAAATGGA 
AAACAGGAGTCATAACCAATAATGC 
1.5  58.0 
  26 (a) F 
26 (a) R 
AGTGCCAAAGTGGTTCGTTT 
GGGGTCCTTGCTCTCCTATC 
1.5  58.0 
  26 (b) F 
26 (b) R 
GCACCGGTTCAGTACAAAAG 
AGTTTGTGAAGGGACAATGGA 
1.5  58.0 
  26 (c) F 
26 (c) R 
ATCCTCATCCTTGGAAGAATCC 
GACCATGACAGGCTCTTTCTTC 
1.5  57.0 
  27 F 
27 R 
TTGAAAGAGGCAGGAAAGAGAC 
AAGAGACATCCTGGTGGTGAGT 
1.5  61.0 
  28 F 
28 R 
GCTTTTCTCAACCATGTTCCTC 
GGGGATAGGGTCACCTTAAAAC 
1.5  57.0 
  29 F 
29 R 
GATTAATCTGCTTCTGGCTTTG 
TGGAAAAACAGACTGACATTGG 
1.5  57.0 
  30 F 
30 R 
CCCATGTTCATTGCAGCATTAT 
GAACGTAGGAATGTGAAGCAAA 
1.5  58.5 
  31 F 
31 R 
AGGGTCATGTTATGTGGCTCAG 
CAGCTGTTTCTTGTTTGTGC 
1.5  58.5 
  32 F 
32 R 
TTCAGTCTTTTCCTCTGTACTGG 
GCTCTGAAACATTTGCAGCAT 
1.5  58.5 
  33 F 
33 R 
ACTCCTACCAACCCCCTAAATC 
GTGGTGGTGCACATCTGTAGTC 
2.5  58.5 
  34 F 
34 R 
TTCTGAAAGCATTCCATGTCC 
TTTTCTGGTGCTTTGTTGAGAG 
2.5  58.5 
  35 F 
35 R 
GCCAACAATAGCAACCTCTTTT 
ACATGTGTGCATCATTTAGGT 
2.5  58.5 
  36 F 
36 R 
GCATATGTGTTCATGCATGTGT 
CTGCTTGGTGATCAGTCTCACT 
1.5  58.5 
  37 F 
37 R 
AGATGCATCAGCAAAACGTAAC 
GCATCTAGGCAAAGGTCTTTT 
1.5  58.5 
  38 F 
38 R 
GAATAACAACAGCCAGTTGCAC 
CTGTGAACTTCGTGGATGTAGG 
1.5  58.5 
  39 F 
39 R 
TAACAGACACCAGCAGAGAAGC 
TGTTCAAGTCTGAAAGCAATCC 
2.5  58.5 
  40 F 
40 R 
TTCTCTGCGCATTTCTGTATTC 
CTGTCCTCCCATCATGTAACAA 
1.5  58.5 
  41 F 
41 R 
GACAAGTTAGCATCAGGGCAAT 
GAAAAAGAGGACAGTGGATTTG 
1.5  57.0 
  42 F 
42 R 
CTCACCTACAAGCAACTCTTGG 
TACGCATACACTTGCAGTGACA 
1.5  57.0 
  43 (a) F 
43 (a) R 
CTTATCCAACTTGGCCAGAAAC 
TCAAACAGGACACAGACTGGTT 
1.5  57.0 
  43 (b) F 
43 (b) R 
GGGTACAACACATGCAGAAATG 
GTGGATCAATATCCTCGGAAAG 
1.5  57.0 
  43 (c) F 
43 (c) R 
GGTCTCCATAATCAGACCTTGA 
GATTCCCCGTAAGCAATGTATC 
3.5  57.0                                                                                   
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Primers for Sequence Homology of EYS across species 
 
 
 
Species  Gene and 
exon  
SEQUENCE ( 5`￿………………….3`)  Size 
(bp) 
Mg  Temp 
Human  EYS exon 14  TGCTTATGCAATCCAGGCTA 
AGATGCAGGTCTTTGCAGGT 
104  1.5  58.5 
  EYS exon 26  AAGCACGACATTCTCCCAAC 
CCCCCTAGAGACAACTGGAG 
543  1.5  58.5 
  EYS exon 43  ACAACCTTGGCGACAGAACT 
CCACCCAACCCAAAGTACAC 
552  1.5  60.8 
  GAPDH 
exon 4 
TGCATTCGCCCTCTTAATG 
ATCAGCCAGGTGGCTCCTC 
322  1.5  60.8 
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